
<html lang="en"     class="pb-page"  data-request-id="18c5ea71-3d9d-41c4-bd75-bb9ec8d3329b"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;issue:issue:10.1021/jmcmar.2019.62.issue-17;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.9b00794;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases" /></meta><meta name="dc.Creator" content="Richard D.  Caldwell" /></meta><meta name="dc.Creator" content="Hui  Qiu" /></meta><meta name="dc.Creator" content="Ben C.  Askew" /></meta><meta name="dc.Creator" content="Andrew T.  Bender" /></meta><meta name="dc.Creator" content="Nadia  Brugger" /></meta><meta name="dc.Creator" content="Montserrat  Camps" /></meta><meta name="dc.Creator" content="Mohanraj  Dhanabal" /></meta><meta name="dc.Creator" content="Vikram  Dutt" /></meta><meta name="dc.Creator" content="Thomas  Eichhorn" /></meta><meta name="dc.Creator" content="Anna S.  Gardberg" /></meta><meta name="dc.Creator" content="Andreas  Goutopoulos" /></meta><meta name="dc.Creator" content="Roland  Grenningloh" /></meta><meta name="dc.Creator" content="Jared  Head" /></meta><meta name="dc.Creator" content="Brian  Healey" /></meta><meta name="dc.Creator" content="Brian L.  Hodous" /></meta><meta name="dc.Creator" content="Bayard R.  Huck" /></meta><meta name="dc.Creator" content="Theresa L.  Johnson" /></meta><meta name="dc.Creator" content="Christopher  Jones" /></meta><meta name="dc.Creator" content="Reinaldo C.  Jones" /></meta><meta name="dc.Creator" content="Igor  Mochalkin" /></meta><meta name="dc.Creator" content="Federica  Morandi" /></meta><meta name="dc.Creator" content="Ngan  Nguyen" /></meta><meta name="dc.Creator" content="Michael  Meyring" /></meta><meta name="dc.Creator" content="Justin R.  Potnick" /></meta><meta name="dc.Creator" content="Dusica Cvetinovic  Santos" /></meta><meta name="dc.Creator" content="Ralf  Schmidt" /></meta><meta name="dc.Creator" content="Brian  Sherer" /></meta><meta name="dc.Creator" content="Adam  Shutes" /></meta><meta name="dc.Creator" content="Klaus  Urbahns" /></meta><meta name="dc.Creator" content="Ariele Viacava  Follis" /></meta><meta name="dc.Creator" content="Ansgar A.  Wegener" /></meta><meta name="dc.Creator" content="Simone C.  Zimmerli" /></meta><meta name="dc.Creator" content="Lesley  Liu-Bujalski" /></meta><meta name="dc.Description" content="Bruton’s tyrosine kinase (BTK) inhibitors such as ibrutinib hold a prominent role in the treatment of B cell malignancies. However, further refinement is needed to this class of agents, particularl..." /></meta><meta name="Description" content="Bruton’s tyrosine kinase (BTK) inhibitors such as ibrutinib hold a prominent role in the treatment of B cell malignancies. However, further refinement is needed to this class of agents, particularl..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 1, 2019" /></meta><meta name="dc.Type" content="news" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00794" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00794" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00794" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00794" /></link>
        
    
    

<title>Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00794" /></meta><meta property="og:title" content="Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/large/jm9b00794_0016.jpeg" /></meta><meta property="og:description" content="Bruton’s tyrosine kinase (BTK) inhibitors such as ibrutinib hold a prominent role in the treatment of B cell malignancies. However, further refinement is needed to this class of agents, particularly in terms of adverse events (potentially driven by kinase promiscuity), which preclude their evaluation in nononcology indications. Here, we report the discovery and preclinical characterization of evobrutinib, a potent, obligate covalent inhibitor with high kinase selectivity. Evobrutinib displayed sufficient preclinical pharmacokinetic and pharmacodynamic characteristics which allowed for in vivo evaluation in efficacy models. Moreover, the high selectivity of evobrutinib for BTK over epidermal growth factor receptor and other Tec family kinases suggested a low potential for off-target related adverse effects. Clinical investigation of evobrutinib is ongoing in several autoimmune diseases, including multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00794"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00794">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00794&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00794&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00794&amp;href=/doi/10.1021/acs.jmedchem.9b00794" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 17</span><span class="cit-fg-pageRange">, 7643-7655</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/17" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b00370" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/acs.jmedchem.9b00024" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Richard D. Caldwell</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Richard D. Caldwell</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EMD Serono Research & Development Institute, Inc. (a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</div></div><span class="conrtib-corresp"><strong>*</strong>For R.D.C.: phone, 978−294-1100; fax, 781-681-2691; E-mail, <a href="/cdn-cgi/l/email-protection#45372c262d2437216b2624292132202929052028213620372a2b2a6b262a28"><span class="__cf_email__" data-cfemail="86f4efe5eee7f4e2a8e5e7eae2f1e3eaeac6e3ebe2f5e3f4e9e8e9a8e5e9eb">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Richard+D.++Caldwell">Richard D. Caldwell</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hui Qiu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hui Qiu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EMD Serono Research & Development Institute, Inc. (a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</div></div><span class="conrtib-corresp"><strong>*</strong>For H.Q.: phone, +1 978 294 1442; fax, +1 978 294 1400; E-mail, <a href="/cdn-cgi/l/email-protection#157d607c3b647c60557078716670677a7b7a3b767a78"><span class="__cf_email__" data-cfemail="0b637e62257a627e4b6e666f786e7964656425686466">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hui++Qiu">Hui Qiu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ben C. Askew</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ben C. Askew</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EMD Serono Research & Development Institute, Inc. (a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ben+C.++Askew">Ben C. Askew</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Andrew T. Bender</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andrew T. Bender</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EMD Serono Research & Development Institute, Inc. (a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andrew+T.++Bender">Andrew T. Bender</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nadia Brugger</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nadia Brugger</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EMD Serono Research & Development Institute, Inc. (a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nadia++Brugger">Nadia Brugger</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Montserrat Camps</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Montserrat Camps</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EMD Serono Research & Development Institute, Inc. (a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Montserrat++Camps">Montserrat Camps</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mohanraj Dhanabal</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mohanraj Dhanabal</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EMD Serono Research & Development Institute, Inc. (a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mohanraj++Dhanabal">Mohanraj Dhanabal</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Vikram Dutt</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Vikram Dutt</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EMD Serono Research & Development Institute, Inc. (a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Vikram++Dutt">Vikram Dutt</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Thomas Eichhorn</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Thomas Eichhorn</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EMD Serono Research & Development Institute, Inc. (a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Thomas++Eichhorn">Thomas Eichhorn</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anna S. Gardberg</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anna S. Gardberg</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EMD Serono Research & Development Institute, Inc. (a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anna+S.++Gardberg">Anna S. Gardberg</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Andreas Goutopoulos</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andreas Goutopoulos</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EMD Serono Research & Development Institute, Inc. (a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andreas++Goutopoulos">Andreas Goutopoulos</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Roland Grenningloh</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Roland Grenningloh</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EMD Serono Research & Development Institute, Inc. (a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Roland++Grenningloh">Roland Grenningloh</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jared Head</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jared Head</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EMD Serono Research & Development Institute, Inc. (a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jared++Head">Jared Head</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Brian Healey</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brian Healey</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EMD Serono Research & Development Institute, Inc. (a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brian++Healey">Brian Healey</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Brian L. Hodous</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brian L. Hodous</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EMD Serono Research & Development Institute, Inc. (a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brian+L.++Hodous">Brian L. Hodous</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bayard R. Huck</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bayard R. Huck</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EMD Serono Research & Development Institute, Inc. (a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bayard+R.++Huck">Bayard R. Huck</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Theresa L. Johnson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Theresa L. Johnson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EMD Serono Research & Development Institute, Inc. (a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Theresa+L.++Johnson">Theresa L. Johnson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christopher Jones</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christopher Jones</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EMD Serono Research & Development Institute, Inc. (a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christopher++Jones">Christopher Jones</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Reinaldo C. Jones</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Reinaldo C. Jones</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EMD Serono Research & Development Institute, Inc. (a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Reinaldo+C.++Jones">Reinaldo C. Jones</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Igor Mochalkin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Igor Mochalkin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EMD Serono Research & Development Institute, Inc. (a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Igor++Mochalkin">Igor Mochalkin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Federica Morandi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Federica Morandi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EMD Serono Research & Development Institute, Inc. (a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Federica++Morandi">Federica Morandi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ngan Nguyen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ngan Nguyen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EMD Serono Research & Development Institute, Inc. (a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ngan++Nguyen">Ngan Nguyen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael Meyring</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael Meyring</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EMD Serono Research & Development Institute, Inc. (a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Meyring">Michael Meyring</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Justin R. Potnick</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Justin R. Potnick</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EMD Serono Research & Development Institute, Inc. (a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Justin+R.++Potnick">Justin R. Potnick</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dusica Cvetinovic Santos</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dusica Cvetinovic Santos</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EMD Serono Research & Development Institute, Inc. (a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dusica+Cvetinovic++Santos">Dusica Cvetinovic Santos</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ralf Schmidt</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ralf Schmidt</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EMD Serono Research & Development Institute, Inc. (a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ralf++Schmidt">Ralf Schmidt</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Brian Sherer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brian Sherer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EMD Serono Research & Development Institute, Inc. (a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brian++Sherer">Brian Sherer</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Adam Shutes</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Adam Shutes</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EMD Serono Research & Development Institute, Inc. (a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Adam++Shutes">Adam Shutes</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Klaus Urbahns</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Klaus Urbahns</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EMD Serono Research & Development Institute, Inc. (a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Klaus++Urbahns">Klaus Urbahns</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ariele Viacava Follis</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ariele Viacava Follis</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EMD Serono Research & Development Institute, Inc. (a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ariele+Viacava++Follis">Ariele Viacava Follis</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ansgar A. Wegener</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ansgar A. Wegener</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EMD Serono Research & Development Institute, Inc. (a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ansgar+A.++Wegener">Ansgar A. Wegener</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Simone C. Zimmerli</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Simone C. Zimmerli</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EMD Serono Research & Development Institute, Inc. (a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Simone+C.++Zimmerli">Simone C. Zimmerli</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Lesley Liu-Bujalski</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lesley Liu-Bujalski</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EMD Serono Research & Development Institute, Inc. (a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lesley++Liu-Bujalski">Lesley Liu-Bujalski</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00794&amp;href=/doi/10.1021%2Facs.jmedchem.9b00794" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 17</span><span class="cit-pageRange">, 7643–7655</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 1, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>15 May 2019</li><li><span class="item_label"><b>Published</b> online</span>1 August 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 September 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00794" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00794</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D7643%26pageCount%3D13%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DRichard%2BD.%2BCaldwell%252C%2BHui%2BQiu%252C%2BBen%2BC.%2BAskew%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D17%26contentID%3Dacs.jmedchem.9b00794%26title%3DDiscovery%2Bof%2BEvobrutinib%253A%2BAn%2BOral%252C%2BPotent%252C%2Band%2BHighly%2BSelective%252C%2BCovalent%2BBruton%25E2%2580%2599s%2BTyrosine%2BKinase%2B%2528BTK%2529%2BInhibitor%2Bfor%2Bthe%2BTreatment%2Bof%2BImmunological%2BDiseases%26numPages%3D13%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D7655%26publicationDate%3DSeptember%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00794"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">12268</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">24</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00794" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;D. Caldwell&quot;},{&quot;first_name&quot;:&quot;Hui&quot;,&quot;last_name&quot;:&quot;Qiu&quot;},{&quot;first_name&quot;:&quot;Ben&quot;,&quot;last_name&quot;:&quot;C. Askew&quot;},{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;T. Bender&quot;},{&quot;first_name&quot;:&quot;Nadia&quot;,&quot;last_name&quot;:&quot;Brugger&quot;},{&quot;first_name&quot;:&quot;Montserrat&quot;,&quot;last_name&quot;:&quot;Camps&quot;},{&quot;first_name&quot;:&quot;Mohanraj&quot;,&quot;last_name&quot;:&quot;Dhanabal&quot;},{&quot;first_name&quot;:&quot;Vikram&quot;,&quot;last_name&quot;:&quot;Dutt&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;Eichhorn&quot;},{&quot;first_name&quot;:&quot;Anna&quot;,&quot;last_name&quot;:&quot;S. Gardberg&quot;},{&quot;first_name&quot;:&quot;Andreas&quot;,&quot;last_name&quot;:&quot;Goutopoulos&quot;},{&quot;first_name&quot;:&quot;Roland&quot;,&quot;last_name&quot;:&quot;Grenningloh&quot;},{&quot;first_name&quot;:&quot;Jared&quot;,&quot;last_name&quot;:&quot;Head&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;Healey&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;L. Hodous&quot;},{&quot;first_name&quot;:&quot;Bayard&quot;,&quot;last_name&quot;:&quot;R. Huck&quot;},{&quot;first_name&quot;:&quot;Theresa&quot;,&quot;last_name&quot;:&quot;L. Johnson&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;Jones&quot;},{&quot;first_name&quot;:&quot;Reinaldo&quot;,&quot;last_name&quot;:&quot;C. Jones&quot;},{&quot;first_name&quot;:&quot;Igor&quot;,&quot;last_name&quot;:&quot;Mochalkin&quot;},{&quot;first_name&quot;:&quot;Federica&quot;,&quot;last_name&quot;:&quot;Morandi&quot;},{&quot;first_name&quot;:&quot;Ngan&quot;,&quot;last_name&quot;:&quot;Nguyen&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Meyring&quot;},{&quot;first_name&quot;:&quot;Justin&quot;,&quot;last_name&quot;:&quot;R. Potnick&quot;},{&quot;first_name&quot;:&quot;Dusica&quot;,&quot;last_name&quot;:&quot;Cvetinovic Santos&quot;},{&quot;first_name&quot;:&quot;Ralf&quot;,&quot;last_name&quot;:&quot;Schmidt&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;Sherer&quot;},{&quot;first_name&quot;:&quot;Adam&quot;,&quot;last_name&quot;:&quot;Shutes&quot;},{&quot;first_name&quot;:&quot;Klaus&quot;,&quot;last_name&quot;:&quot;Urbahns&quot;},{&quot;first_name&quot;:&quot;Ariele&quot;,&quot;last_name&quot;:&quot;Viacava Follis&quot;},{&quot;first_name&quot;:&quot;Ansgar&quot;,&quot;last_name&quot;:&quot;A. Wegener&quot;},{&quot;first_name&quot;:&quot;Simone&quot;,&quot;last_name&quot;:&quot;C. Zimmerli&quot;},{&quot;first_name&quot;:&quot;Lesley&quot;,&quot;last_name&quot;:&quot;Liu-Bujalski&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;01&quot;,&quot;issue&quot;:&quot;17&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;7643-7655&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00794&quot;},&quot;abstract&quot;:&quot;Bruton’s tyrosine kinase (BTK) inhibitors such as ibrutinib hold a prominent role in the treatment of B cell malignancies. However, further refinement is needed to this class of agents, particularly in terms of adverse events (potentially driven by kinase promiscuity), which preclude their evaluation in nononcology indications. Here, we report the discovery and preclinical characterization of evobrutinib, a potent, obligate covalent inhibitor with high kinase selectivity. Evobrutinib displayed sufficient preclinical pharmacokinetic and pharmacodynamic characteristics which allowed for in vivo evaluation in efficacy models. Moreover, the high selectivity of evobrutinib for BTK over epidermal growth factor receptor and other Tec family kinases suggested a low potential for off-target related adverse effects. Clinical investigation of evobrutinib is ongoing in several autoimmune diseases, including multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00794&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00794" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00794&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00794" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00794&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00794" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00794&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00794&amp;href=/doi/10.1021/acs.jmedchem.9b00794" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00794" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00794" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00794%26sid%3Dliteratum%253Aachs%26pmid%3D31368705%26genre%3Darticle%26aulast%3DCaldwell%26date%3D2019%26atitle%3DDiscovery%2Bof%2BEvobrutinib%253A%2BAn%2BOral%252C%2BPotent%252C%2Band%2BHighly%2BSelective%252C%2BCovalent%2BBruton%25E2%2580%2599s%2BTyrosine%2BKinase%2B%2528BTK%2529%2BInhibitor%2Bfor%2Bthe%2BTreatment%2Bof%2BImmunological%2BDiseases%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D17%26spage%3D7643%26epage%3D7655%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/17" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/jmcmar.2019.62.issue-17/20190912/jmcmar.2019.62.issue-17.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/medium/jm9b00794_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/large/jm9b00794_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00794&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Bruton’s tyrosine kinase (BTK) inhibitors such as ibrutinib hold a prominent role in the treatment of B cell malignancies. However, further refinement is needed to this class of agents, particularly in terms of adverse events (potentially driven by kinase promiscuity), which preclude their evaluation in nononcology indications. Here, we report the discovery and preclinical characterization of evobrutinib, a potent, obligate covalent inhibitor with high kinase selectivity. Evobrutinib displayed sufficient preclinical pharmacokinetic and pharmacodynamic characteristics which allowed for in vivo evaluation in efficacy models. Moreover, the high selectivity of evobrutinib for BTK over epidermal growth factor receptor and other Tec family kinases suggested a low potential for off-target related adverse effects. Clinical investigation of evobrutinib is ongoing in several autoimmune diseases, including multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68782" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68782" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Bruton’s tyrosine kinase (BTK) is a member of the Tec family of tyrosine kinases and is expressed in B cells, macrophages, and monocytes but not in T cells.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> BTK plays a crucial role in signaling through the B cell receptor (BCR) and the Fcγ receptor (FcγR) in B cells and myeloid cells, respectively.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Indeed, mutations in the human <i>Btk</i> gene can result in the B cell specific immunodeficiency, X-linked agammaglobulinemia, which is characterized by a block in pre-B cell differentiation; this leads to a lack of B cells and plasma cells and markedly reduced levels of serum immunoglobulins.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Likewise, <i>Btk</i> mutations in mice with X-linked immunodeficiency and targeted deletion of <i>Btk</i> in knockout mice result in defects in B cell development and proliferation.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> However, pharmacological inhibition of BTK has not resulted in depletion of B cells in preclinical models.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Consequently, BTK is considered a promising therapeutic target for the treatment of various diseases involving B cell and/or macrophage activation such as B cell malignancies, asthma, rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a></div><div class="NLM_p">The small molecule irreversible BTK inhibitor, ibrutinib, which covalently targets Cys481 within the ATP-binding pocket, is approved for the treatment of mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma, Waldenström’s macroglobulinemia, and marginal zone lymphoma, as well as graft versus host disease.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Ibrutinib demonstrated clinical efficacy in previously difficult-to-treat lymphomas such as treatment-resistant/refractory CLL.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> However, this first in class BTK inhibitor has also shown side effects, including bleeding, rash, diarrhea, and atrial fibrillation, which have been attributed, in part, to off-target kinase-inhibitory related effects on the epidermal growth factor receptor (EGFR) and other Tec family kinases.<a onclick="showRef(event, 'ref10 ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12 ref13">(10−13)</a></div><div class="NLM_p">With the aim of improving the overall tolerability of BTK inhibitors while maintaining the efficacy of ibrutinib, new BTK inhibitors are being developed that have more refined pharmacologic profiles.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Additionally, these agents are designed to circumvent the inhibitory effect of ibrutinib on antibody-dependent cell-mediated cytotoxicity, which may be important for the activity of other oncology therapies administered concomitantly with a BTK inhibitor.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> In 2017, acalabrutinib became the initial second-generation, covalent BTK inhibitor to be approved by the FDA for the treatment of MCL.<a onclick="showRef(event, 'ref9 ref14'); return false;" href="javascript:void(0);" class="ref ref9 ref14">(9,14)</a> However, for chronic autoimmune indications, clinical development progress has lagged behind that of oncology indications. Recently, there has been increased interest in the development of BTK inhibitors in the autoimmune/inflammatory arena.</div><div class="NLM_p last">Herein, we describe work which led to the identification of the potent and irreversibly covalent BTK<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> inhibitor, evobrutinib (<b>A18</b>, M2951), for the treatment of autoimmune diseases. Evobrutinib has excellent kinome selectivity, particularly against EGFR, an acceptable preclinical pharmacokinetic/pharmacodynamic (PK/PD) profile, and is efficacious in in vivo efficacy models of rheumatoid arthritis. Evobrutinib is being evaluated in clinical development for treatment of various immunological diseases.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00177" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00177" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Medicinal Chemistry Strategy</h3><div class="NLM_p">The target profile for a development candidate for chronic administration in autoimmune diseases included potency, high BTK kinase-selectivity, particularly against EGFR, and moderate clearance. It was hypothesized this profile would result in a low daily dose which should minimize the risk of liver damage; as covalent binding, combined with a high daily dose, has been reported to be linked to drug-induced liver injury.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><div class="NLM_p last">To achieve BTK potency and kinase selectivity simultaneously, we employed multiple strategies. First, it was desired to have an obligate type covalent inhibitor in which the covalent binding is essential for the potency of the molecule. Additionally, targeting Cys481 with a warhead to form a covalent bond enhances selectivity because only 10 other kinases, BLK, BMX, EGFR, ERBB2, ERBB4, ITK, JAK3, TEC, MKK7, and TXK, contain cysteine in the same region of the receptor. Finally, interaction with the gatekeeper Thr474 further increases selectivity as only 20% of all human kinases have threonine as a gatekeeper residue.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Identification of a Novel Hinge Binder</h3><div class="NLM_p">Work to identify suitable chemical starting points began with analysis of the X-ray crystal structure of <b>B43</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3gen">3gen</a>).<a onclick="showRef(event, 'ref18 ref20'); return false;" href="javascript:void(0);" class="ref ref18 ref20">(18,20)</a><b>B43</b> is a moderately potent inhibitor of BTK and occupies the ATP binding pocket of the BTK kinase domain. The amino-pyrimidine group, acting as a hinge binder, forms interactions with the gatekeeper residue Thr474 as well as backbone carbonyl and amide N interactions with Glu475 and Met477, respectively. The <i>O</i>-linked phenoxy phenyl group occupies the long and narrow selectivity pocket adjacent to gatekeeper Thr474, and the lipophilic cyclopentyl group sits in the ribose pocket, which is near Cys481, providing an indication of the proper vectors and angles for the desired covalent connection.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/medium/jm9b00794_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/large/jm9b00794_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. X-ray structure of BTK ligand <b>B43</b> bound to the BTK kinase domain.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/large/jm9b00794_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00794&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Structure–activity relationship (SAR) exploration focused on replacing the pyrrolopyrimidine of <b>B43</b> with other similarly substituted hinge binding moieties bearing aryl linkers appended with an acrylamide warhead. This work revealed that several hinge binding moieties were tolerated for potent BTK inhibitory activity (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The pyrimidine analogue <b>A3</b> showed excellent inhibition of BTK in a biochemical assay,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> while the removal of the 2-amino moiety led to nearly 10-fold loss in potency in compound <b>A4</b>. Pyridine analogue <b>A5</b> also showed excellent BTK inhibitory activity, and both <b>A3</b> and <b>A5</b> showed 25–30-fold more potent inhibition of BTK versus EGFR. However, <b>A5</b> had unacceptable activity in the hERG (human ether-a-go-go-related gene) channel assay (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00794/suppl_file/jm9b00794_si_001.pdf" class="ext-link">Supporting Information</a>). In contrast to <b>A3</b> and <b>A5</b>, pyrimidine analogues such as <b>A7</b>, with opposite orientation of the hinge binder, did not provide an acceptable ratio of inhibition of BTK over EGFR and were subsequently deprioritized. In addition, analysis of the crystal structures of <b>A5</b> and <b>A7</b> demonstrated that these hinge binders both achieve interactions in the identified hinge region while maintaining the critical vectors and angles required to effectively engage the back pocket and Cys481 as covalent BTK inhibitors (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Finally, attaching the linker to the hinge binder through an N atom as in compound <b>A8</b> also provided good inhibition of BTK but was equipotent at inhibiting EGFR. On the basis of these data, the amino-pyrimidine hinge binder with the amino moiety oriented adjacent to gatekeeper residue Thr474, as in A3 and A5, was selected for further exploration.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR for Hinge-Binder Optimization<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/medium/jm9b00794_0007.gif" alt="" id="GRAPHIC-d7e581-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/medium/jm9b00794_0008.gif" alt="" id="gr7" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">hERG, human ether-a-go-go-related gene; IC<sub>50</sub>, half-maximal inhibitory concentration; <i>K</i><sub>i</sub>, inhibitory constant; SAR, structure–activity relationship</p></div></div><div></div></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/medium/jm9b00794_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/large/jm9b00794_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Overlay of crystal structures of <b>A5</b> and <b>A7</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/large/jm9b00794_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00794&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Optimization of the Linker</h3><div class="NLM_p">Further characterization of the hit molecule <b>A3</b> showed that, although it demonstrated good potency in the human peripheral blood mononuclear cell (PBMC) assay<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> (IC<sub>50</sub> = 9.9 nM), this molecule had poor solubility (<2.4 μM) (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) and poor metabolic stability (high intrinsic clearance, Cl<sub>int</sub> = 277 μL/min/mg) in human liver microsomes. Subsequent efforts focused on modification of <b>A3</b> to improve solubility and metabolic stability. Preliminary SAR and X-ray cocrystal information suggested that the modification of the linker moiety might be amenable for addressing low solubility of the series. Replacing the flat aromatic ring in compound <b>A3</b> with a saturated moiety, such as the diamino cyclohexane ring in analogue <b>A9</b>, showed good improvement in solubility versus <b>A3</b> (134 vs 2.4 μM) and metabolic stability (Cl<sub>int</sub> = 27 vs 277 μL/min/mg), without significant loss in enzyme potency.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR for Linker Optimization<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/medium/jm9b00794_0009.gif" alt="" id="GRAPHIC-d7e653-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/medium/jm9b00794_0010.gif" alt="" id="gr8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Cl<sub>int</sub>, intrinsic clearance; HLM, human liver microsomes; PBMC, peripheral blood mononuclear cell</p></div></div><div></div></div><div class="NLM_p">Various saturated linkers were evaluated with the goal of improving potency in the enzymatic assay (<10 nM). Modifications such as moving the amino group around the cyclohexyl ring, changing the size of the ring or adding a bridge unit into the linker, maintained the high solubility, however, did not lead to any meaningful boost in potency for <b>A10</b>–<b>A12</b>. Continued exploration of the linker moiety showed that attachment of the linker to the hinge binding core via a secondary amine, such as in compound <b>A13</b>, was not tolerated. It was hypothesized that this substitution caused steric collision between the linker and the protons at the proximal phenyl ring, which altered the vector of the linker toward the Cys481. In contrast, analogue <b>A14</b>, with the reversed linker, was 220-fold more potent in enzymatic assay but suffered from a poor human microsomal stability. Additional exploration revealed that the pyrrolidine linker in <b>A15</b> was less well tolerated. Introduction of a spiral linker boosted the potency in molecule <b>A16</b>. Unfortunately, <b>A16</b> showed poor microsomal stability and an unacceptable hERG profile.</div><div class="NLM_p last">Shifting the N atom in <b>A14</b> as depicted in <b>A17</b> led to a more than 200-fold reduction in enzymatic potency (IC<sub>50</sub> 1510 nM for <b>A17</b> vs 6.5 nM for <b>A14</b>). Insertion of one methylene group into <b>A17</b> led to the discovery of <b>A18</b> (evobrutinib). Evobrutinib <b>A18</b> showed excellent potency in the biochemical and PBMC assays, favorable permeability in the Caco-2 assay, good solubility and microsomal stability, and acceptable hERG inhibition (see <a href="/doi/suppl/10.1021/acs.jmedchem.9b00794/suppl_file/jm9b00794_si_001.pdf" class="ext-link">Supporting Information</a> for assay methods). Finally, a hydroxyl group was added in molecule <b>A19</b> to reduce lipophilicity.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Back Pocket Optimization</h3><div class="NLM_p">Additional modifications directed to the back pocket to further improve microsomal stability of <b>A18</b> (evobrutinib) proved to be unsuccessful (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Substitutions at the proximal phenyl ring (<b>A20</b>,<b>A21</b>) resulted in a dramatic loss in potency on BTK inhibitory activity. No improvement in metabolic stability was observed from modifications of the distal phenyl ring (<b>A22</b>–<b>A25</b>). Only analogues <b>A23</b> and <b>A24</b> displayed similar BTK inhibition compared to <b>A18</b>, both with no obvious improvement in clearance. Subsequently, efforts to optimize the back pocket were not pursued further.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. SAR for Selectivity-Pocket Optimization (Proximal and Distal Ring Modifications)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/medium/jm9b00794_0011.gif" alt="" id="GRAPHIC-d7e762-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/medium/jm9b00794_0012.gif" alt="" id="gr9" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">BTK, Bruton’s tyrosine kinase; Cl<sub>int</sub>, intrinsic clearance; HLM, human liver microsomes; IC<sub>50</sub>, half-maximal inhibitory concentration.</p></div></div><div></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Warhead Optimization</h3><div class="NLM_p">Identification of an optimal warhead to engage the Cys481 residue was driven by the goal of designing an obligate covalent inhibitor of BTK. A diverse array of warheads was evaluated to optimize potency, reactivity, and plasma stability and to identify a suitable covalent inhibitor for further in vivo studies (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Analogues bearing an acrylamide warhead such as that of ibrutinib<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> displayed acceptable biochemical and cellular potency, as exemplified in analogue <b>A18</b>. Replacement of the acrylamide of <b>A18</b> by the acetamide moiety in compound <b>A27</b> resulted in an analogue with no significant BTK inhibitory activity, demonstrating the requirement of a warhead for efficient inhibition of BTK. Compounds such as <b>A28</b>–<b>A30</b>, bearing warheads that are theoretically highly reactive,<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> did show excellent enzyme inhibitory activity but suffered from unacceptable plasma stability. These results were attributed to the high reactivity of the warheads. It was speculated that these compounds were binding nonspecifically to cellular components before they were able to reach the target. Substitution with Michael acceptors that are theoretically less reactive than acrylamide<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> led to a decrease in BTK inhibitory activity compared to compound <b>A18</b>, as seen with analogue <b>A32</b>. On the basis of these data, compound <b>A18</b>, bearing an acrylamide warhead, possessed the optimal combination of potency, reactivity, and plasma stability to be selected for additional profiling.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. SAR for Warhead Optimization</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/medium/jm9b00794_0013.gif" alt="" id="GRAPHIC-d7e829-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/medium/jm9b00794_0014.gif" alt="" id="gr10" /></img><div></div></div><div class="NLM_p last">The obligatory nature of covalent inhibition with <b>A18</b> was further confirmed by comparing its activity with that of <b>A27</b> against a mutant BTK kinase domain with a cysteine to serine substitution, which resulted in a lack of covalent binding by either molecule. Both compounds inhibited the BTK mutant with similarly low potency (IC<sub>50</sub> 8.6–8.7 μM), reflecting their reversible affinities for the BTK kinase domain without any covalent binding. Thus, while <b>A27</b> showed minimal inhibitory activity regardless of Cys481 binding, the approximately 1000-fold increase in potency of <b>A18</b> against the wild-type BTK kinase domain demonstrated that its potency is derived from covalent engagement of Cys481. Both <b>A18</b> and <b>A19</b> were further characterized in PK/PD studies in mice.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> PK/PD Studies</h3><div class="NLM_p">To confirm whether the in vitro effects with <b>A18</b> and <b>A19</b> translated into B cell inhibition in vivo, these compounds were tested head-to-head in a B cell stimulation assay in normal C57BL/6 mice.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Both compounds were dosed at 1 mg/kg orally.</div><div class="NLM_p">Compound <b>A19</b> inhibited B cell activation by 42% and 15% at 1 and 24 h after dosing, respectively (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Compound <b>A18</b> (evobrutinib) achieved a greater B cell inhibition of 71% and 25% at 1 and 24 h. This was despite a lower maximum plasma concentration (<i>C</i><sub>max</sub>) of <b>A18</b> compared to <b>A19</b> (52 versus 257 nM). These data showed that <b>A18</b> was a more potent B cell inhibitor than <b>A19</b> in vivo.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/medium/jm9b00794_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/large/jm9b00794_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. PK/PD studies in mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/large/jm9b00794_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00794&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Synthesis of Evobrutinib (<b>A18</b>)</h3><div class="NLM_p">The synthesis of evobrutinib (<b>A18</b>) began with regioselective nucleophilic substitution of the 6-chloride of 5,6-dichloropyrimidin-4-amine by the primary amine of <i>tert</i>-butyl 4-(aminomethyl)piperidine-1-carboxylate, which led to generation of <i>tert</i>-butyl 4-{[(6-amino-5-chloropyrimidin-4-yl)amino]methyl}piperidine-1-carboxylate (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Subsequent Suzuki coupling of this chloropyrimidine intermediate with phenoxyphenylboronic acid yielded the molecule <i>tert</i>-butyl 4-({[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino}methyl)piperidine-1-carboxylate. Deprotection under acidic conditions and subsequent neutralization afforded the piperidine derivative 5-(4-phenoxy-phenyl)-<i>N</i>-piperidin-4-ylmethyl-pyrimidine-4,6-diamine. Finally, the acrylamide was introduced to give the target compound <i>N</i>-[(1-acryloylpiperidin-4-yl)methyl]-5-(4-phenoxyphenyl)pyrimidine-4,6-diamine (<b>A18</b>; evobrutinib; step d).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/medium/jm9b00794_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/large/jm9b00794_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Synthetic route for evobrutinib. (a) DBU, DMF, 90 °C, 91%; (b) 4-phenoxylphenyl boronic acid, Pd(OAc)<sub>2</sub>, <i>S</i>-phos, K<sub>2</sub>CO<sub>3</sub>, dioxane–H<sub>2</sub>O (10:1 v/v), 150 °C, 48%; (c) HCl, MeOH, rt; (d) acryloyl chloride, NaHCO<sub>3</sub>, H<sub>2</sub>O–THF (1:10, v/v), rt, 9%</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/large/jm9b00794_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00794&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Characterization of Evobrutinib: Biophysical Confirmation of Covalent, Irreversible Binding</h3><div class="NLM_p">Covalent binding to Cys481 is confirmed by analysis of the X-ray crystal structure of evobrutinib bound to the BTK kinase domain, showing continuous electron density between Cys481 and the evobrutinib warhead (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/medium/jm9b00794_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/large/jm9b00794_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Crystal structure of evobrutinib bound to the BTK kinase domain.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/large/jm9b00794_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00794&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Mass Spectrometry</h3><div class="NLM_p last">Reversed-phase (RP)–LC–MS analysis of intact BTK and BTK plus evobrutinib further confirmed the covalent nature of evobrutinib binding and indicated 1:1 stoichiometry (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00794/suppl_file/jm9b00794_si_001.pdf" class="ext-link">Figure S1</a> in the Supporting Information). Thus, evobrutinib is bound to only one cysteine residue on the BTK kinase domain. Orthogonal confirmation of evobrutinib–BTK covalent binding with 1:1 stoichiometry was also achieved by isothermal calorimetry (see <a href="/doi/suppl/10.1021/acs.jmedchem.9b00794/suppl_file/jm9b00794_si_001.pdf" class="ext-link">Figure S2</a> in the Supporting Information).</div></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Jump Dilution Assay</h3><div class="NLM_p last">BTK IC<sub>50</sub> was measured routinely for each compound to drive medicinal chemistry optimization. In addition, a jump dilution assay was used to qualitatively check the irreversible nature of key compounds (see <a href="/doi/suppl/10.1021/acs.jmedchem.9b00794/suppl_file/jm9b00794_si_001.pdf" class="ext-link">Supporting Information</a>). Lack of recovery of enzymatic activity was consistent with irreversible inhibition of BTK by evobrutinib (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.9b00794/suppl_file/jm9b00794_si_001.pdf" class="ext-link">Figure S3</a>). In general, time-dependent BTK IC<sub>50</sub> correlated well with the <i>K</i><sub>inact</sub>/<i>K</i><sub>i</sub> ratio (where <i>K</i><sub>i</sub> is the affinity of initial noncovalent binding, and <i>K</i><sub>inact</sub> is the maximum potential rate of enzyme inactivation), which represents the second-order rate constant for the reaction of evobrutinib with BTK (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00794/suppl_file/jm9b00794_si_001.pdf" class="ext-link">Figure S4</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.9b00794/suppl_file/jm9b00794_si_001.pdf" class="ext-link">Table S1</a> in the Supporting Information).<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div></div><div id="sec2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Evobrutinib Kinase Selectivity</h3><div class="NLM_p">The high kinase selectivity of evobrutinib is derived from multiple factors. Its obligate covalent binding to a rare cysteine residue and interaction with a unique threonine gatekeeper-mediated selectivity pocket in structurally related kinases accounts for much of the agent’s high kinase selectivity. For kinases with a similarly situated cysteine residue, selectivity can be explained by examination of the primary structure. The tyrosine kinase BMX, whose sequence identity is the most similar to that of BTK, presented an insurmountable challenge in achieving selectivity (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00794/suppl_file/jm9b00794_si_001.pdf" class="ext-link">Table S2</a> in the Supporting Information). The Tec kinase ITK also shares a high degree of homology to BTK but contains a bulky gatekeeper phenylalanine residue, which explains the higher observed selectivity of evobrutinib for BTK over ITK. Conversely, other cysteine containing kinases that are not inhibited by evobrutinib diverge more structurally from BTK, BMX, and ITK (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00794/suppl_file/jm9b00794_si_001.pdf" class="ext-link">Figure S5</a> in the Supporting Information).</div><div class="NLM_p">Evobrutinib’s selectivity for BTK over EGFR is explained by analysis of the global differences between the structures of the two cysteine-containing kinases. Upon binding to BTK, evobrutinib and ibrutinib resulted in a relatively small displacement of N- and C-lobes in relation to one another. On the other hand, EGFR showed a dramatic rearrangement in the N-lobe when targeted by ibrutinib (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00794/suppl_file/jm9b00794_si_001.pdf" class="ext-link">Figure S5</a> in the Supporting Information). It is hypothesized that the 1,3-disubstituted pattern on the piperidine ring in ibrutinib allows the warhead to rotate to adapt to kinases that move their N lobes.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> In contrast, the evobrutinib warhead is more constrained, having a 1,4-substitution on the piperidine linker and thus cannot accommodate kinases that upon binding rearrange their N lobe, such as EGFR. This is demonstrated in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>, which shows that selectivity for BTK over EGFR was lost in <b>A14</b> which, similar to ibrutinib, had a 1,3 attachment to the piperidine ring.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Selectivity of <b>A14</b> and Evobrutinib for BTK and EGFR</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/medium/jm9b00794_0015.gif" alt="" id="GRAPHIC-d7e1076-autogenerated" /></img><div></div></div><div class="NLM_p">The higher kinase selectivity of evobrutinib compared with ibrutinib is illustrated in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>. Ibrutinib inhibited seven Cys481-containing kinases compared with only two for evobrutinib. Unlike evobrutinib, ibrutinib does not require covalent binding for potency, as it showed only an approximately 10-fold reduction in potency against the Cys481S mutant compared to wild-type BTK. The ibrutinib scaffold, lacking the acrylamide warhead, showed similar potency toward BTK and comparable selectivity against 236 kinases tested.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Comparison of Evobrutinib and Ibrutinib Selectivity for BTK and Other Kinases</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">evobrutinib</th><th class="colsep0 rowsep0" align="center">ibrutinib</th><th class="colsep0 rowsep0" align="center">ibrutinib–no warhead</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BTK IC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">8.9</td><td class="colsep0 rowsep0" align="left">0.2</td><td class="colsep0 rowsep0" align="left">4.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BTK (Cys481S) KD IC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">8700</td><td class="colsep0 rowsep0" align="left">2.2</td><td class="colsep0 rowsep0" align="left">1.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">kinase selectivity at 1 μM (no. of kinases inhibited by >80%/total number of wild-type kinases tested)</td><td class="colsep0 rowsep0" align="left">2/233</td><td class="colsep0 rowsep0" align="left">17/236</td><td class="colsep0 rowsep0" align="left">18/236</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">no. of Cys481-containing kinases inhibited</td><td class="colsep0 rowsep0" align="left">2 (BMX, TEC)</td><td class="colsep0 rowsep0" align="left">7 (EGFR, ERBB4, BLK, BMX, TEC, TXK, ITK)</td><td class="colsep0 rowsep0" align="left">4 (BMX, TEC, BLK, TXK)</td></tr></tbody></table></div></div></div><div id="sec2_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Preclinical Pharmacokinetic Studies</h3><div class="NLM_p last">Evaluation of evobrutinib PK in mice, rats, and dogs indicated that evobrutinib is rapidly absorbed after oral administration, with <i>C</i><sub>max</sub> reached between 0.25 and 1 h (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00794/suppl_file/jm9b00794_si_001.pdf" class="ext-link">Table S3</a> in the Supporting Information). Evobrutinib demonstrated moderate clearance in mice and high clearance in rats and dogs. The plasma half-life was short (∼1 h) in all animal species. The oral bioavailability was low (<5% in rats) to moderate (up to 25% in mice) restricted by hepatic and possibly intestinal first-pass metabolism.</div></div><div id="sec2_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Activity of Evobrutinib in Collagen-Induced Arthritis</h3><div class="NLM_p">Evobrutinib was tested in a rat collagen-induced arthritis (CIA) model. Female Lewis rats with semiestablished type II collagen arthritis<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a> were treated once daily for 11 days (days 6–16) by oral gavage with vehicle (20% hydroxy-propyl-β-cyclodextrin in H<sub>2</sub>O), evobrutinib (0.3, 1, 3, 10, or 30 mg/kg), or the reference compound methotrexate (MTX, 0.1 mg/kg). Animals were terminated on study day 17. Efficacy evaluation was based on daily ankle caliper measurements and histopathologic evaluation of ankles and knees.</div><div class="NLM_p">Disease-induced ankle-swelling was significantly reduced (<i>P</i> ≤ 0.05) for rats treated with evobrutinib 3 mg/kg (days 11–17), 10 mg/kg (days 11–17), 30 mg/kg (days 10–17), or MTX (days 11–17), compared with vehicle (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A). Ankle histopathology scores were also reduced with evobrutinib in a dose-dependent manner compared to vehicle (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B). The IC<sub>50</sub> for evobrutinib was 5.180 mg/kg.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/medium/jm9b00794_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/large/jm9b00794_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Rat CIA model: rats treated with evobrutinib, MTX, or vehicle. (A) Ankle thickness, <i>n</i> = 4 for normal controls, <i>n</i> = 10 per treatment group; <i>P</i> ≤  0.05 ANOVA to vehicle control. (B) Histopathology score, <i>n</i> = 10 per treatment group; <i>P</i> ≤  0.05 ANOVA to vehicle control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/large/jm9b00794_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00794&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75851" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75851" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, we have described the discovery and preclinical characterization of evobrutinib (<b>A18</b>), a potent, obligate covalent BTK inhibitor with high kinase selectivity. Evobrutinib was derived from design and subsequent optimization of analogues based on the analysis of the crystal structure of the BTK inhibitor, <b>B43</b>. Evobrutinib displayed suitable preclinical pharmacokinetic and promising pharmacodynamic characteristics. Evobrutinib also demonstrated efficacy in a rat model of rheumatoid arthritis.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Moreover, the high selectivity of evobrutinib for BTK over EGFR and other Tec family kinases indicates that it may have a low potential for off-target related adverse effects. The results of ongoing clinical trials in various autoimmune diseases will enhance our understanding of the efficacy and safety of evobrutinib.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08214" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08214" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p"><sup>1</sup>H NMR experiments were recorded on a Varian 500 MHz VNMRS spectrometer equipped with a Varian One NMR probe, or a Bruker Avance III 400 MHz spectrometer equipped with a Bruker 400 BBO probe. Chemical shifts are expressed in δ ppm referenced to an internal standard, tetramethylsilane (δ = 0 ppm). All microwave reactions were conducted using the Biotage Initiator. All hydrogenation reactions were conducted using the H-Cube apparatus manufactured by ThalesNano. Abbreviations used in describing peak signals are br = broad signal, s = singlet, d = doublet, dd = doublet of doublets, t = triplet, q = quartet, m = multiplet. All final compounds were determined to have purity >95% by HPLC. The purity was assessed using an Agilent 1100 HPLC system (Agilent Technologies) with an XBridge column (C18, 3.5 μm, 4.6 mm × 50 mm). Mass spectra were recorded on an electrospray mass spectrometer (ES-MS) in electrospray ionization positive (ESI+) mode. High-resolution mass spectrometry (HRMS) experiments were performed on a CapLC (1100 series, Agilent Technologies) which was coupled to the Synapt G1 HDMS (Waters, Milford, MA) mass spectrometer using ESI as the ionization source.</div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Synthesis of <b>A3</b>, <b>A8</b>, <b>A9</b>, <b>A18</b> (Synthesis of <b>A4-A7</b>, <b>A10-A17</b>, and <b>A19-A31</b> As Shown in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b00794/suppl_file/jm9b00794_si_001.pdf" class="ext-link">Supporting Information</a>), and <i>N</i>-(3-{[6-Amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]oxy}phenyl)acrylamide (<b>A3</b>)</h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Step 1</h4><div class="NLM_p last">To a 20 mL microwave vial with stir bar, was added 5,6-dichloropyrimidin-4-amine (300.00 mg, 1.83 mmol), 3-aminophenol (0.30 g, 2.74 mmol; 1.50 equiv), and cesium carbonate (894.06 mg, 2.74 mmol), followed by <i>N</i>, <i>N</i>-dimethyl-acetamide (4.00 mL). The reaction mixture was run in a microwave at 150 °C for 1 h before it was filtered. The collected solution (6-(3-aminophenoxy)-5-chloropyrimidin-4-amine) was concentrated and carried to the next step without further purification. [ES-MS] (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>10</sub>H<sub>10</sub>ClN<sub>4</sub>O [M + H]<sup>+</sup> 237, found 237.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> Step 2</h4><div class="NLM_p last">To a microwave vial containing 6-(3-amino-phenoxy)-5-chloro-pyrimidin-4-ylamine (433.08 mg, 1.83 mmol), (4-phenoxyphenyl)boronic acid (450.42 mg, 2.10 mmol), and cesium carbonate (1311.78 mg, 4.03 mmol) was added dioxane (14 mL) and water (1.4 mL). The mixture was degassed for 5 min with N<sub>2</sub> before palladium(ii) acetate (20.54 mg, 0.09 mmol) and 2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl (75.13 mg, 0.18 mmol) were added. The reaction was microwaved at 150 °C for 90 min before it was filtered through a filtration funnel with a Celite pad. The collected solution was concentrated and purified by silica gel chromatography (28 g silica, ethyl acetate/methanol = 1/10) to give 6-(3-amino-phenoxy)-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamine (1.17g, 70% yield) as a yellow solid. [ES-MS] (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>19</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup> 371, found 371.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> Step 3</h4><div class="NLM_p last">To a 20 mL reaction vial, was added acrylic acid (0.01 mL, 0.12 mmol), bis(2-oxo-3-oxazolidinyl)phosphinic chloride (42.04 mg, 0.17 mmol), dioxane (3.00 mL), and <i>N</i>,<i>N</i>-diisopropylethylamine (0.07 mL, 0.41 mmol). The mixture was stirred at room temperature for 1 h before 6-(3-aminophenoxy)-5-(4-phenoxyphenyl) pyrimidin-4-amine (40.00 mg, 0.08 mmol) was added. The reaction was stirred at room temperature overnight. The reaction was stirred at room temperature for 12 h before it was concentrated and purified by silica gel chromatography (25 g Biotage silicon column, 50–100% ethyl acetate/hexane, then 0–40% methanol/ethyl acetate) to afford the title compound (<b>A3</b>) (7 mg, 20% yield) as a white solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 10.14 (s, 1 H), 8.00 (s, 1 H), 7.41 (s, 1 H), 7.36–7.30 (m, 5H), 7.22 (t, 1 H), 7.09 (t, 1 H), 7.03–7.01 (m, 4H), 6.71 (d, 1 H), 6.53 (broad s, 2H), 6.34 (dd, 1 H), 6.1 8 (d, 1 H), 5.69 (d, 1 H). [ES-MS] (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>21</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup> 425, found 425.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> <i>N</i>-{3-[6-Amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-acrylamide (<b>A8</b>)</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> Step 1</h4><div class="NLM_p last">Into a 20 mL vial was placed 5,6-dichloropyrimidin-4-amine (500 mg, 3.05 mmol) was added benzene-1,3-diamine (329.72 mg, 3.05 mmol) and a premade mixture of TFA:TEA (1:1 mol) (347.64 mg: 308.52 mg) dissolved in DMSO (6 mL). The mixture was heated at 90 °C overnight before it was purified by silica gel chromatography (25 g Biotage silicon column, 0–40% methanol/ethyl acetate) to afford <i>N</i>-4-(3-aminophenyl)-5-chloropyrimidine-4,6-diamine (591 mg, 82% yield) as a brown syrup. [ES-MS] (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>10</sub>H<sub>11</sub>ClN<sub>5</sub> [M + H]<sup>+</sup> 236, found 236.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> Step 2</h4><div class="NLM_p last">Into a 20 mL microwave vial was placed <i>N</i>-(3-amino-phenyl)-5-chloro-pyrimidine-4,6-diamine (200.00 mg, 0.85 mmol), (4-phenoxyphenyl)boronic acid (272.45 mg, 1.27 mmol), palladium acetate (9.53 mg, 0.04 mmol, 0.05 equiv), 2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl (34.84 mg, 0.08 mmol), and potassium carbonate (351.86 mg, 2.55 mmol) followed by dissolved dioxane (3.00 mL) and water (0.30 mL). The reaction was stirred at 150 °C for 3 h before it was concentrated and purified by silica gel chromatography (25 g, 80–100% EtOAc/hexanes, then 0–20% methanol/ethyl acetate) to afford the <i>N</i>-4-(3-aminophenyl)-5-(4-phenoxyphenyl)pyrimidine-4,6-diamine (167.90 mg, 54% yield) as a yellow solid. [ES-MS] (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>20</sub>N<sub>5</sub>O [M + H]<sup>+</sup> 370, found 370.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> Step 3</h4><div class="NLM_p last">In a vial was placed <i>N</i>-(3-amino-phenyl)-5-(4-phenoxy-phenyl)-pyrimidine-4,6-diamine (400.00 mg, 1.08 mmol) in DCM (10.00 mL, 156.01 mmol), ethyl-diisopropyl-amine (0.72 mL, 4.33 mmol, 4.00 equiv), acrylic acid (156.06 mg, 2.17 mmol), and 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide (1.28 mL, 4.33 mmol). The reaction was stirred at room temperature for 2 h before it was purified with prep-HPLC (38–42% acetonitrile in 0.1% NH<sub>4</sub>OH in H<sub>2</sub>O) to afford the title compound (<b>A8</b>) (166 mg, 36% yield) as a white solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 10.03 (s, 1 H), 8.08 (s, 1H), 7.73 (s, 1H), 7.32 (m, 2H), 7.27 (m, 3H), 7.17 (m, 8H), 6.45 (m, 1H), 6.25 (m, 1H), 5.73 (m, 3H). [ES-MS] (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>22</sub>N<sub>5</sub>O [M + H]<sup>+</sup> 424, found 424.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> <i>N</i>-(<i>cis</i>-(3-{[6-Amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino}cyclohexyl)prop-2-enamide (<b>A9</b>)</h3><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> Step 1</h4><div class="NLM_p last">Into a 20 mL vial was placed 5,6-dichloro-pyrimidin-4-ylamine (600.00 mg, 3.66 mmol), <i>cis</i>-<i>tert</i>-butyl <i>N</i>-(3-aminocyclohexyl)carbamate (940.89 mg, 2.20 mmol), and ethyl-diisopropyl-amine (1.91 mL, 10.98 mmol, 3.00 equiv) followed by NMP (6.00 mL). The reaction was stirred at 160 °C for 3 h before it was purified by silica gel chromatography (50 g, 30–80% ethyl acetate/hexanes) to afford <i>cis</i>-<i>tert</i>-butyl <i>N</i>-{3-[(6-amino-5-chloropyrimidin-4-yl)amino]cyclohexyl}carbamate (429.90 mg, 17.2% yield) as a yellow solid. [ES-MS] (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>15</sub>H<sub>25</sub>ClN<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 342, found 342</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Step 2</h4><div class="NLM_p last">Into a 20 mL microwave vial was placed <i>cis</i>-<i>tert</i>-butyl <i>N</i>-{3-[(6-amino-5-chloropyrimidin-4-yl)amino]cyclohexyl}carbamate (420.00 mg, 0.61 mmol, 1.00 equiv), 4-phenoxyphenyl)boronic acid (394.45 mg, 1.84 mmol), palladium acetate (13.79 mg, 0.06 mmol), 2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl (50.44 mg, 0.12 mmol), and potassium carbonate (509.42 mg, 3.69 mmol) followed by dioxane (4.00 mL) and water (0.40 mL). The reaction was heated for 3 h at 150 °C before it was purified by silica gel chromatography (25 g, 60–100% ethyl acetate/hexane, then 0–20% MeOH/EtOAc) to afford <i>cis-</i><i>tert</i>-butyl <i>N</i>-(3-{[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino}cyclohexyl)carbamate (399.00 mg, 68% yield) as a white solid. [ES-MS] (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>34</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 476, found 476.</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Step 3</h4><div class="NLM_p last">Into a 20 mL vial containing <i>cis</i>-<i>tert</i>-butyl <i>N</i>-(3-{[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino}cyclohexyl)carbamate (700.00 mg, 0.74 mmol), methanol (5.00 mL) was added hydrogen chloride (3.68 mL, 7.36 mmol) (2.0 M solution in Et<sub>2</sub>O). The reaction was stirred at room temperature for 12 h before it was concentrated and <i>cis</i>-<i>N</i>4-(3-aminocyclohexyl)-5-(4-phenoxyphenyl)pyrimidine-4,6-diamine was used in the next step without further purification. [ES-MS] (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>26</sub>N<sub>5</sub>O [M + H]<sup>+</sup> 376, found 376.</div></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> Step 4</h4><div class="NLM_p last">To a 20 mL vial was added <i>cis</i>-<i>N</i>4-(3-aminocyclohexyl)-5-(4-phenoxyphenyl)pyrimidine-4,6-diamine (550.00 mg, 0.73 mmol), sodium hydrogen carbonate (369.17 mg, 4.39 mmol) suspended in water (2.00 mL), THF (20.00 mL), and acryloyl chloride (0.15 mL, 1.83 mmol). The reaction was stirred at room temperature for 12 h before it was purified by silica gel chromatography (55 g KPNH silica, 0–100% methanol/ethyl acetate) to afford the title compound (<b>A9</b>) (40 mg, 13% yield) as a white solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 7.94 (m, 2H), 7.41 (m, 2H), 7.12 (m, 7H), 6.06 (m, 2H), 5.5 (m, 3H), 4.80 (d, <i>J</i> = 8 Hz, 1H), 3.92 (m, 1H), 3.61 (m, 1H), 1.95 (m, 1H), 1.70 (m, 3H), 1.25 (m, 1H), 1.07 (m, 3H). [ES-MS] (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>28</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 430, found 430.</div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> <i>N</i>-[(1-Acryloylpiperidin-4-yl)methyl]-5-(4-phenoxyphenyl)pyrimidine-4,6-diamine (<b>A18</b>)</h3><div id="sec4_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> Step 1</h4><div class="NLM_p last">A suspension of 5,6-dichloro-pyrimidin-4-ylamine (1.00 g, 6.10 mmol) in dry <i>N</i>,<i>N</i>-dimethylformamide (10 mL) was treated with 4-aminomethylpiperidine-1-carboxylic acid <i>tert</i>-butyl ester (1.62 mL, 7.62 mmol) followed by DBU (1.19 mL, 7.93 mmol). The contents were heated to 90 °C for 17 h (overnight). Water (2 mL) was then added to the reaction, and the resulting white suspension was stirred overnight. The solids were filtered and dried under high vacuum to give <i>tert</i>-butyl 4-{[(6-amino-5-chloropyrimidin-4-yl)amino]methyl}piperidine-1-carboxylate (1.90 g, 91.2%) as a white solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 7.81 (s, 1H), 6.66 (t, <i>J</i> = 4 Hz, 1H), 6.42 (s, 2H), 3.89 (d, <i>J</i> = 16 Hz, 2H), 3.23 (m, 2H), 2.66 (d, <i>J</i> = 4 Hz, 1H), 1.75 (m, 1H), 1.59 (d, <i>J</i> = 12 Hz, 2H), 1.39 (s, 9H), 1.0 (m, 2H). [ES-MS] (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>15</sub>H<sub>25</sub>ClN<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 342, found 342.</div></div><div id="sec4_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> Step 2</h4><div class="NLM_p last">Into a 20 mL microwave vial was placed <i>tert</i>-butyl 4-[(6-amino-5-chloropyrimidin-4-yl)amino]methylpiperidine-1-carboxylate (797.30 mg; 2.33 mmol), (4-phenoxyphenyl)boronic acid (748.79 mg, 3.50 mmol), palladium(ii) acetate (26.18 mg, 0.12 mmol), 2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl (95.75 mg, 0.23 mmol), potassium carbonate (967.03 mg, 7.00 mmol), dioxane (9.00 mL), and water (0.90 mL). The reaction was then heated in the microwave for 2 h at 150 °C. The reaction mixture was then filtered, then concentrated to dryness. The resulting residue was dissolved with DCM (2 mL) then purified by silica gel chromatography (50 g, 80–100% EtOAc/hexanes, then 0–40% MeOH/EtOAc) to give <i>tert</i>-butyl 4-({[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino}methyl)piperidine-1-carboxylate (534.6 mg, 48.2% yield). [ES-MS] (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>34</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 476, found 476.</div></div><div id="sec4_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Step 3</h4><div class="NLM_p last">Into a 20 mL vial containing 4-([6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]aminomethyl)piperidine-1-carboxylate (534.60 mg, 1.12 mmol, 1.00 equiv) methanol (4.00 mL) was added hydrogen chloride (5.62 mL, 11.24 mmol) (2.0 M solution in Et<sub>2</sub>O). The reaction was stirred at room temperature for 18 h. The reaction was then concentrated to dryness to give 5-(4-phenoxyphenyl)-<i>N</i>-(piperidin-4-ylmethyl)pyrimidine-4,6-diamine which was used without purification. [ES-MS] (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>26</sub>N<sub>5</sub>O [M + H]<sup>+</sup> 376, found 376.</div></div><div id="sec4_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> Step 4</h4><div class="NLM_p last">To a 20 mL vial was added 5-(4-phenoxyphenyl)-<i>N</i>-(piperidin-4-ylmethyl)pyrimidine-4,6-diamine (210.00 mg, 0.56 mmol, 1.00 equiv), sodium bicarbonate (70.48 mg, 0.84 mmol, 1.50 equiv), THF (8.00 mL, 98.74 mmol, 176.55 equiv), and water (0.80 mL, 44.41 mmol, 79.40 equiv). The mixture was cooled to 0 °C on an ice bath. Acryloyl chloride (0.15 mL, 1.83 mmol) was then added dropwise. The ice bath was removed, and the reaction was stirred at room temperature for 12 h before it was purified by silica gel chromatography (25 g KPNH silica, 0–100% methanol/ethyl acetate) to afford the title compound (<b>A18</b>) (21 mg, 8.7% yield) was synthesized with a similar protocol to prepared as described in the main body of the article. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 7.93 (s, 1 H), 7.40–7.08 (m, 9H), 6.76 (dd, <i>J</i> = 4 Hz, 1 H), 6.04 (d, <i>J</i> = 4 Hz, 1 H), 5.61 (d, <i>J</i> = 4 Hz, 1 H), 5.43 (s, 2H), 4.34 (d, <i>J</i> = 12 Hz, 1 H), 3.98 (d, <i>J</i> = 8 Hz, 1 H), 3.12 (m, 2H), 2.95 (m, 1 H), 2.56 (m, 1 H), 1.81 (m, 1 H), 1.59 (m, 2H), 0.92 (m, 2H). [ES-MS] (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>28</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 430, found 430.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i43"><a href="/doi/suppl/10.1021/acs.jmedchem.9b00794" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35574" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35574" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b00794" class="ext-link">10.1021/acs.jmedchem.9b00794</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Assay details; mass spectrometry; isothermal calorimetry; jump dilution assay; kinase selectivity; animal studies; preclinical PK studies; synthesis of compounds <b>A4</b>–<b>A7</b>, <b>A10</b>–<b>A17</b>, <b>A19</b>; synthesis of compounds <b>A20</b>–<b>A26</b>; synthesis of compounds <b>A27</b>–<b>A31</b>; references and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00794/suppl_file/jm9b00794_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00794/suppl_file/jm9b00794_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00794/suppl_file/jm9b00794_si_001.pdf">jm9b00794_si_001.pdf (1.08 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00794/suppl_file/jm9b00794_si_002.csv">jm9b00794_si_002.csv (2.83 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDBs <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3gen">3gen</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5p9j">5p9j</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5yu9">5yu9</a>]. Authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.9b00794" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60315" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60315" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard D. Caldwell</span> - <span class="hlFld-Affiliation affiliation">EMD Serono Research & Development Institute, Inc.
(a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#61130802090013054f02000d0516040d0d21040c051204130e0f0e4f020e0c"><span class="__cf_email__" data-cfemail="92e0fbf1faf3e0f6bcf1f3fef6e5f7fefed2f7fff6e1f7e0fdfcfdbcf1fdff">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hui Qiu</span> - <span class="hlFld-Affiliation affiliation">EMD Serono Research & Development Institute, Inc.
(a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#8ce4f9e5a2fde5f9cce9e1e8ffe9fee3e2e3a2efe3e1"><span class="__cf_email__" data-cfemail="f8908d91d689918db89d959c8b9d8a979697d69b9795">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ben C. Askew</span> - <span class="hlFld-Affiliation affiliation">EMD Serono Research & Development Institute, Inc.
(a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</span>; 
    <span>Present Address:
                        B.C.A.: Breakthrough Chemistry Advisors, 266 Arrowhead Road, Marshfield, Massachusetts 02050, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew T. Bender</span> - <span class="hlFld-Affiliation affiliation">EMD Serono Research & Development Institute, Inc.
(a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nadia Brugger</span> - <span class="hlFld-Affiliation affiliation">EMD Serono Research & Development Institute, Inc.
(a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Montserrat Camps</span> - <span class="hlFld-Affiliation affiliation">EMD Serono Research & Development Institute, Inc.
(a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</span>; 
    <span>Present Address:
                        M.C.: 45 Chemin de Cazers Bas, 81100 Castres, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mohanraj Dhanabal</span> - <span class="hlFld-Affiliation affiliation">EMD Serono Research & Development Institute, Inc.
(a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vikram Dutt</span> - <span class="hlFld-Affiliation affiliation">EMD Serono Research & Development Institute, Inc.
(a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas Eichhorn</span> - <span class="hlFld-Affiliation affiliation">EMD Serono Research & Development Institute, Inc.
(a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anna S. Gardberg</span> - <span class="hlFld-Affiliation affiliation">EMD Serono Research & Development Institute, Inc.
(a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</span>; 
    <span>Present Address:
                        A.S.G.: Constellation Pharmaceuticals, 215 First Street, Suite 200, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andreas Goutopoulos</span> - <span class="hlFld-Affiliation affiliation">EMD Serono Research & Development Institute, Inc.
(a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Roland Grenningloh</span> - <span class="hlFld-Affiliation affiliation">EMD Serono Research & Development Institute, Inc.
(a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jared Head</span> - <span class="hlFld-Affiliation affiliation">EMD Serono Research & Development Institute, Inc.
(a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian Healey</span> - <span class="hlFld-Affiliation affiliation">EMD Serono Research & Development Institute, Inc.
(a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</span>; 
    <span>Present Address:
                        B.H.: UMass Boston—Venture Development Center, 100 Morrissey Boulevard, Boston, Massachusetts 02125, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian L. Hodous</span> - <span class="hlFld-Affiliation affiliation">EMD Serono Research & Development Institute, Inc.
(a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</span>; 
    <span>Present Address:
                        B.L.H.: Accent Therapeutics, 65 Hayden Avenue, Lexington, Cambridge, MA 02421, USA</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bayard R. Huck</span> - <span class="hlFld-Affiliation affiliation">EMD Serono Research & Development Institute, Inc.
(a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Theresa L. Johnson</span> - <span class="hlFld-Affiliation affiliation">EMD Serono Research & Development Institute, Inc.
(a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher Jones</span> - <span class="hlFld-Affiliation affiliation">EMD Serono Research & Development Institute, Inc.
(a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Reinaldo C. Jones</span> - <span class="hlFld-Affiliation affiliation">EMD Serono Research & Development Institute, Inc.
(a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Igor Mochalkin</span> - <span class="hlFld-Affiliation affiliation">EMD Serono Research & Development Institute, Inc.
(a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</span>; 
    <span>Present Address:
                        I.M.: Vertex Pharmaceuticals, 3215 Merryfield Row, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Federica Morandi</span> - <span class="hlFld-Affiliation affiliation">EMD Serono Research & Development Institute, Inc.
(a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</span>; 
    <span>Present Address:
                        F.M.: Roche Innovation Centre Basel, Pharma Research and Early Development, Hoffmann La Roche, Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ngan Nguyen</span> - <span class="hlFld-Affiliation affiliation">EMD Serono Research & Development Institute, Inc.
(a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</span>; 
    <span>Present Address:
                        N.N.: Advanced Instruments, LLC., Two Technology Way, Norwood, Massachusetts 02062, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Meyring</span> - <span class="hlFld-Affiliation affiliation">EMD Serono Research & Development Institute, Inc.
(a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</span>; 
    <span>Present Address:
                        M.M.: Nuvisan GmbH, Site Grafing, Am Feld 32, 85567 Grafing, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Justin R. Potnick</span> - <span class="hlFld-Affiliation affiliation">EMD Serono Research & Development Institute, Inc.
(a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dusica Cvetinovic Santos</span> - <span class="hlFld-Affiliation affiliation">EMD Serono Research & Development Institute, Inc.
(a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ralf Schmidt</span> - <span class="hlFld-Affiliation affiliation">EMD Serono Research & Development Institute, Inc.
(a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian Sherer</span> - <span class="hlFld-Affiliation affiliation">EMD Serono Research & Development Institute, Inc.
(a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Adam Shutes</span> - <span class="hlFld-Affiliation affiliation">EMD Serono Research & Development Institute, Inc.
(a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</span>; 
    <span>Present Address:
                        A.S.: Boston Cheese Cellar, 8 Birch St, Roslindale, Massachusetts 02131, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Klaus Urbahns</span> - <span class="hlFld-Affiliation affiliation">EMD Serono Research & Development Institute, Inc.
(a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ariele Viacava Follis</span> - <span class="hlFld-Affiliation affiliation">EMD Serono Research & Development Institute, Inc.
(a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ansgar A. Wegener</span> - <span class="hlFld-Affiliation affiliation">EMD Serono Research & Development Institute, Inc.
(a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Simone C. Zimmerli</span> - <span class="hlFld-Affiliation affiliation">EMD Serono Research & Development Institute, Inc.
(a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lesley Liu-Bujalski</span> - <span class="hlFld-Affiliation affiliation">EMD Serono Research & Development Institute, Inc.
(a Business of Merck KGaA, Darmstadt, Germany), 45 A Middlesex Turnpike, Billerica, Massachusetts 01821, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): All authors are or were employees of EMD Serono (a business of Merck KGaA, Darmstadt, Germany) at the time that the work was conducted.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i56">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30425" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30425" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Dr Momar Toure and Dr Shashank Kulkarni from EMD Serono for their guidance in drafting and reviewing the manuscript. Medical writing support was provided by Fiona Scott, Ph.D., Bioscript Science, Macclesfield, UK, and funded by Merck KGaA, Darmstadt, Germany. The manuscript was written in accordance with Good Publication Practice (GPP3) guidelines (<a href="http://www.ismpp.org/gpp3" class="extLink">http://www.ismpp.org/gpp3</a>). This work was funded by EMD Serono Inc. (a business of Merck KGaA, Darmstadt, Germany).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">BCR</td><td class="NLM_def"><p class="first last">B cell receptor</p></td></tr><tr><td class="NLM_term">BTK</td><td class="NLM_def"><p class="first last">Bruton’s tyrosine kinase</p></td></tr><tr><td class="NLM_term">Cl<sub>int</sub></td><td class="NLM_def"><p class="first last">intrinsic clearance</p></td></tr><tr><td class="NLM_term">CLL</td><td class="NLM_def"><p class="first last">chronic lymphocytic leukemia</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximum plasma concentration</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">ES-MS</td><td class="NLM_def"><p class="first last">electrospray-mass spectrometer</p></td></tr><tr><td class="NLM_term">FcγR</td><td class="NLM_def"><p class="first last">Fc-gamma receptor</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-a-go-go-related gene</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsomes</p></td></tr><tr><td class="NLM_term">HRMS</td><td class="NLM_def"><p class="first last">high-resolution mass spectrometer</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">half-maximal inhibitory concentration</p></td></tr><tr><td class="NLM_term"><i>K</i><sub>i</sub></td><td class="NLM_def"><p class="first last">inhibitory constant</p></td></tr><tr><td class="NLM_term">MCL</td><td class="NLM_def"><p class="first last">mantle cell lymphoma</p></td></tr><tr><td class="NLM_term">PBMC</td><td class="NLM_def"><p class="first last">peripheral blood mononuclear cell</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pharmacodynamic</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i58">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37207" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37207" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 27 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, T.</span></span> <span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase is involved in innate and adaptive immunity</span>. <i>Histol. Histopathol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">945</span>– <span class="NLM_lpage">955</span>, <span class="refDoi"> DOI: 10.14670/HH-20.945</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.14670%2FHH-20.945" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=15944945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpsFKjtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2005&pages=945-955&author=C.+Brunnerauthor=B.+Mullerauthor=T.+Wirth&title=Bruton%E2%80%99s+tyrosine+kinase+is+involved+in+innate+and+adaptive+immunity&doi=10.14670%2FHH-20.945"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's Tyrosine Kinase is involved in innate and adaptive immunity</span></div><div class="casAuthors">Brunner, C.; Mueller, B.; Wirth, T.</div><div class="citationInfo"><span class="NLM_cas:title">Histology and Histopathology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">945-955</span>CODEN:
                <span class="NLM_cas:coden">HIHIES</span>;
        ISSN:<span class="NLM_cas:issn">0213-3911</span>.
    
            (<span class="NLM_cas:orgname">Jimenez Godoy, S.A.</span>)
        </div><div class="casAbstract">A review.  Btk is a cytoplasmic tyrosine kinase, which is mainly involved in B cell receptor signaling.  Gene targeting expts. revealed that Btk is important for B cell development and function.  However, Btk is not only expressed in B cells, but also in most other hematopoietic lineages except for T cells and plasma cells.  Recently we found that Btk is involved in Toll-like receptor signaling.  Toll-like receptors play an important role in innate immunity.  They are highly expressed on mast cells, macrophages and dendritic cells, which are essential for the recognition and consequently for the elimination of microbial pathogens.  Therefore Btk might play an important role for the function of immunocompetent cells of innate as well as adaptive immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQA-9NFdeNr7Vg90H21EOLACvtfcHk0lj_XyGTgBLFew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpsFKjtL4%253D&md5=97cbcc5df2704d4b58933085ab8ff929</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.14670%2FHH-20.945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14670%252FHH-20.945%26sid%3Dliteratum%253Aachs%26aulast%3DBrunner%26aufirst%3DC.%26aulast%3DMuller%26aufirst%3DB.%26aulast%3DWirth%26aufirst%3DT.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520is%2520involved%2520in%2520innate%2520and%2520adaptive%2520immunity%26jtitle%3DHistol.%2520Histopathol.%26date%3D2005%26volume%3D20%26spage%3D945%26epage%3D955%26doi%3D10.14670%2FHH-20.945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Satterthwaite, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, O. N.</span></span> <span> </span><span class="NLM_article-title">Btk function in B cell development and response</span>. <i>Semin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">316</span>, <span class="refDoi"> DOI: 10.1006/smim.1998.0123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.1006%2Fsmim.1998.0123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=9695187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADyaK1cXltlCiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1998&pages=309-316&author=A.+B.+Satterthwaiteauthor=Z.+Liauthor=O.+N.+Witte&title=Btk+function+in+B+cell+development+and+response&doi=10.1006%2Fsmim.1998.0123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Btk function in B cell development and response</span></div><div class="casAuthors">Satterthwaite, Anne B.; Li, Zuomei; Witte, Owen N.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Immunology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">309-316</span>CODEN:
                <span class="NLM_cas:coden">SEIME2</span>;
        ISSN:<span class="NLM_cas:issn">1044-5323</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">A review with 85 refs.  Mutations in Bruton's tyrosine kinase (Btk) result in the B cell immunodeficiencies XLA (X-linked agammaglobulinemia) in humans and Xid (X-linked immunodeficiency) in mice.  Both the maintenance of peripheral B cell nos. and their response to B cell antigen receptor (BCR) crosslinking depend on Btk.  Btk integrates signals from multiple cell surface receptors, including BCR and G-protein coupled receptors.  These Btk dependent signals control B cell proliferation and survival by mediating Ca2+ flux, activating JNK and p38 and inducing cell cycle regulatory genes.  (c) 1998 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVrVOyUeT25bVg90H21EOLACvtfcHk0lj_XyGTgBLFew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXltlCiuro%253D&md5=f03605bc9f39d663d28794c7b7e40138</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1006%2Fsmim.1998.0123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fsmim.1998.0123%26sid%3Dliteratum%253Aachs%26aulast%3DSatterthwaite%26aufirst%3DA.%2BB.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26atitle%3DBtk%2520function%2520in%2520B%2520cell%2520development%2520and%2520response%26jtitle%3DSemin.%2520Immunol.%26date%3D1998%26volume%3D10%26spage%3D309%26epage%3D316%26doi%3D10.1006%2Fsmim.1998.0123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabuchi, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Astrakhan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humblet-Baron, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kipp, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chae, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellmeier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, O. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawlings, D. J.</span></span> <span> </span><span class="NLM_article-title">Sustained correction of B-cell development and function in a murine model of X-linked agammaglobulinemia (XLA) using retroviral-mediated gene transfer</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">1281</span>– <span class="NLM_lpage">1290</span>, <span class="refDoi"> DOI: 10.1182/blood-2003-09-3044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.1182%2Fblood-2003-09-3044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=15142874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnt1ekurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2004&pages=1281-1290&author=P.+W.+Yuauthor=R.+S.+Tabuchiauthor=R.+M.+Katoauthor=A.+Astrakhanauthor=S.+Humblet-Baronauthor=K.+Kippauthor=K.+Chaeauthor=W.+Ellmeierauthor=O.+N.+Witteauthor=D.+J.+Rawlings&title=Sustained+correction+of+B-cell+development+and+function+in+a+murine+model+of+X-linked+agammaglobulinemia+%28XLA%29+using+retroviral-mediated+gene+transfer&doi=10.1182%2Fblood-2003-09-3044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Sustained correction of B-cell development and function in a murine model of X-linked agammaglobulinemia (XLA) using retroviral-mediated gene transfer</span></div><div class="casAuthors">Yu, Phyllis W.; Tabuchi, Ruby S.; Kato, Roberta M.; Astrakhan, Alexander; Humblet-Baron, Stephanie; Kipp, Kevin; Chae, Keun; Ellmeier, Wilfried; Witte, Owen N.; Rawlings, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1281-1290</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">X-linked agammaglobulinemia (XLA) is a human immunodeficiency caused by mutations in Bruton tyrosine kinase (Btk) and characterized by an arrest in early B-cell development, near absence of serum Ig, and recurrent bacterial infections.  Using Btk- and Tec-deficient mice (BtkTec-/-) as a model for XLA, the authors detd. if Btk gene therapy could correct this disorder.  Bone marrow (BM) from 5-fluorouracil (5FU)-treated BtkTec-/- mice was transduced with a retroviral vector expressing human Btk and transplanted into BtkTec-/- recipients.  Mice engrafted with transduced hematopoietic cells exhibited rescue of both primary and peripheral B-lineage development, recovery of peritoneal B1 B cells, and correction of serum IgM and IgG3 levels.  Gene transfer also restored T-independent type II immune responses, and B-cell antigen receptor (BCR) proliferative responses.  B-cell progenitors derived from Btk-transduced stem cells exhibited higher levels of Btk expression than non-B cells; and marking studies demonstrated a selective advantage for Btk-transduced B-lineage cells.  BM derived from primary recipients also rescued Btk-dependent function in secondary hosts that had received a transplant.  Together, these data demonstrate that gene transfer into hematopoietic stem cells can reconstitute Btk-dependent B-cell development and function in vivo, and strongly support the feasibility of pursuing Btk gene transfer for XLA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWU45QAUL06rVg90H21EOLACvtfcHk0lj_XyGTgBLFew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnt1ekurY%253D&md5=579ecc97f831b699fddb4cc2b8a3ddb9</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1182%2Fblood-2003-09-3044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2003-09-3044%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DP.%2BW.%26aulast%3DTabuchi%26aufirst%3DR.%2BS.%26aulast%3DKato%26aufirst%3DR.%2BM.%26aulast%3DAstrakhan%26aufirst%3DA.%26aulast%3DHumblet-Baron%26aufirst%3DS.%26aulast%3DKipp%26aufirst%3DK.%26aulast%3DChae%26aufirst%3DK.%26aulast%3DEllmeier%26aufirst%3DW.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26aulast%3DRawlings%26aufirst%3DD.%2BJ.%26atitle%3DSustained%2520correction%2520of%2520B-cell%2520development%2520and%2520function%2520in%2520a%2520murine%2520model%2520of%2520X-linked%2520agammaglobulinemia%2520%2528XLA%2529%2520using%2520retroviral-mediated%2520gene%2520transfer%26jtitle%3DBlood%26date%3D2004%26volume%3D104%26spage%3D1281%26epage%3D1290%26doi%3D10.1182%2Fblood-2003-09-3044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, W. N.</span></span> <span> </span><span class="NLM_article-title">Regulation of B lymphocyte development and activation by Bruton’s tyrosine kinase</span>. <i>Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">147</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1385/IR:23:2-3:147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.1385%2FIR%3A23%3A2-3%3A147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=11444380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltFWqsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2001&pages=147-156&author=W.+N.+Khan&title=Regulation+of+B+lymphocyte+development+and+activation+by+Bruton%E2%80%99s+tyrosine+kinase&doi=10.1385%2FIR%3A23%3A2-3%3A147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase</span></div><div class="casAuthors">Khan, Wasif N.</div><div class="citationInfo"><span class="NLM_cas:title">Immunologic Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2 & 3</span>),
    <span class="NLM_cas:pages">147-156</span>CODEN:
                <span class="NLM_cas:coden">IMRSEB</span>;
        ISSN:<span class="NLM_cas:issn">0257-277X</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">A review discussed the role of Bruton's tyrosine kinase in B lymphocyte development and activation.  The generation and maintenance of B lymphocytes is controlled by biochem. signals transmitted by the B cell antigen receptor (BCR) complex.  These signals are transduced by multiple cytoplasmic protein tyrosine kinases (PTKs) including Lyn, Syk, and Bruton's tyrosine kinase (BTK).  Upon BCR engagement, these PTKs activate downstream effectors, including transcription factors that modulate gene expression.  In turn, activation of downstream effectors is crit. for B cell survival, cell cycle progression, and antibody prodn.  Our studies focus on the role of BTK in these biol. responses.  We have discovered that BTK is required for activation of the BCR-responsive transcription factor, NF-κB.  Furthermore, BTK-dependent activation of NF-κB is essential for reprogramming the expression of genes that control B cell survival and proliferation.  The biochem. mechanisms by which BTK regulates signaling components that activate NF-κB, and the identification of BTK-responsive genes are under investigation.  Elucidation of these regulatory mechanisms is expected to reveal new therapeutic targets for B cell pathologies involving defects in BTK, including X-linked agammaglobulinemia (XLA).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx0btKIFSX9LVg90H21EOLACvtfcHk0lhEcp0LFQxKcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltFWqsb0%253D&md5=564d950f06ab14daff2b45f5a3d863f4</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1385%2FIR%3A23%3A2-3%3A147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1385%252FIR%253A23%253A2-3%253A147%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DW.%2BN.%26atitle%3DRegulation%2520of%2520B%2520lymphocyte%2520development%2520and%2520activation%2520by%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DImmunol.%2520Res.%26date%3D2001%26volume%3D23%26spage%3D147%26epage%3D156%26doi%3D10.1385%2FIR%3A23%3A2-3%3A147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nyhoff, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barron, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonami, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kendall, P. L.</span></span> <span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase is not essential for B cell survival beyond early developmental stages</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>200</i></span>,  <span class="NLM_fpage">2352</span>– <span class="NLM_lpage">2361</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1701489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.4049%2Fjimmunol.1701489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=29483358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltFSltbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=200&publication_year=2018&pages=2352-2361&author=L.+E.+Nyhoffauthor=E.+S.+Clarkauthor=B.+L.+Barronauthor=R.+H.+Bonamiauthor=W.+N.+Khanauthor=P.+L.+Kendall&title=Bruton%E2%80%99s+tyrosine+kinase+is+not+essential+for+B+cell+survival+beyond+early+developmental+stages&doi=10.4049%2Fjimmunol.1701489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's Tyrosine Kinase Is Not Essential for B Cell Survival beyond Early Developmental Stages</span></div><div class="casAuthors">Nyhoff, Lindsay E.; Clark, Emily S.; Barron, Bridgette L.; Bonami, Rachel H.; Khan, Wasif N.; Kendall, Peggy L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">200</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2352-2361</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a crucial regulator of B cell signaling and is a therapeutic target for lymphoma and autoimmune disease.  BTK-deficient patients suffer from humoral immunodeficiency, as their B cells fail to progress beyond the bone marrow.  However, the role of Btk in fully developed, mature peripheral B cells is not well understood.  Anal. using BTK inhibitors is complicated by suboptimal inhibition, off-target effects, or failure to eliminate BTK's adaptor function.  Therefore a Btkflox/Cre-ERT2 mouse model was developed and used to excise Btk after B cell populations were established.  Mice lacking Btk from birth are known to have reduced follicular (FO) compartments, with expanded transitional populations, suggesting a block in development.  In adult Btkflox/Cre-ERT2 mice, Btk excision did not reduce FO B cells, which persisted for weeks.  Autoimmune-prone B1 cells also survived conditional Btk excision, contrasting their near absence in global Btk-deficient mice.  Therefore, Btk supports BCR signaling during selection into the FO and B1 compartments, but is not needed to maintain these cell populations.  B1-related natural IgM levels remained normal, contrasting global Btk deficiency, but B cell proliferation and T-independent type II immunization responses were blunted.  Thus, B cells have nuanced signaling responses that are differentially regulated by Btk for development, survival, and function.  These findings raise the possibility that Btk may also be expendable for survival of mature human B cells, therefore requiring prolonged dosing to be effective, and that success of BTK inhibitors may depend in part on off-target effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoP6akmBuHl2bVg90H21EOLACvtfcHk0lhEcp0LFQxKcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltFSltbo%253D&md5=c1e633a39d298ce08a70906db3ad577c</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1701489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1701489%26sid%3Dliteratum%253Aachs%26aulast%3DNyhoff%26aufirst%3DL.%2BE.%26aulast%3DClark%26aufirst%3DE.%2BS.%26aulast%3DBarron%26aufirst%3DB.%2BL.%26aulast%3DBonami%26aufirst%3DR.%2BH.%26aulast%3DKhan%26aufirst%3DW.%2BN.%26aulast%3DKendall%26aufirst%3DP.%2BL.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520is%2520not%2520essential%2520for%2520B%2520cell%2520survival%2520beyond%2520early%2520developmental%2520stages%26jtitle%3DJ.%2520Immunol.%26date%3D2018%26volume%3D200%26spage%3D2352%26epage%3D2361%26doi%3D10.4049%2Fjimmunol.1701489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balazs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barck, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carano, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeForge, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrando, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallion, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannetti, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribling, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciejewski, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staker, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span> <span> </span><span class="NLM_article-title">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1038/nchembio.481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.1038%2Fnchembio.481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=21113169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=41-50&author=J.+A.+Di+Paoloauthor=T.+Huangauthor=M.+Balazsauthor=J.+Barbosaauthor=K.+H.+Barckauthor=B.+J.+Bravoauthor=R.+A.+Caranoauthor=J.+Darrowauthor=D.+R.+Daviesauthor=L.+E.+DeForgeauthor=L.+Diehlauthor=R.+Ferrandoauthor=S.+L.+Gallionauthor=A.+M.+Giannettiauthor=P.+Griblingauthor=V.+Hurezauthor=S.+G.+Hymowitzauthor=R.+Jonesauthor=J.+E.+Kropfauthor=W.+P.+Leeauthor=P.+M.+Maciejewskiauthor=S.+A.+Mitchellauthor=H.+Rongauthor=B.+L.+Stakerauthor=J.+A.+Whitneyauthor=S.+Yehauthor=W.+B.+Youngauthor=C.+Yuauthor=J.+Zhangauthor=K.+Reifauthor=K.+S.+Currie&title=Specific+Btk+inhibition+suppresses+B+cell-+and+myeloid+cell-mediated+arthritis&doi=10.1038%2Fnchembio.481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span></div><div class="casAuthors">Di Paolo, Julie A.; Huang, Tao; Balazs, Mercedesz; Barbosa, James; Barck, Kai H.; Bravo, Brandon J.; Carano, Richard A. D.; Darrow, James; Davies, Douglas R.; DeForge, Laura E.; Diehl, Lauri; Ferrando, Ronald; Gallion, Steven L.; Giannetti, Anthony M.; Gribling, Peter; Hurez, Vincent; Hymowitz, Sarah G.; Jones, Randall; Kropf, Jeffrey E.; Lee, Wyne P.; Maciejewski, Patricia M.; Mitchell, Scott A.; Rong, Hong; Staker, Bart L.; Whitney, J. Andrew; Yeh, Sherry; Young, Wendy B.; Yu, Christine; Zhang, Juan; Reif, Karin; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-50</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a therapeutic target for rheumatoid arthritis, but the cellular and mol. mechanisms by which Btk mediates inflammation are poorly understood.  Here we describe the discovery of CGI1746, a small-mol. Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation.  CGI1746 has exquisite selectivity for Btk and inhibits both auto- and transphosphorylation steps necessary for enzyme activation.  Using CGI1746, we demonstrate that Btk regulates inflammatory arthritis by two distinct mechanisms.  CGI1746 blocks B cell receptor-dependent B cell proliferation and in prophylactic regimens reduces autoantibody levels in collagen-induced arthritis.  In macrophages, Btk inhibition abolishes FcγRIII-induced TNFα, IL-1β and IL-6 prodn.  Accordingly, in myeloid- and FcγR-dependent autoantibody-induced arthritis, CGI1746 decreases cytokine levels within joints and ameliorates disease.  These results provide new understanding of the function of Btk in both B cell- or myeloid cell-driven disease processes and provide a compelling rationale for targeting Btk in rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoegiZYoitP57Vg90H21EOLACvtfcHk0lgR6N277XEvyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP&md5=99d925c71bc1b201191ebde0f1c0b50f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.481%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBarck%26aufirst%3DK.%2BH.%26aulast%3DBravo%26aufirst%3DB.%2BJ.%26aulast%3DCarano%26aufirst%3DR.%2BA.%26aulast%3DDarrow%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DD.%2BR.%26aulast%3DDeForge%26aufirst%3DL.%2BE.%26aulast%3DDiehl%26aufirst%3DL.%26aulast%3DFerrando%26aufirst%3DR.%26aulast%3DGallion%26aufirst%3DS.%2BL.%26aulast%3DGiannetti%26aufirst%3DA.%2BM.%26aulast%3DGribling%26aufirst%3DP.%26aulast%3DHurez%26aufirst%3DV.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DMaciejewski%26aufirst%3DP.%2BM.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DStaker%26aufirst%3DB.%2BL.%26aulast%3DWhitney%26aufirst%3DJ.%2BA.%26aulast%3DYeh%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DSpecific%2520Btk%2520inhibition%2520suppresses%2520B%2520cell-%2520and%2520myeloid%2520cell-mediated%2520arthritis%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D41%26epage%3D50%26doi%3D10.1038%2Fnchembio.481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Puri, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gold, M. R.</span></span> <span> </span><span class="NLM_article-title">B-cell receptor signaling inhibitors for treatment of autoimmune inflammatory diseases and B-cell malignancies</span>. <i>Int. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">427</span>, <span class="refDoi"> DOI: 10.3109/08830185.2013.818140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.3109%2F08830185.2013.818140" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=23886342" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFygsrrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=397-427&author=K.+D.+Puriauthor=J.+A.+Di+Paoloauthor=M.+R.+Gold&title=B-cell+receptor+signaling+inhibitors+for+treatment+of+autoimmune+inflammatory+diseases+and+B-cell+malignancies&doi=10.3109%2F08830185.2013.818140"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">B-Cell Receptor Signaling Inhibitors for Treatment of Autoimmune Inflammatory Diseases and B-Cell Malignancies</span></div><div class="casAuthors">Puri, Kamal D.; Di Paolo, Julie A.; Gold, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">International Reviews of Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">397-427</span>CODEN:
                <span class="NLM_cas:coden">IRIMEH</span>;
        ISSN:<span class="NLM_cas:issn">0883-0185</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  B-cell receptor (BCR) signaling is essential for normal B-cell development, selection, survival, proliferation, and differentiation into antibody-secreting cells.  Similarly, this pathway plays a key role in the pathogenesis of multiple B-cell malignancies.  Genetic and pharmacol. approaches have established an important role for the Spleen tyrosine kinase (Syk), Bruton's tyrosine kinase (Btk), and phosphatidylinositol 3-kinase isoform p110delta (PI3Kδ) in coupling the BCR and other BCRs to B-cell survival, migration, and activation.  In the past few years, several small-mol. inhibitory drugs that target PI3Kδ, Btk, and Syk have been developed and shown to have efficacy in clin. trials for the treatment of several types of B-cell malignancies.  Emerging preclin. data have also shown a crit. role of BCR signaling in the activation and function of self-reactive B cells that contribute to autoimmune diseases.  Because BCR signaling plays a major role in both B-cell-mediated autoimmune inflammation and B-cell malignancies, inhibition of this pathway may represent a promising new strategy for treating these diseases.  This review summarizes recent achievements in the mechanism of action, pharmacol. properties, and clin. activity and toxicity of these BCR signaling inhibitors, with a focus on their emerging role in treating lymphoid malignancies and autoimmune disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpLDUjmfDEurVg90H21EOLACvtfcHk0lgR6N277XEvyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFygsrrO&md5=85ace1d58bb75405311bfe4a613ae2a7</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.3109%2F08830185.2013.818140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F08830185.2013.818140%26sid%3Dliteratum%253Aachs%26aulast%3DPuri%26aufirst%3DK.%2BD.%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%2BA.%26aulast%3DGold%26aufirst%3DM.%2BR.%26atitle%3DB-cell%2520receptor%2520signaling%2520inhibitors%2520for%2520treatment%2520of%2520autoimmune%2520inflammatory%2520diseases%2520and%2520B-cell%2520malignancies%26jtitle%3DInt.%2520Rev.%2520Immunol.%26date%3D2013%26volume%3D32%26spage%3D397%26epage%3D427%26doi%3D10.3109%2F08830185.2013.818140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulligan, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaeger, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devereux, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barr, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kipps, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cymbalista, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pocock, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thornton, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caligaris-Cappio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robak, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuster, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montillo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dearden, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fardis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGreivy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmen, P.</span></span> <span> </span><span class="NLM_article-title">Resonate Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>371</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1400376</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.1056%2FNEJMoa1400376" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=24881631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1egsbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=213-223&author=J.+C.+Byrdauthor=J.+R.+Brownauthor=S.+O%E2%80%99Brienauthor=J.+C.+Barrientosauthor=N.+E.+Kayauthor=N.+M.+Reddyauthor=S.+Coutreauthor=C.+S.+Tamauthor=S.+P.+Mulliganauthor=U.+Jaegerauthor=S.+Devereuxauthor=P.+M.+Barrauthor=R.+R.+Furmanauthor=T.+J.+Kippsauthor=F.+Cymbalistaauthor=C.+Pocockauthor=P.+Thorntonauthor=F.+Caligaris-Cappioauthor=T.+Robakauthor=J.+Delgadoauthor=S.+J.+Schusterauthor=M.+Montilloauthor=A.+Schuhauthor=S.+de+Vosauthor=D.+Gillauthor=A.+Bloorauthor=C.+Deardenauthor=C.+Morenoauthor=J.+J.+Jonesauthor=A.+D.+Chuauthor=M.+Fardisauthor=J.+McGreivyauthor=F.+Clowauthor=D.+F.+Jamesauthor=P.+Hillmen&title=Resonate+Investigators.+Ibrutinib+versus+ofatumumab+in+previously+treated+chronic+lymphoid+leukemia&doi=10.1056%2FNEJMoa1400376"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia</span></div><div class="casAuthors">Byrd, J. C.; Brown, J. R.; O'Brien, S.; Barrientos, J. C.; Kay, N. E.; Reddy, N. M.; Coutre, S.; Tam, C. S.; Mulligan, S. P.; Jaeger, U.; Devereux, S.; Barr, P. M.; Furman, R. R.; Kipps, T. J.; Cymbalista, F.; Pocock, C.; Thornton, P.; Caligaris-Cappio, F.; Robak, T.; Delgado, J.; Schuster, S. J.; Montillo, M.; Schuh, A.; de Vos, S.; Gill, D.; Bloor, A.; Dearden, C.; Moreno, C.; Jones, J. J.; Chu, A. D.; Fardis, M.; McGreivy, J.; Clow, F.; James, D. F.; Hillmen, P.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">213-223, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are assocd. with a poor outcome.  We evaluated the efficacy of ibrutinib, a covalent inhibitor of Bruton's tyrosine kinase, in patients at risk for a poor outcome.  Methods: In this multicenter, open-label, phase 3 study, we randomly assigned 391 patients with relapsed or refractory CLL or SLL to receive daily ibrutinib or the anti-CD20 antibody ofatumumab.  The primary end point was the duration of progression-free survival, with the duration of overall survival and the overall response rate as secondary end points.  Results: At a median follow-up of 9.4 mo, ibrutinib significantly improved progression-free survival; the median duration was not reached in the ibrutinib group (with a rate of progression-free survival of 88% at 6 mo), as compared with a median of 8.1 mo in the ofatumumab group (hazard ratio for progression or death in the ibrutinib group, 0.22; P < 0.001).  Ibrutinib also significantly improved overall survival (hazard ratio for death, 0.43; P = 0.005).  At 12 mo, the overall survival rate was 90% in the ibrutinib group and 81% in the ofatumumab group.  The overall response rate was significantly higher in the ibrutinib group than in the ofatumumab group (42.6% vs. 4.1%, P < 0.001).  An addnl. 20% of ibrutinib-treated patients had a partial response with lymphocytosis.  Similar effects were obsd. regardless of whether patients had a chromosome 17p13.1 deletion or resistance to purine analogs.  The most frequent nonhematol. adverse events were diarrhea, fatigue, pyrexia, and nausea in the ibrutinib group and fatigue, infusion-related reactions, and cough in the ofatumumab group.  Conclusions: Ibrutinib, as compared with ofatumumab, significantly improved progression-free survival, overall survival, and response rate among patients with previously treated CLL or SLL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCuX1vrLZxQLVg90H21EOLACvtfcHk0lgR6N277XEvyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1egsbrN&md5=87b692d35faa0fb8666bb945746fb9b0</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1400376&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1400376%26sid%3Dliteratum%253Aachs%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DKay%26aufirst%3DN.%2BE.%26aulast%3DReddy%26aufirst%3DN.%2BM.%26aulast%3DCoutre%26aufirst%3DS.%26aulast%3DTam%26aufirst%3DC.%2BS.%26aulast%3DMulligan%26aufirst%3DS.%2BP.%26aulast%3DJaeger%26aufirst%3DU.%26aulast%3DDevereux%26aufirst%3DS.%26aulast%3DBarr%26aufirst%3DP.%2BM.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DKipps%26aufirst%3DT.%2BJ.%26aulast%3DCymbalista%26aufirst%3DF.%26aulast%3DPocock%26aufirst%3DC.%26aulast%3DThornton%26aufirst%3DP.%26aulast%3DCaligaris-Cappio%26aufirst%3DF.%26aulast%3DRobak%26aufirst%3DT.%26aulast%3DDelgado%26aufirst%3DJ.%26aulast%3DSchuster%26aufirst%3DS.%2BJ.%26aulast%3DMontillo%26aufirst%3DM.%26aulast%3DSchuh%26aufirst%3DA.%26aulast%3Dde%2BVos%26aufirst%3DS.%26aulast%3DGill%26aufirst%3DD.%26aulast%3DBloor%26aufirst%3DA.%26aulast%3DDearden%26aufirst%3DC.%26aulast%3DMoreno%26aufirst%3DC.%26aulast%3DJones%26aufirst%3DJ.%2BJ.%26aulast%3DChu%26aufirst%3DA.%2BD.%26aulast%3DFardis%26aufirst%3DM.%26aulast%3DMcGreivy%26aufirst%3DJ.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DJames%26aufirst%3DD.%2BF.%26aulast%3DHillmen%26aufirst%3DP.%26atitle%3DResonate%2520Investigators.%2520Ibrutinib%2520versus%2520ofatumumab%2520in%2520previously%2520treated%2520chronic%2520lymphoid%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26spage%3D213%26epage%3D223%26doi%3D10.1056%2FNEJMoa1400376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devereux, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaves, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awan, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woyach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lannutti, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fardis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGreivy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamdy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothbaum, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diacovo, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span> <span> </span><span class="NLM_article-title">Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1509981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.1056%2FNEJMoa1509981" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=26641137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOlur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=323-332&author=J.+C.+Byrdauthor=B.+Harringtonauthor=S.+O%E2%80%99Brienauthor=J.+A.+Jonesauthor=A.+Schuhauthor=S.+Devereuxauthor=J.+Chavesauthor=W.+G.+Wierdaauthor=F.+T.+Awanauthor=J.+R.+Brownauthor=P.+Hillmenauthor=D.+M.+Stephensauthor=P.+Ghiaauthor=J.+C.+Barrientosauthor=J.+M.+Pagelauthor=J.+Woyachauthor=D.+Johnsonauthor=J.+Huangauthor=X.+Wangauthor=A.+Kapteinauthor=B.+J.+Lannuttiauthor=T.+Coveyauthor=M.+Fardisauthor=J.+McGreivyauthor=A.+Hamdyauthor=W.+Rothbaumauthor=R.+Izumiauthor=T.+G.+Diacovoauthor=A.+J.+Johnsonauthor=R.+R.+Furman&title=Acalabrutinib+%28ACP-196%29+in+relapsed+chronic+lymphocytic+leukemia&doi=10.1056%2FNEJMoa1509981"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia</span></div><div class="casAuthors">Byrd, John C.; Harrington, Bonnie; O'Brien, Susan; Jones, Jeffrey A.; Schuh, Anna; Devereux, Steve; Chaves, Jorge; Wierda, William G.; Awan, Farrukh T.; Brown, Jennifer R.; Hillmen, Peter; Stephens, Deborah M.; Ghia, Paolo; Barrientos, Jacqueline C.; Pagel, John M.; Woyach, Jennifer; Johnson, Dave; Huang, Jane; Wang, Xiaolin; Kaptein, Allard; Lannutti, Brian J.; Covey, Todd; Fardis, Maria; McGreivy, Jesse; Hamdy, Ahmed; Rothbaum, Wayne; Izumi, Raquel; Diacovo, Thomas G.; Johnson, Amy J.; Furman, Richard R.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">323-332</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Irreversible inhibition of Bruton's tyrosine kinase (BTK) by ibrutinib represents an important therapeutic advance for the treatment of chronic lymphocytic leukemia (CLL).  However, ibrutinib also irreversibly inhibits alternative kinase targets, which potentially compromises its therapeutic index.  Acalabrutinib (ACP-196) is a more selective, irreversible BTK inhibitor that is specifically designed to improve on the safety and efficacy of first-generation BTK inhibitors.  In this uncontrolled, phase 1-2, multicenter study, we administered oral acalabrutinib to 61 patients who had relapsed CLL to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of acalabrutinib.  Patients were treated with acalabrutinib at a dose of 100 to 400 mg once daily in the dose-escalation (phase 1) portion of the study and 100 mg twice daily in the expansion (phase 2) portion.  The median age of the patients was 62 years, and patients had received a median of three previous therapies for CLL; 31% had chromosome 17p13.1 deletion, and 75% had unmutated Ig heavy-chain variable genes.  No dose-limiting toxic effects occurred during the dose-escalation portion of the study.  The most common adverse events obsd. were headache (in 43% of the patients), diarrhea (in 39%), and in- creased wt. (in 26%).  Most adverse events were of grade 1 or 2.  At a median follow- up of 14.3 mo, the overall response rate was 95%, including 85% with a partial response and 10% with a partial response with lymphocytosis; the remaining 5% of patients had stable disease.  Among patients with chromosome 17p13.1 deletion, the overall response rate was 100%.  No cases of Richter's transformation (CLL that has evolved into large-cell lymphoma) and only one case of CLL progression have occurred.  In this study, the selective BTK inhibitor acalabrutinib had promising safety and efficacy profiles in patients with relapsed CLL, including those with chromosome 17p13.1 deletion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGHCPciF9hPrVg90H21EOLACvtfcHk0lja_MFg1S_85g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOlur%252FI&md5=d20e0158f9ea308b9d06fa668154516e</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1509981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1509981%26sid%3Dliteratum%253Aachs%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DHarrington%26aufirst%3DB.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DJ.%2BA.%26aulast%3DSchuh%26aufirst%3DA.%26aulast%3DDevereux%26aufirst%3DS.%26aulast%3DChaves%26aufirst%3DJ.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DAwan%26aufirst%3DF.%2BT.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DHillmen%26aufirst%3DP.%26aulast%3DStephens%26aufirst%3DD.%2BM.%26aulast%3DGhia%26aufirst%3DP.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DPagel%26aufirst%3DJ.%2BM.%26aulast%3DWoyach%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DKaptein%26aufirst%3DA.%26aulast%3DLannutti%26aufirst%3DB.%2BJ.%26aulast%3DCovey%26aufirst%3DT.%26aulast%3DFardis%26aufirst%3DM.%26aulast%3DMcGreivy%26aufirst%3DJ.%26aulast%3DHamdy%26aufirst%3DA.%26aulast%3DRothbaum%26aufirst%3DW.%26aulast%3DIzumi%26aufirst%3DR.%26aulast%3DDiacovo%26aufirst%3DT.%2BG.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26atitle%3DAcalabrutinib%2520%2528ACP-196%2529%2520in%2520relapsed%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26spage%3D323%26epage%3D332%26doi%3D10.1056%2FNEJMoa1509981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bitar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadeghian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murina, A.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib-associated pityriasis rosea-like rash</span>. <i>JAAD Case Rep</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">55</span>– <span class="NLM_lpage">57</span>, <span class="refDoi"> DOI: 10.1016/j.jdcr.2017.06.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.1016%2Fj.jdcr.2017.06.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=29387749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A280%3ADC%252BC1MvmtVOguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&pages=55-57&author=C.+Bitarauthor=A.+Sadeghianauthor=L.+Sullivanauthor=A.+Murina&title=Ibrutinib-associated+pityriasis+rosea-like+rash&doi=10.1016%2Fj.jdcr.2017.06.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib-associated pityriasis rosea-like rash</span></div><div class="casAuthors">Bitar Carole; Sadeghian Azeen; Murina Andrea; Sullivan Lacey</div><div class="citationInfo"><span class="NLM_cas:title">JAAD case reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-57</span>
        ISSN:<span class="NLM_cas:issn">2352-5126</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQbpurTOGw_P02yPDyEFiigfW6udTcc2eaigDpn2Fscerntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvmtVOguw%253D%253D&md5=cfaa97dc12fe02df38ea167eba2f012a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.jdcr.2017.06.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jdcr.2017.06.035%26sid%3Dliteratum%253Aachs%26aulast%3DBitar%26aufirst%3DC.%26aulast%3DSadeghian%26aufirst%3DA.%26aulast%3DSullivan%26aufirst%3DL.%26aulast%3DMurina%26aufirst%3DA.%26atitle%3DIbrutinib-associated%2520pityriasis%2520rosea-like%2520rash%26jtitle%3DJAAD%2520Case%2520Rep%26date%3D2018%26volume%3D4%26spage%3D55%26epage%3D57%26doi%3D10.1016%2Fj.jdcr.2017.06.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Weerdt, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koopmans, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kater, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Gelder, M.</span></span> <span> </span><span class="NLM_article-title">Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">1629</span>– <span class="NLM_lpage">1639</span>, <span class="refDoi"> DOI: 10.3324/haematol.2017.164103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.3324%2Fhaematol.2017.164103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=28775119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2js7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2017&pages=1629-1639&author=I.+de+Weerdtauthor=S.+M.+Koopmansauthor=A.+P.+Katerauthor=M.+van+Gelder&title=Incidence+and+management+of+toxicity+associated+with+ibrutinib+and+idelalisib%3A+a+practical+approach&doi=10.3324%2Fhaematol.2017.164103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach</span></div><div class="casAuthors">de Weerdt, Iris; Koopmans, Suzanne M.; Kater, Arnon P.; Van Gelder, Michel</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1629-1639</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">1592-8721</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">The use of novel B-cell receptor signaling inhibitors results in high response rates and long progression-free survival in patients with indolent B-cell malignancies, such as chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma and Waldenstrom macroglobulinemia.  Ibrutinib, the first-in-class inhibitor of Bruton tyrosine kinase, and idelalisib, the first-in-class inhibitor of phosphatidylinositol 3-kinase α, have recently been approved for the treatment of several indolent B-cell malignancies.  These drugs are esp. being used for previously unmet needs, i.e., for patients with relapsed or refractory disease, high-risk cytogenetic or mol. abnormalities, or with comorbidities.  Treatment with ibrutinib and idelalisib is generally well tolerated, even by elderly patients.  However, the use of these drugs may come with toxicities that are distinct from the side effects of immunochemotherapy.  In this review we discuss the most commonly reported and/or most clin. relevant adverse events assocd. with these B-cell receptor inhibitors, with special emphasis on recommendations for their management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyZRp7XuwODLVg90H21EOLACvtfcHk0lgyaP0zE6ZPKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2js7jE&md5=63198531f21c5cc5ca64ead536e5684a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2017.164103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2017.164103%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BWeerdt%26aufirst%3DI.%26aulast%3DKoopmans%26aufirst%3DS.%2BM.%26aulast%3DKater%26aufirst%3DA.%2BP.%26aulast%3Dvan%2BGelder%26aufirst%3DM.%26atitle%3DIncidence%2520and%2520management%2520of%2520toxicity%2520associated%2520with%2520ibrutinib%2520and%2520idelalisib%253A%2520a%2520practical%2520approach%26jtitle%3DHaematologica%26date%3D2017%26volume%3D102%26spage%3D1629%26epage%3D1639%26doi%3D10.3324%2Fhaematol.2017.164103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McMullen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boey, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ooi, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seymour, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, C. S.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">3829</span>– <span class="NLM_lpage">3830</span>, <span class="refDoi"> DOI: 10.1182/blood-2014-10-604272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.1182%2Fblood-2014-10-604272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=25498454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvFGi" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=3829-3830&author=J.+R.+McMullenauthor=E.+J.+Boeyauthor=J.+Y.+Ooiauthor=J.+F.+Seymourauthor=M.+J.+Keatingauthor=C.+S.+Tam&title=Ibrutinib+increases+the+risk+of+atrial+fibrillation%2C+potentially+through+inhibition+of+cardiac+PI3K-Akt+signaling&doi=10.1182%2Fblood-2014-10-604272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling</span></div><div class="casAuthors">McMullen, Julie R.; Boey, Esther J. H.; Ooi, Jenny Y. Y.; Seymour, John F.; Keating, Michael J.; Tam, Constantine S.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">3829-3830</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">This article describes on ibrutinib increases risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling.  Ibrutinib-induced atrial fibrillation (AF) may be due to on-target inhibition of Bruton's tyrosine kinase BTK and related kinases such as tec protein tyrosine kinase (TEC) were expressed in human heart tissue.  The expressions of BTK and TEC transcripts were higher in atrial tissue under conditions of AF than sinus rhythm.  Ibrutinib significantly reduced PI3K-Akt activity in cardiac cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ5R0Y9luwnLVg90H21EOLACvtfcHk0lgyaP0zE6ZPKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvFGi&md5=365755ef44550dc25545e683414c8b58</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-10-604272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-10-604272%26sid%3Dliteratum%253Aachs%26aulast%3DMcMullen%26aufirst%3DJ.%2BR.%26aulast%3DBoey%26aufirst%3DE.%2BJ.%26aulast%3DOoi%26aufirst%3DJ.%2BY.%26aulast%3DSeymour%26aufirst%3DJ.%2BF.%26aulast%3DKeating%26aufirst%3DM.%2BJ.%26aulast%3DTam%26aufirst%3DC.%2BS.%26atitle%3DIbrutinib%2520increases%2520the%2520risk%2520of%2520atrial%2520fibrillation%252C%2520potentially%2520through%2520inhibition%2520of%2520cardiac%2520PI3K-Akt%2520signaling%26jtitle%3DBlood%26date%3D2014%26volume%3D124%26spage%3D3829%26epage%3D3830%26doi%3D10.1182%2Fblood-2014-10-604272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span> <span> </span><span class="NLM_article-title">Second-generation inhibitors of Bruton tyrosine kinase</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">80</span>, <span class="refDoi"> DOI: 10.1186/s13045-016-0313-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.1186%2Fs13045-016-0313-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=27590878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVajtr7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=80&author=J.+Wuauthor=C.+Liuauthor=S.+T.+Tsuiauthor=D.+Liu&title=Second-generation+inhibitors+of+Bruton+tyrosine+kinase&doi=10.1186%2Fs13045-016-0313-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Second-generation inhibitors of Bruton tyrosine kinase</span></div><div class="casAuthors">Wu, Jingjing; Liu, Christina; Tsui, Stella T.; Liu, Delong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">80/1-80/7</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Bruton tyrosine kinase (BTK) is a crit. effector mol. for B cell development and plays a major role in lymphoma genesis.  Ibrutinib is the first-generation BTK inhibitor.  Ibrutinib has off-target effects on EGFR, ITK, and Tec family kinases, which explains the untoward effects of ibrutinib.  Resistance to ibrutinib was also reported.  The C481S mutation in the BTK kinase domain was reported to be a major mechanism of resistance to ibrutinib.  This review summarizes the clin. development of novel BTK inhibitors, ACP-196 (acalabrutinib), ONO/GS-4059, and BGB-3111.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb086cwyJYLrVg90H21EOLACvtfcHk0lgyaP0zE6ZPKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVajtr7L&md5=b6140d9f7a24665131f5e772d55f29eb</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1186%2Fs13045-016-0313-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-016-0313-y%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DTsui%26aufirst%3DS.%2BT.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DSecond-generation%2520inhibitors%2520of%2520Bruton%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D9%26spage%3D80%26doi%3D10.1186%2Fs13045-016-0313-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span> <i>CALQUENCE (Acalabrutinib) US Prescribing Information</i>; <span class="NLM_publisher-name">US Food and Drug Administration</span>, <span class="NLM_year">2017</span>; <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/210259s000lbl.pdf" class="extLink">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/210259s000lbl.pdf</a> (accessed December 6, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+CALQUENCE+%28Acalabrutinib%29+US+Prescribing+Information%3B+US+Food+and+Drug+Administration%2C+2017%3B+https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2017%2F210259s000lbl.pdf+%28accessed+December+6%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DCALQUENCE%2520%2528Acalabrutinib%2529%2520US%2520Prescribing%2520Information%26pub%3DUS%2520Food%2520and%2520Drug%2520Administration%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haselmayer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camps, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu-Bujalski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Head, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Mahony, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerli, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruns, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grenningloh, R.</span></span> <span> </span><span class="NLM_article-title">Efficacy and pharmacodynamic modeling of the BTK inhibitor evobrutinib in autoimmune disease models</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>202</i></span>,  <span class="NLM_fpage">2888</span>– <span class="NLM_lpage">2906</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1800583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.4049%2Fjimmunol.1800583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=30988116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvF2ntLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=202&publication_year=2019&pages=2888-2906&author=P.+Haselmayerauthor=M.+Campsauthor=L.+Liu-Bujalskiauthor=N.+Nguyenauthor=F.+Morandiauthor=J.+Headauthor=A.+O%E2%80%99Mahonyauthor=S.+C.+Zimmerliauthor=L.+Brunsauthor=A.+Benderauthor=P.+Schroederauthor=R.+Grenningloh&title=Efficacy+and+pharmacodynamic+modeling+of+the+BTK+inhibitor+evobrutinib+in+autoimmune+disease+models&doi=10.4049%2Fjimmunol.1800583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and pharmacodynamic modeling of the BTK inhibitor evobrutinib in autoimmune disease models</span></div><div class="casAuthors">Haselmayer, Philipp; Camps, Montserrat; Liu-Bujalski, Lesley; Nguyen, Ngan; Morandi, Federica; Head, Jared; O'Mahony, Alison; Zimmerli, Simone C.; Bruns, Lisa; Bender, Andrew T.; Schroeder, Patricia; Grenningloh, Roland</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">202</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2888-2906</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Because of its role in mediating both B cell and Fc receptor signaling, Bruton's tyrosine kinase (BTK) is a promising target for the treatment of autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).  Evobrutinib is a novel, highly selective, irreversible BTK inhibitor that potently inhibits BCR- and Fc receptor-mediated signaling and, thus, subsequent activation and function of human B cells and innate immune cells such as monocytes and basophils.  We evaluated evobrutinib in preclin. models of RA and SLE and characterized the relationship between BTK occupancy and inhibition of disease activity.  In mouse models of RA and SLE, orally administered evobrutinib displayed robust efficacy, as demonstrated by redn. of disease severity and histol. damage.  In the SLE model, evobrutinib inhibited B cell activation, reduced autoantibody prodn. and plasma cell nos., and normalized B and T cell subsets.  In the RA model, efficacy was achieved despite failure to reduce autoantibodies.  Pharmacokinetic/pharmacodynamic modeling showed that mean BTK occupancy in blood cells of 80% was linked to near-complete disease inhibition in both RA and SLE mouse models.  In addn., evobrutinib inhibited mast cell activation in a passive cutaneous anaphylaxis model.  Thus, evobrutinib achieves efficacy by acting both on B cells and innate immune cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLVxS4palhvbVg90H21EOLACvtfcHk0lg5m6IamQvisw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvF2ntLg%253D&md5=9a339003f40e52527127ac12a2593ae9</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1800583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1800583%26sid%3Dliteratum%253Aachs%26aulast%3DHaselmayer%26aufirst%3DP.%26aulast%3DCamps%26aufirst%3DM.%26aulast%3DLiu-Bujalski%26aufirst%3DL.%26aulast%3DNguyen%26aufirst%3DN.%26aulast%3DMorandi%26aufirst%3DF.%26aulast%3DHead%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DA.%26aulast%3DZimmerli%26aufirst%3DS.%2BC.%26aulast%3DBruns%26aufirst%3DL.%26aulast%3DBender%26aufirst%3DA.%26aulast%3DSchroeder%26aufirst%3DP.%26aulast%3DGrenningloh%26aufirst%3DR.%26atitle%3DEfficacy%2520and%2520pharmacodynamic%2520modeling%2520of%2520the%2520BTK%2520inhibitor%2520evobrutinib%2520in%2520autoimmune%2520disease%2520models%26jtitle%3DJ.%2520Immunol.%26date%3D2019%26volume%3D202%26spage%3D2888%26epage%3D2906%26doi%3D10.4049%2Fjimmunol.1800583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montalban, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staikov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piasecka-Stryczynska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willmer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dangond, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syed, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolinsky, J.</span></span> <span> </span><span class="NLM_article-title">on behalf of the Evobrutinib Phase 2 Study Group. Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>380</i></span>,  <span class="NLM_fpage">2406</span>– <span class="NLM_lpage">2417</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1901981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.1056%2FNEJMoa1901981" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=31075187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A280%3ADC%252BB3M7ksVagtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2019&pages=2406-2417&author=X.+Montalbanauthor=D.+L.+Arnoldauthor=M.+S.+Weberauthor=I.+Staikovauthor=K.+Piasecka-Stryczynskaauthor=J.+Willmerauthor=E.+C.+Martinauthor=F.+Dangondauthor=S.+Syedauthor=J.+Wolinsky&title=on+behalf+of+the+Evobrutinib+Phase+2+Study+Group.+Placebo-controlled+trial+of+an+oral+BTK+inhibitor+in+multiple+sclerosis&doi=10.1056%2FNEJMoa1901981"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis</span></div><div class="casAuthors">Montalban Xavier; Arnold Douglas L; Weber Martin S; Staikov Ivan; Piasecka-Stryczynska Karolina; Willmer Jonathan; Martin Emily C; Dangond Fernando; Syed Sana; Wolinsky Jerry S</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2406-2417</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Bruton's tyrosine kinase (BTK) regulates the functions of B cells and myeloid cells that are implicated in the pathogenesis of multiple sclerosis.  Evobrutinib is a selective oral BTK inhibitor that has been shown to inhibit B-cell activation both in vitro and in vivo.  METHODS:  In this double-blind, randomized, phase 2 trial, we assigned patients with relapsing multiple sclerosis to one of five groups: placebo, evobrutinib (at a dose of 25 mg once daily, 75 mg once daily, or 75 mg twice daily), or open-label dimethyl fumarate (DMF) as a reference.  The primary end point was the total (cumulative) number of gadolinium-enhancing lesions identified on T1-weighted magnetic resonance imaging at weeks 12, 16, 20, and 24.  Key secondary end points included the annualized relapse rate and change from baseline in the score on the Expanded Disability Status Scale (EDSS).  RESULTS:  A total of 267 patients were randomly assigned to a trial group.  The mean (±SD) total number of gadolinium-enhancing lesions during weeks 12 through 24 was 3.85±5.44 in the placebo group, 4.06±8.02 in the evobrutinib 25-mg group, 1.69±4.69 in the evobrutinib 75-mg once-daily group, 1.15±3.70 in the evobrutinib 75-mg twice-daily group, and 4.78±22.05 in the DMF group.  The baseline adjusted rate ratios for the total number of lesions over time as compared with placebo were 1.45 in the evobrutinib 25-mg group (P = 0.32), 0.30 in the evobrutinib 75-mg once-daily group (P = 0.005), and 0.44 in the evobrutinib 75-mg twice-daily group (P = 0.06).  The unadjusted annualized relapse rate at week 24 was 0.37 in the placebo group, 0.57 in the evobrutinib 25-mg group, 0.13 in the evobrutinib 75-mg once-daily group, 0.08 in the evobrutinib 75-mg twice-daily group, and 0.20 in the DMF group.  There was no significant effect of trial group on the change from baseline in the EDSS score.  Elevations in liver aminotransferase values were observed with evobrutinib.  CONCLUSIONS:  Patients with relapsing multiple sclerosis who received 75 mg of evobrutinib once daily had significantly fewer enhancing lesions during weeks 12 through 24 than those who received placebo.  There was no significant difference with placebo for either the 25-mg once-daily or 75-mg twice-daily dose of evobrutinib, nor in the annualized relapse rate or disability progression at any dose.  Longer and larger trials are required to determine the effect and risks of evobrutinib in patients with multiple sclerosis. (Funded by EMD Serono; ClinicalTrials.gov number, NCT02975349.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS0eXPD9j4rwiO2kE7krGOBfW6udTcc2eaWfXc03ZllKrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7ksVagtA%253D%253D&md5=f3e5d3911404f5df778d06340b986ccf</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1901981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1901981%26sid%3Dliteratum%253Aachs%26aulast%3DMontalban%26aufirst%3DX.%26aulast%3DArnold%26aufirst%3DD.%2BL.%26aulast%3DWeber%26aufirst%3DM.%2BS.%26aulast%3DStaikov%26aufirst%3DI.%26aulast%3DPiasecka-Stryczynska%26aufirst%3DK.%26aulast%3DWillmer%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DE.%2BC.%26aulast%3DDangond%26aufirst%3DF.%26aulast%3DSyed%26aufirst%3DS.%26aulast%3DWolinsky%26aufirst%3DJ.%26atitle%3Don%2520behalf%2520of%2520the%2520Evobrutinib%2520Phase%25202%2520Study%2520Group.%2520Placebo-controlled%2520trial%2520of%2520an%2520oral%2520BTK%2520inhibitor%2520in%2520multiple%2520sclerosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D380%26spage%3D2406%26epage%3D2417%26doi%3D10.1056%2FNEJMoa1901981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, R. G.</span></span> <span> </span><span class="NLM_article-title">Idiosyncratic toxicity: a convergence of risk factors</span>. <i>Annu. Rev. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1146/annurev.med.58.072905.160823</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.1146%2Fannurev.med.58.072905.160823" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=16958561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisV2jsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2007&pages=17-34&author=R.+G.+Ulrich&title=Idiosyncratic+toxicity%3A+a+convergence+of+risk+factors&doi=10.1146%2Fannurev.med.58.072905.160823"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Idiosyncratic toxicity: a convergence of risk factors</span></div><div class="casAuthors">Ulrich, Roger G.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">17-34</span>CODEN:
                <span class="NLM_cas:coden">ARMCAH</span>;
        ISSN:<span class="NLM_cas:issn">0066-4219</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The therapeutic margin for any drug is based on both toxicity and efficacy.  Generally, toxicity is dose-dependent and is driven either by the therapeutic target or by an untoward target.  However, idiosyncratic toxicities are usually not obsd. until a drug has been on the market and has gained broad exposure.  Except in the case of pharmacokinetic interactions, these toxicities are not driven solely by drug exposure but rather depend on several drug- and patient-related risk factors.  Drug-related risk factors include metab., bioactivation and covalent binding, and the inhibition of key cell functions.  Patient-related risk factors include underlying disease, age, gender, comedications, nutritional status, activation of the innate immune system, phys. activity, and genetic predispositions.  Idiosyncratic toxicity can occur when a convergence of risk factors, including drug exposure, tips the risk-benefit balance away from benefit and toward risk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4gp_C2QKITbVg90H21EOLACvtfcHk0lg5m6IamQvisw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisV2jsLs%253D&md5=8f2b7ffb21a38b648a83bc1a8430a17c</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1146%2Fannurev.med.58.072905.160823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.med.58.072905.160823%26sid%3Dliteratum%253Aachs%26aulast%3DUlrich%26aufirst%3DR.%2BG.%26atitle%3DIdiosyncratic%2520toxicity%253A%2520a%2520convergence%2520of%2520risk%2520factors%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2007%26volume%3D58%26spage%3D17%26epage%3D34%26doi%3D10.1146%2Fannurev.med.58.072905.160823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuglstatter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondru, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span> <span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">4539</span>– <span class="NLM_lpage">4550</span>, <span class="refDoi"> DOI: 10.1021/jm300035p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300035p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsVChsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4539-4550&author=Y.+Louauthor=T.+D.+Owensauthor=A.+Kuglstatterauthor=R.+K.+Kondruauthor=D.+M.+Goldstein&title=Bruton%E2%80%99s+tyrosine+kinase+inhibitors%3A+approaches+to+potent+and+selective+inhibition%2C+preclinical+and+clinical+evaluation+for+inflammatory+diseases+and+B+cell+malignancies&doi=10.1021%2Fjm300035p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's Tyrosine Kinase Inhibitors: Approaches to Potent and Selective Inhibition, Preclinical and Clinical Evaluation for Inflammatory Diseases and B Cell Malignancies</span></div><div class="casAuthors">Lou, Yan; Owens, Timothy D.; Kuglstatter, Andreas; Kondru, Rama K.; Goldstein, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4539-4550</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRzAwa4gtFprVg90H21EOLACvtfcHk0lgfp-FUVuVMKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsVChsb8%253D&md5=b470ba4ec4867e4bfb8d1cfa92b1cc6d</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm300035p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300035p%26sid%3Dliteratum%253Aachs%26aulast%3DLou%26aufirst%3DY.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DKondru%26aufirst%3DR.%2BK.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%253A%2520approaches%2520to%2520potent%2520and%2520selective%2520inhibition%252C%2520preclinical%2520and%2520clinical%2520evaluation%2520for%2520inflammatory%2520diseases%2520and%2520B%2520cell%2520malignancies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4539%26epage%3D4550%26doi%3D10.1021%2Fjm300035p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheerens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprengeler, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrill, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendonca, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grothaus, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffery, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spoerke, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honigberg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalrymple, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, J. T.</span></span> <span> </span><span class="NLM_article-title">Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200600221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.1002%2Fcmdc.200600221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=17154430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=58-61&author=Z.+Panauthor=H.+Scheerensauthor=S.+J.+Liauthor=B.+E.+Schultzauthor=P.+A.+Sprengelerauthor=L.+C.+Burrillauthor=R.+V.+Mendoncaauthor=M.+D.+Sweeneyauthor=K.+C.+Scottauthor=P.+G.+Grothausauthor=D.+A.+Jefferyauthor=J.+M.+Spoerkeauthor=L.+A.+Honigbergauthor=P.+R.+Youngauthor=S.+A.+Dalrympleauthor=J.+T.+Palmer&title=Discovery+of+selective+irreversible+inhibitors+for+Bruton%E2%80%99s+tyrosine+kinase&doi=10.1002%2Fcmdc.200600221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective irreversible inhibitors for bruton's tyrosine kinase</span></div><div class="casAuthors">Pan, Zhengying; Scheerens, Heleen; Li, Shyr-Jiann; Schultz, Brian E.; Sprengeler, Paul A.; Burrill, L. Chuck; Mendonca, Rohan V.; Sweeney, Michael D.; Scott, Keana C. K.; Grothaus, Paul G.; Jeffery, Douglas A.; Spoerke, Jill M.; Honigberg, Lee A.; Young, Peter R.; Dalrymple, Stacie A.; Palmer, James T.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-61</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Synthesis and pharmacol. evaluation of a series of peptidomimetic quinoline derivs. was undertaken to evaluate their efficacy in acting as selective irreversible inhibitors of Bruton's tyrosine kinase (Btk).  With the relative scarcity of knowledge on the inhibition of Btk it is crucial to discover a potent and selective tool compd. for this kinase.  Herein is described the discovery of selective irreversible Btk inhibitors and their efficacy in a mouse RA model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovT3kBCYECdbVg90H21EOLACvtfcHk0lgfp-FUVuVMKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbg%253D&md5=023ba8bca9942ad0127d7cf32293e9d2</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200600221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200600221%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DS.%2BJ.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DBurrill%26aufirst%3DL.%2BC.%26aulast%3DMendonca%26aufirst%3DR.%2BV.%26aulast%3DSweeney%26aufirst%3DM.%2BD.%26aulast%3DScott%26aufirst%3DK.%2BC.%26aulast%3DGrothaus%26aufirst%3DP.%2BG.%26aulast%3DJeffery%26aufirst%3DD.%2BA.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DYoung%26aufirst%3DP.%2BR.%26aulast%3DDalrymple%26aufirst%3DS.%2BA.%26aulast%3DPalmer%26aufirst%3DJ.%2BT.%26atitle%3DDiscovery%2520of%2520selective%2520irreversible%2520inhibitors%2520for%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D58%26epage%3D61%26doi%3D10.1002%2Fcmdc.200600221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marcotte, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arduini, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hession, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miatkowski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wildes, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cullen, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mertsching, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romanowski, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvian, L. F.</span></span> <span> </span><span class="NLM_article-title">Structures of human Bruton’s tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases</span>. <i>Protein Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">429</span>– <span class="NLM_lpage">439</span>, <span class="refDoi"> DOI: 10.1002/pro.321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.1002%2Fpro.321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=20052711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisFOhtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2010&pages=429-439&author=D.+J.+Marcotteauthor=Y.+T.+Liuauthor=R.+M.+Arduiniauthor=C.+A.+Hessionauthor=K.+Miatkowskiauthor=C.+P.+Wildesauthor=P.+F.+Cullenauthor=V.+Hongauthor=B.+T.+Hopkinsauthor=E.+Mertschingauthor=T.+J.+Jenkinsauthor=M.+J.+Romanowskiauthor=D.+P.+Bakerauthor=L.+F.+Silvian&title=Structures+of+human+Bruton%E2%80%99s+tyrosine+kinase+in+active+and+inactive+conformations+suggest+a+mechanism+of+activation+for+TEC+family+kinases&doi=10.1002%2Fpro.321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases</span></div><div class="casAuthors">Marcotte, Douglas J.; Liu, Yu-Ting; Arduini, Robert M.; Hession, Catherine A.; Miatkowski, Konrad; Wildes, Craig P.; Cullen, Patrick F.; Hong, Victor; Hopkins, Brian T.; Mertsching, Elisabeth; Jenkins, Tracy J.; Romanowski, Michael J.; Baker, Darren P.; Silvian, Laura F.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">429-439</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">1469-896X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK), a member of the TEC family of kinases, plays a crucial role in B-cell maturation and mast cell activation.  Although the structures of the unphosphorylated mouse BTK kinase domain and the unphosphorylated and phosphorylated kinase domains of human ITK are known, understanding the kinase selectivity profiles of BTK inhibitors has been hampered by the lack of availability of a high resoln., ligand-bound BTK structure.  Here, we report the crystal structures of the human BTK kinase domain bound to either Dasatinib (BMS-354825) at 1.9 Å resoln. or to 4-amino-5-(4-phenoxyphenyl)-7H-pyrrolospyrimidin-7-yl-cyclopentane at 1.6 Å resoln.  This data provides information relevant to the development of small mol. inhibitors targeting BTK and the TEC family of nonreceptor tyrosine kinases.  Anal. of the structural differences between the TEC and Src families of kinases near the Trp-Glu-Ile motif in the N-terminal region of the kinase domain suggests a mechanism of regulation of the TEC family members.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBETS8unO82rVg90H21EOLACvtfcHk0lgfp-FUVuVMKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisFOhtbs%253D&md5=8c2dae6949f8bdb627d68ee14edc8d4f</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Fpro.321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpro.321%26sid%3Dliteratum%253Aachs%26aulast%3DMarcotte%26aufirst%3DD.%2BJ.%26aulast%3DLiu%26aufirst%3DY.%2BT.%26aulast%3DArduini%26aufirst%3DR.%2BM.%26aulast%3DHession%26aufirst%3DC.%2BA.%26aulast%3DMiatkowski%26aufirst%3DK.%26aulast%3DWildes%26aufirst%3DC.%2BP.%26aulast%3DCullen%26aufirst%3DP.%2BF.%26aulast%3DHong%26aufirst%3DV.%26aulast%3DHopkins%26aufirst%3DB.%2BT.%26aulast%3DMertsching%26aufirst%3DE.%26aulast%3DJenkins%26aufirst%3DT.%2BJ.%26aulast%3DRomanowski%26aufirst%3DM.%2BJ.%26aulast%3DBaker%26aufirst%3DD.%2BP.%26aulast%3DSilvian%26aufirst%3DL.%2BF.%26atitle%3DStructures%2520of%2520human%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520active%2520and%2520inactive%2520conformations%2520suggest%2520a%2520mechanism%2520of%2520activation%2520for%2520TEC%2520family%2520kinases%26jtitle%3DProtein%2520Sci.%26date%3D2010%26volume%3D19%26spage%3D429%26epage%3D439%26doi%3D10.1002%2Fpro.321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu-Bujalski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Follis, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goutopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grenningloh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Head, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mochalkin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neagu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherer, B.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">2939</span>– <span class="NLM_lpage">2944</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.07.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.1016%2Fj.bmcl.2018.07.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=30122225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1yrsrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=2939-2944&author=H.+Qiuauthor=L.+Liu-Bujalskiauthor=R.+D.+Caldwellauthor=A.+V.+Follisauthor=A.+Gardbergauthor=A.+Goutopoulosauthor=R.+Grenninglohauthor=J.+Headauthor=T.+Johnsonauthor=R.+Jonesauthor=I.+Mochalkinauthor=F.+Morandiauthor=C.+Neaguauthor=B.+Sherer&title=Discovery+of+potent%2C+highly+selective+covalent+irreversible+BTK+inhibitors+from+a+fragment+hit&doi=10.1016%2Fj.bmcl.2018.07.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit</span></div><div class="casAuthors">Qiu, Hui; Liu-Bujalski, Lesley; Caldwell, Richard D.; Follis, Ariele Viacava; Gardberg, Anna; Goutopoulos, Andreas; Grenningloh, Roland; Head, Jared; Johnson, Theresa; Jones, Reinaldo; Mochalkin, Igor; Morandi, Federica; Neagu, Constantin; Sherer, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2939-2944</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Bruton's Tyrosine Kinase (BTK) is a member of the TEC kinase family that is expressed in cells of hematopoietic lineage (e.g., in B cells, macrophages, monocytes, and mast cells).  Small mol. covalent irreversible BTK inhibitor targeting Cys481 within the ATP-binding pocket, for example ibrutinib, has been applied in the treatment of B-cell malignancies.  Starting from a fragment hit, we discovered a novel series of potent covalent irreversible BTK inhibitors that occupy selectivity pocket of the active site of the BTK kinase domain.  Guided by x-ray structures and a fragment-based drug design (FBDD) approach, we generated mols. showing comparable cellular potency to ibrutinib and higher kinome selectivity against undesirable off-targets like EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUzH2Fde_MUbVg90H21EOLACvtfcHk0liyGYmial6OCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1yrsrfJ&md5=f4019ea46ab1a06cab875c0b7af5b1fd</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.07.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.07.008%26sid%3Dliteratum%253Aachs%26aulast%3DQiu%26aufirst%3DH.%26aulast%3DLiu-Bujalski%26aufirst%3DL.%26aulast%3DCaldwell%26aufirst%3DR.%2BD.%26aulast%3DFollis%26aufirst%3DA.%2BV.%26aulast%3DGardberg%26aufirst%3DA.%26aulast%3DGoutopoulos%26aufirst%3DA.%26aulast%3DGrenningloh%26aufirst%3DR.%26aulast%3DHead%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DMochalkin%26aufirst%3DI.%26aulast%3DMorandi%26aufirst%3DF.%26aulast%3DNeagu%26aufirst%3DC.%26aulast%3DSherer%26aufirst%3DB.%26atitle%3DDiscovery%2520of%2520potent%252C%2520highly%2520selective%2520covalent%2520irreversible%2520BTK%2520inhibitors%2520from%2520a%2520fragment%2520hit%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D2939%26epage%3D2944%26doi%3D10.1016%2Fj.bmcl.2018.07.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widen, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harki, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brummond, K. M.</span></span> <span> </span><span class="NLM_article-title">Covalent modifiers: a chemical perspective on the reactivity of alpha, beta-unsaturated carbonyls with thiols via hetero-Michael addition reactions</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">839</span>– <span class="NLM_lpage">885</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00788</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00788" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BC28XitV2rtbnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=839-885&author=P.+A.+Jacksonauthor=J.+C.+Widenauthor=D.+A.+Harkiauthor=K.+M.+Brummond&title=Covalent+modifiers%3A+a+chemical+perspective+on+the+reactivity+of+alpha%2C+beta-unsaturated+carbonyls+with+thiols+via+hetero-Michael+addition+reactions&doi=10.1021%2Facs.jmedchem.6b00788"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions</span></div><div class="casAuthors">Jackson, Paul A.; Widen, John C.; Harki, Daniel A.; Brummond, Kay M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">839-885</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Although Michael acceptors display a potent and broad spectrum of bioactivity, they have largely been ignored in drug discovery because of their presumed indiscriminate reactivity.  As such, a dearth of information exists relevant to the thiol reactivity of natural products and their analogs possessing this moiety.  In the midst of recently approved acrylamide-contg. drugs, it is clear that a good understanding of the hetero-Michael addn. reaction and the relative reactivities of biol. thiols with Michael acceptors under physiol. conditions is needed for the design and use of these compds. as biol. tools and potential therapeutics.  This Perspective provides information that will contribute to this understanding, such as kinetics of thiol addn. reactions, bioactivities, as well as steric and electronic factors that influence the electrophilicity and reversibility of Michael acceptors.  This Perspective is focused on α,β-unsatd. carbonyls given their preponderance in bioactive natural products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn4jDqxoos17Vg90H21EOLACvtfcHk0liyGYmial6OCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitV2rtbnM&md5=36d3be5bf688c4e4a8cf4bcf42073009</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00788%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DP.%2BA.%26aulast%3DWiden%26aufirst%3DJ.%2BC.%26aulast%3DHarki%26aufirst%3DD.%2BA.%26aulast%3DBrummond%26aufirst%3DK.%2BM.%26atitle%3DCovalent%2520modifiers%253A%2520a%2520chemical%2520perspective%2520on%2520the%2520reactivity%2520of%2520alpha%252C%2520beta-unsaturated%2520carbonyls%2520with%2520thiols%2520via%2520hetero-Michael%2520addition%2520reactions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D839%26epage%3D885%26doi%3D10.1021%2Facs.jmedchem.6b00788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwobel, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wondrousch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koleva, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madden, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuurmann, G.</span></span> <span> </span><span class="NLM_article-title">Prediction of Michael-type acceptor reactivity toward glutathione</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1576</span>– <span class="NLM_lpage">1585</span>, <span class="refDoi"> DOI: 10.1021/tx100172x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx100172x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1akt7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2010&pages=1576-1585&author=J.+A.+Schwobelauthor=D.+Wondrouschauthor=Y.+K.+Kolevaauthor=J.+C.+Maddenauthor=M.+T.+Croninauthor=G.+Schuurmann&title=Prediction+of+Michael-type+acceptor+reactivity+toward+glutathione&doi=10.1021%2Ftx100172x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of Michael-Type Acceptor Reactivity toward Glutathione</span></div><div class="casAuthors">Schwobel, Johannes A. H.; Wondrousch, Dominik; Koleva, Yana K.; Madden, Judith C.; Cronin, Mark T. D.; Schuurmann, Gerrit</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1576-1585</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A model has been developed to predict the kinetic rate consts. (kGSH) of α,β-unsatd. Michael acceptor compds. for their reaction with glutathione (GSH).  The model uses the local charge-limited electrophilicity index ωq at the β-carbon atom as a descriptor of reactivity, a descriptor for resonance stabilization of the transition state, and one for steric hindrance at the reaction sites involved.  Overall, the Michael addn. model performs well (r2 = 0.91; rms = 0.34).  It includes various classes of compds. with double and triple bonds, linear and cyclic systems, and compds. with and without substituents in the α-position.  Comparison of exptl. and predicted rate consts. demonstrates even better performance of the model for individual classes of compds. (e.g., for aldehydes, r2 = 0.97 and rms = 0.15; for ketones, r2 = 0.95 and rms = 0.35).  The model also allows for the prediction of the RC50 values from the Schultz chemoassay, the accuracy being close to the interlab. exptl. error.  Furthermore, kGSH and assocd. RC50 values can be predicted in cases where exptl. measurements are not possible or restricted, for example, because of low soly. or high volatility.  The model has the potential to provide information to assist in the assessment and categorization of toxicants and in the application of integrated testing strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomptlZNO-ZPrVg90H21EOLACvtfcHk0liyGYmial6OCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1akt7jL&md5=a4ec98f9001e66973e994520aca58492</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Ftx100172x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx100172x%26sid%3Dliteratum%253Aachs%26aulast%3DSchwobel%26aufirst%3DJ.%2BA.%26aulast%3DWondrousch%26aufirst%3DD.%26aulast%3DKoleva%26aufirst%3DY.%2BK.%26aulast%3DMadden%26aufirst%3DJ.%2BC.%26aulast%3DCronin%26aufirst%3DM.%2BT.%26aulast%3DSchuurmann%26aufirst%3DG.%26atitle%3DPrediction%2520of%2520Michael-type%2520acceptor%2520reactivity%2520toward%2520glutathione%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2010%26volume%3D23%26spage%3D1576%26epage%3D1585%26doi%3D10.1021%2Ftx100172x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grenningloh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Head, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haselmayer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu-Bujalski, L.</span></span> <span> </span><span class="NLM_article-title">Ability of Bruton’s tyrosine kinase inhibitors to sequester Y551 and prevent phosphorylation determines potency for inhibition of Fc receptor but not B-cell receptor signaling</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">208</span>– <span class="NLM_lpage">219</span>, <span class="refDoi"> DOI: 10.1124/mol.116.107037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.1124%2Fmol.116.107037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=28062735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpsFajtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2017&pages=208-219&author=A.+T.+Benderauthor=A.+Gardbergauthor=A.+Pereiraauthor=T.+Johnsonauthor=Y.+Wuauthor=R.+Grenninglohauthor=J.+Headauthor=F.+Morandiauthor=P.+Haselmayerauthor=L.+Liu-Bujalski&title=Ability+of+Bruton%E2%80%99s+tyrosine+kinase+inhibitors+to+sequester+Y551+and+prevent+phosphorylation+determines+potency+for+inhibition+of+Fc+receptor+but+not+B-cell+receptor+signaling&doi=10.1124%2Fmol.116.107037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Ability of Bruton's tyrosine kinase inhibitors to sequester Y551 and prevent phosphorylation determines potency for inhibition of Fc receptor but not B-cell receptor signaling</span></div><div class="casAuthors">Bender, Andrew T.; Gardberg, Anna; Pereira, Albertina; Johnson, Theresa; Wu, Yin; Grenningloh, Roland; Head, Jared; Morandi, Federica; Haselmayer, Philipp; Liu-Bujalski, Lesley</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">208-219</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is expressed in a variety of hematopoietic cells.  Btk has been demonstrated to regulate signaling downstream of the B-cell receptor (BCR), Fc receptors (FcRs), and toll-like receptors.  It has become an attractive drug target because its inhibition may provide significant efficacy by simultaneously blocking multiple disease mechanisms.  Consequently, a large no. of Btk inhibitors have been developed.  These compds. have diverse binding modes, and both reversible and irreversible inhibitors have been developed.  Reported herein, we have tested nine Btk inhibitors and characterized on a mol. level how their interactions with Btk define their ability to block different signaling pathways.  By solving the crystal structures of Btk inhibitors bound to the enzyme, we discovered that the compds. can be classified by their ability to trigger sequestration of Btk residue Y551.  In cells, we found that sequestration of Y551 renders it inaccessible for phosphorylation.  The ability to sequester Y551 was an important determinant of potency against FcγR signaling as Y551 sequestering compds. were more potent for inhibiting basophils and mast cells.  This result was true for the inhibition of FcγR signaling as well.  In contrast, Y551 sequestration was less a factor in detg. potency against BCR signaling.  We also found that Btk activity is regulated differentially in basophils and B cells.  These results elucidate important determinants for Btk inhibitor potency against different signaling pathways and provide insight for designing new compds. with a broader inhibitory profile that will likely result in greater efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrN8F--ON3M7Vg90H21EOLACvtfcHk0lhOycvhE1icVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpsFajtr8%253D&md5=f869d52d6bc1aabf352988787ff1cbcf</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1124%2Fmol.116.107037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.116.107037%26sid%3Dliteratum%253Aachs%26aulast%3DBender%26aufirst%3DA.%2BT.%26aulast%3DGardberg%26aufirst%3DA.%26aulast%3DPereira%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DGrenningloh%26aufirst%3DR.%26aulast%3DHead%26aufirst%3DJ.%26aulast%3DMorandi%26aufirst%3DF.%26aulast%3DHaselmayer%26aufirst%3DP.%26aulast%3DLiu-Bujalski%26aufirst%3DL.%26atitle%3DAbility%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%2520to%2520sequester%2520Y551%2520and%2520prevent%2520phosphorylation%2520determines%2520potency%2520for%2520inhibition%2520of%2520Fc%2520receptor%2520but%2520not%2520B-cell%2520receptor%2520signaling%26jtitle%3DMol.%2520Pharmacol.%26date%3D2017%26volume%3D91%26spage%3D208%26epage%3D219%26doi%3D10.1124%2Fmol.116.107037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitty, A.</span></span> <span> </span><span class="NLM_article-title">The resurgence of covalent drugs</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1038/nrd3410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.1038%2Fnrd3410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=21455239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=307-317&author=J.+Singhauthor=R.+C.+Petterauthor=T.+A.+Baillieauthor=A.+Whitty&title=The+resurgence+of+covalent+drugs&doi=10.1038%2Fnrd3410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of covalent drugs</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Baillie, Thomas A.; Whitty, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-317</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Covalent drugs haveproved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project.  There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium.  This Review surveys the prevalence and pharmacol. advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreDCEmORV_NbVg90H21EOLACvtfcHk0lhOycvhE1icVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D&md5=2190289081e151416c097be4a5b04460</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrd3410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3410%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DWhitty%26aufirst%3DA.%26atitle%3DThe%2520resurgence%2520of%2520covalent%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D307%26epage%3D317%26doi%3D10.1038%2Fnrd3410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bendele, A.</span></span> <span> </span><span class="NLM_article-title">Animal models of rheumatoid arthritis</span>. <i>J. Musculoskelet. Neuron. Interact.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">377</span>– <span class="NLM_lpage">385</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=15758488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltVOhu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2001&pages=377-385&author=A.+Bendele&title=Animal+models+of+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Animal models of rheumatoid arthritis</span></div><div class="casAuthors">Bendele, A. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Musculoskeletal & Neuronal Interactions</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">377-385</span>CODEN:
                <span class="NLM_cas:coden">JMNIB3</span>;
        ISSN:<span class="NLM_cas:issn">1108-7161</span>.
    
            (<span class="NLM_cas:orgname">Journal of Musculoskeletal and Neuronal Interactions</span>)
        </div><div class="casAbstract">A review.  Animal models of arthritis are used to study pathogenesis of disease and to evaluate potential anti-arthritic drugs for clin. use.  Therefore morphol. similarities to human disease and capacity of the model to predict efficacy in humans are important criteria in model selection.  Animal models of rheumatoid arthritis (RA) with a proven track record of predictability for efficacy in humans include: rat adjuvant arthritis, rat type II collagen arthritis, mouse type II collagen arthritis and antigen-induced arthritis in several species.  Agents currently in clin. use (or trials) that are active in these models include: corticosteroids, methotrexate, nonsteroidal anti-inflammatory drugs, cyclosporin A, leflunomide interleukin-1 receptor antagonist (IL-1ra) and sol. TNF receptors.  For some of these agents, the models also predict that toxicities seen at higher doses for prolonged dosing periods would preclude dosing in humans at levels that might provide disease modifying effects.  Data, conduct and features of the various models of these commonly utilized models of RA as well as some transgenic mouse models and less commonly utilized rodent models will be discussed with emphasis on their similarities to human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwhtLWBEJFcbVg90H21EOLACvtfcHk0lhOycvhE1icVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltVOhu7o%253D&md5=21f16894bcfdad981a6b7d32773431cf</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBendele%26aufirst%3DA.%26atitle%3DAnimal%2520models%2520of%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Musculoskelet.%2520Neuron.%2520Interact.%26date%3D2001%26volume%3D1%26spage%3D377%26epage%3D385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span> <i>Collagen Induced Arthritis (CIA) in Rat</i>; <span class="NLM_publisher-name">Bolder BioPath</span>, <span class="NLM_year">2015</span>; <a href="https://bolderbiopath.com/study/collagen-induced-arthritis-rat/" class="extLink">https://bolderbiopath.com/study/collagen-induced-arthritis-rat/</a> (accessed January 7, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Collagen+Induced+Arthritis+%28CIA%29+in+Rat%3B+Bolder+BioPath%2C+2015%3B+https%3A%2F%2Fbolderbiopath.com%2Fstudy%2Fcollagen-induced-arthritis-rat%2F+%28accessed+January+7%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DCollagen%2520Induced%2520Arthritis%2520%2528CIA%2529%2520in%2520Rat%26pub%3DBolder%2520BioPath%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 24 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Zhouling Xie, Xiaoxiao Yang, Yajun Duan, Jihong Han, <span class="NLM_string-name hlFld-ContribAuthor">Chenzhong Liao</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (3)
                                     , 1283-1345. <a href="https://doi.org/10.1021/acs.jmedchem.0c01511" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01511</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01511%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall-Molecule%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BNononcologic%252BDiseases%26aulast%3DXie%26aufirst%3DZhouling%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D29082020%26date%3D22012021%26volume%3D64%26issue%3D3%26spage%3D1283%26epage%3D1345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Guomeng Xing, Li Liang, Chenglong Deng, Yi Hua, Xingye Chen, Yan Yang, Haichun Liu, Tao Lu, Yadong Chen, <span class="NLM_string-name hlFld-ContribAuthor">Yanmin Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Activity Prediction of Small Molecule Inhibitors for Antirheumatoid Arthritis Targets Based on Artificial Intelligence. </span><span class="cited-content_cbyCitation_journal-name">ACS Combinatorial Science</span><span> <strong>2020,</strong> <em>22 </em>
                                    (12)
                                     , 873-886. <a href="https://doi.org/10.1021/acscombsci.0c00169" title="DOI URL">https://doi.org/10.1021/acscombsci.0c00169</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscombsci.0c00169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscombsci.0c00169%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Combinatorial%2520Science%26atitle%3DActivity%252BPrediction%252Bof%252BSmall%252BMolecule%252BInhibitors%252Bfor%252BAntirheumatoid%252BArthritis%252BTargets%252BBased%252Bon%252BArtificial%252BIntelligence%26aulast%3DXing%26aufirst%3DGuomeng%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D12082020%26date%3D11102020%26date%3D04112020%26volume%3D22%26issue%3D12%26spage%3D873%26epage%3D886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Bin Ma, Tonika Bohnert, Kevin L. Otipoby, Eric Tien, Million Arefayene, Judy Bai, Bekim Bajrami, Eris Bame, Timothy R. Chan, Michael Humora, J. Michael MacPhee, Douglas Marcotte, Devangi Mehta, Claire M. Metrick, George Moniz, Evelyne Polack, Urjana Poreci, Annick Prefontaine, Sarah Sheikh, Patricia Schroeder, Karen Smirnakis, Lei Zhang, Fengmei Zheng, <span class="NLM_string-name hlFld-ContribAuthor">Brian T. Hopkins</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of BIIB068: A Selective, Potent, Reversible Bruton’s Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (21)
                                     , 12526-12541. <a href="https://doi.org/10.1021/acs.jmedchem.0c00702" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00702</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00702%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BBIIB068%25253A%252BA%252BSelective%25252C%252BPotent%25252C%252BReversible%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252BInhibitor%252Bas%252Ban%252BOrally%252BEfficacious%252BAgent%252Bfor%252BAutoimmune%252BDiseases%26aulast%3DMa%26aufirst%3DBin%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D27042020%26date%3D06082020%26date%3D22072020%26volume%3D63%26issue%3D21%26spage%3D12526%26epage%3D12541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Anurag S. Srivastava, Soo Ko, Scott H. Watterson, Mark A. Pattoli, Stacey Skala, Lihong Cheng, Mary T. Obermeier, Rodney Vickery, Lorell N. Discenza, Celia J. D’Arienzo, Kathleen M. Gillooly, Tracy L. Taylor, Claudine Pulicicchio, Kim W. McIntyre, Shiuhang Yip, Peng Li, Dawn Sun, Dauh-Rurng Wu, Jun Dai, Chunlei Wang, Yingru Zhang, Bei Wang, Joseph Pawluczyk, James Kempson, Rulin Zhao, Xiaoping Hou, Richard Rampulla, Arvind Mathur, Michael A. Galella, Luisa Salter-Cid, Joel C. Barrish, Percy H. Carter, Aberra Fura, James R. Burke, <span class="NLM_string-name hlFld-ContribAuthor">Joseph A. Tino</span>. </span><span class="cited-content_cbyCitation_article-title">Driving Potency with Rotationally Stable Atropisomers: Discovery of Pyridopyrimidinedione-Carbazole Inhibitors of BTK. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (11)
                                     , 2195-2203. <a href="https://doi.org/10.1021/acsmedchemlett.0c00335" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00335</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00335%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDriving%252BPotency%252Bwith%252BRotationally%252BStable%252BAtropisomers%25253A%252BDiscovery%252Bof%252BPyridopyrimidinedione-Carbazole%252BInhibitors%252Bof%252BBTK%26aulast%3DSrivastava%26aufirst%3DAnurag%2BS.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D16062020%26date%3D16092020%26date%3D22092020%26date%3D16092020%26volume%3D11%26issue%3D11%26spage%3D2195%26epage%3D2203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xuejun Zhang, Xijun Sheng, Jie Shen, Shoubo Zhang, Wenjie Sun, Chunli Shen, Yi Li, Jun Wang, Huqiang Lv, Minghui Cui, Yuchuan Zhu, Lei Huang, Dongling Hao, Zhibo Qi, Guanglong Sun, Weifeng Mao, Yan Pan, Liang Shen, Xin Li, Guoping Hu, Zhen Gong, Shuhua Han, Jian Li, Shuhui Chen, Ronghua Tu, Xuehai Wang, <span class="NLM_string-name hlFld-ContribAuthor">Chengde Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Evaluation of Pyrazolo[3,4-d]pyridazinone as a Potent and Orally Active Irreversible BTK Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (10)
                                     , 1863-1868. <a href="https://doi.org/10.1021/acsmedchemlett.9b00395" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00395</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00395%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Band%252BEvaluation%252Bof%252BPyrazolo%25255B3%25252C4-d%25255Dpyridazinone%252Bas%252Ba%252BPotent%252Band%252BOrally%252BActive%252BIrreversible%252BBTK%252BInhibitor%26aulast%3DZhang%26aufirst%3DXuejun%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D23082019%26date%3D11122019%26date%3D16122019%26date%3D11122019%26volume%3D11%26issue%3D10%26spage%3D1863%26epage%3D1868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Tao Chen, Hao Xiong, Jing-Fang Yang, Xiao-Lei Zhu, Ren-Yu Qu, <span class="NLM_string-name hlFld-ContribAuthor">Guang-Fu Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Diaryl Ether: A Privileged Scaffold for Drug and Agrochemical Discovery. </span><span class="cited-content_cbyCitation_journal-name">Journal of Agricultural and Food Chemistry</span><span> <strong>2020,</strong> <em>68 </em>
                                    (37)
                                     , 9839-9877. <a href="https://doi.org/10.1021/acs.jafc.0c03369" title="DOI URL">https://doi.org/10.1021/acs.jafc.0c03369</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jafc.0c03369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jafc.0c03369%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Agricultural%2520and%2520Food%2520Chemistry%26atitle%3DDiaryl%252BEther%25253A%252BA%252BPrivileged%252BScaffold%252Bfor%252BDrug%252Band%252BAgrochemical%252BDiscovery%26aulast%3DChen%26aufirst%3DTao%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D27052020%26date%3D11082020%26date%3D11082020%26date%3D29082020%26date%3D11082020%26volume%3D68%26issue%3D37%26spage%3D9839%26epage%3D9877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hongji  Li</span>, <span class="hlFld-ContribAuthor ">Yue  Li</span>, <span class="hlFld-ContribAuthor ">Dandan  Wang</span>, <span class="hlFld-ContribAuthor ">Junfu  Wang</span>, <span class="hlFld-ContribAuthor ">Jinyue  Zhang</span>, <span class="hlFld-ContribAuthor ">Wei  Jiang</span>, <span class="hlFld-ContribAuthor ">Tianyu  Zhou</span>, <span class="hlFld-ContribAuthor ">Chunbo  Liu</span>, <span class="hlFld-ContribAuthor ">Guangbo  Che</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of hydrophilic SERS-imprinted membrane based on graft polymerization for selective detection of L-tyrosine. </span><span class="cited-content_cbyCitation_journal-name">Sensors and Actuators B: Chemical</span><span> <strong>2021,</strong> <em>340 </em>, 129955. <a href="https://doi.org/10.1016/j.snb.2021.129955" title="DOI URL">https://doi.org/10.1016/j.snb.2021.129955</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.snb.2021.129955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.snb.2021.129955%26sid%3Dliteratum%253Aachs%26jtitle%3DSensors%2520and%2520Actuators%2520B%253A%2520Chemical%26atitle%3DSynthesis%252Bof%252Bhydrophilic%252BSERS-imprinted%252Bmembrane%252Bbased%252Bon%252Bgraft%252Bpolymerization%252Bfor%252Bselective%252Bdetection%252Bof%252BL-tyrosine%26aulast%3DLi%26aufirst%3DHongji%26date%3D2021%26volume%3D340%26spage%3D129955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lauren E.  Kueffer</span>, <span class="hlFld-ContribAuthor ">Raji E.  Joseph</span>, <span class="hlFld-ContribAuthor ">Amy H.  Andreotti</span>. </span><span class="cited-content_cbyCitation_article-title">Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Cell and Developmental Biology</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.3389/fcell.2021.655489" title="DOI URL">https://doi.org/10.3389/fcell.2021.655489</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fcell.2021.655489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffcell.2021.655489%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Cell%2520and%2520Developmental%2520Biology%26atitle%3DReining%252Bin%252BBTK%25253A%252BInterdomain%252BInteractions%252Band%252BTheir%252BImportance%252Bin%252Bthe%252BRegulatory%252BControl%252Bof%252BBTK%26aulast%3DKueffer%26aufirst%3DLauren%2BE.%26date%3D2021%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Krista D.  DiSano</span>, <span class="hlFld-ContribAuthor ">Francesca  Gilli</span>, <span class="hlFld-ContribAuthor ">Andrew R.  Pachner</span>. </span><span class="cited-content_cbyCitation_article-title">Memory B Cells in Multiple Sclerosis: Emerging Players in Disease Pathogenesis. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Immunology</span><span> <strong>2021,</strong> <em>12 </em><a href="https://doi.org/10.3389/fimmu.2021.676686" title="DOI URL">https://doi.org/10.3389/fimmu.2021.676686</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fimmu.2021.676686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffimmu.2021.676686%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Immunology%26atitle%3DMemory%252BB%252BCells%252Bin%252BMultiple%252BSclerosis%25253A%252BEmerging%252BPlayers%252Bin%252BDisease%252BPathogenesis%26aulast%3DDiSano%26aufirst%3DKrista%2BD.%26date%3D2021%26date%3D2021%26volume%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stefan F. H.  Neys</span>, <span class="hlFld-ContribAuthor ">Rudi W.  Hendriks</span>, <span class="hlFld-ContribAuthor ">Odilia B. J.  Corneth</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Bruton’s Tyrosine Kinase in Inflammatory and Autoimmune Pathologies. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Cell and Developmental Biology</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.3389/fcell.2021.668131" title="DOI URL">https://doi.org/10.3389/fcell.2021.668131</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fcell.2021.668131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffcell.2021.668131%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Cell%2520and%2520Developmental%2520Biology%26atitle%3DTargeting%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252Bin%252BInflammatory%252Band%252BAutoimmune%252BPathologies%26aulast%3DNeys%26aufirst%3DStefan%2BF.%2BH.%26date%3D2021%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Finn  Sellebjerg</span>, <span class="hlFld-ContribAuthor ">Martin S.  Weber</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting B cells in multiple sclerosis. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Neurology</span><span> <strong>2021,</strong> <em>34 </em>
                                    (3)
                                     , 295-302. <a href="https://doi.org/10.1097/WCO.0000000000000938" title="DOI URL">https://doi.org/10.1097/WCO.0000000000000938</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1097/WCO.0000000000000938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1097%2FWCO.0000000000000938%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Neurology%26atitle%3DTargeting%252BB%252Bcells%252Bin%252Bmultiple%252Bsclerosis%26aulast%3DSellebjerg%26aufirst%3DFinn%26date%3D2021%26date%3D2021%26volume%3D34%26issue%3D3%26spage%3D295%26epage%3D302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hui  Qiu</span>, <span class="hlFld-ContribAuthor ">Zahid  Ali</span>, <span class="hlFld-ContribAuthor ">Andrew  Bender</span>, <span class="hlFld-ContribAuthor ">Richard  Caldwell</span>, <span class="hlFld-ContribAuthor ">Yi-Ying  Chen</span>, <span class="hlFld-ContribAuthor ">Zhizhou  Fang</span>, <span class="hlFld-ContribAuthor ">Anna  Gardberg</span>, <span class="hlFld-ContribAuthor ">Nina  Glaser</span>, <span class="hlFld-ContribAuthor ">Anja  Goettsche</span>, <span class="hlFld-ContribAuthor ">Andreas  Goutopoulos</span>, <span class="hlFld-ContribAuthor ">Roland  Grenningloh</span>, <span class="hlFld-ContribAuthor ">Bettina  Hanschke</span>, <span class="hlFld-ContribAuthor ">Jared  Head</span>, <span class="hlFld-ContribAuthor ">Theresa  Johnson</span>, <span class="hlFld-ContribAuthor ">Christopher  Jones</span>, <span class="hlFld-ContribAuthor ">Reinaldo  Jones</span>, <span class="hlFld-ContribAuthor ">Shashank  Kulkarni</span>, <span class="hlFld-ContribAuthor ">Christine  Maurer</span>, <span class="hlFld-ContribAuthor ">Federica  Morandi</span>, <span class="hlFld-ContribAuthor ">Constantin  Neagu</span>, <span class="hlFld-ContribAuthor ">Sven  Poetzsch</span>, <span class="hlFld-ContribAuthor ">Justin  Potnick</span>, <span class="hlFld-ContribAuthor ">Ralf  Schmidt</span>, <span class="hlFld-ContribAuthor ">Katherine  Roe</span>, <span class="hlFld-ContribAuthor ">Ariele  Viacava Follis</span>, <span class="hlFld-ContribAuthor ">Carolyn  Wing</span>, <span class="hlFld-ContribAuthor ">Xiaohua  Zhu</span>, <span class="hlFld-ContribAuthor ">Brian  Sherer</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of potent and selective reversible Bruton’s tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>40 </em>, 116163. <a href="https://doi.org/10.1016/j.bmc.2021.116163" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.116163</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.116163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.116163%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bpotent%252Band%252Bselective%252Breversible%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DQiu%26aufirst%3DHui%26date%3D2021%26volume%3D40%26spage%3D116163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">William J.  Pitts</span>, <span class="hlFld-ContribAuthor ">Alaric J.  Dyckman</span>. </span><span class="cited-content_cbyCitation_article-title">Multiple Sclerosis. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-43. <a href="https://doi.org/10.1002/0471266949.bmc203.pub2" title="DOI URL">https://doi.org/10.1002/0471266949.bmc203.pub2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc203.pub2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc203.pub2%26sid%3Dliteratum%253Aachs%26atitle%3DMultiple%252BSclerosis%26aulast%3DPitts%26aufirst%3DWilliam%2BJ.%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D43%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiamin  Zheng</span>, <span class="hlFld-ContribAuthor ">Jun  Wu</span>, <span class="hlFld-ContribAuthor ">Xiao  Ding</span>, <span class="hlFld-ContribAuthor ">Hong C.  Shen</span>, <span class="hlFld-ContribAuthor ">Ge  Zou</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecule approaches to treat autoimmune and inflammatory diseases (Part I): Kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>38 </em>, 127862. <a href="https://doi.org/10.1016/j.bmcl.2021.127862" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.127862</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.127862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.127862%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSmall%252Bmolecule%252Bapproaches%252Bto%252Btreat%252Bautoimmune%252Band%252Binflammatory%252Bdiseases%252B%252528Part%252BI%252529%25253A%252BKinase%252Binhibitors%26aulast%3DZheng%26aufirst%3DJiamin%26date%3D2021%26volume%3D38%26spage%3D127862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">H. Yesid  Estupiñán</span>, <span class="hlFld-ContribAuthor ">Anna  Berglöf</span>, <span class="hlFld-ContribAuthor ">Rula  Zain</span>, <span class="hlFld-ContribAuthor ">C. I. Edvard  Smith</span>. </span><span class="cited-content_cbyCitation_article-title">Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Cell and Developmental Biology</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.3389/fcell.2021.630942" title="DOI URL">https://doi.org/10.3389/fcell.2021.630942</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fcell.2021.630942&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffcell.2021.630942%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Cell%2520and%2520Developmental%2520Biology%26atitle%3DComparative%252BAnalysis%252Bof%252BBTK%252BInhibitors%252Band%252BMechanisms%252BUnderlying%252BAdverse%252BEffects%26aulast%3DEstupi%25C3%25B1%25C3%25A1n%26aufirst%3DH.%2BYesid%26date%3D2021%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Philipp  von Hundelshausen</span>, <span class="hlFld-ContribAuthor ">Wolfgang  Siess</span>. </span><span class="cited-content_cbyCitation_article-title">Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (5)
                                     , 1103. <a href="https://doi.org/10.3390/cancers13051103" title="DOI URL">https://doi.org/10.3390/cancers13051103</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13051103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13051103%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DBleeding%252Bby%252BBruton%252BTyrosine%252BKinase-Inhibitors%25253A%252BDependency%252Bon%252BDrug%252BType%252Band%252BDisease%26aulast%3Dvon%2BHundelshausen%26aufirst%3DPhilipp%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D5%26spage%3D1103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jinsha  Liu</span>, <span class="hlFld-ContribAuthor ">Joey Paolo  Ting</span>, <span class="hlFld-ContribAuthor ">Shams  Al-Azzam</span>, <span class="hlFld-ContribAuthor ">Yun  Ding</span>, <span class="hlFld-ContribAuthor ">Sepideh  Afshar</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (6)
                                     , 2805. <a href="https://doi.org/10.3390/ijms22062805" title="DOI URL">https://doi.org/10.3390/ijms22062805</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22062805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22062805%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DTherapeutic%252BAdvances%252Bin%252BDiabetes%25252C%252BAutoimmune%25252C%252Band%252BNeurological%252BDiseases%26aulast%3DLiu%26aufirst%3DJinsha%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D6%26spage%3D2805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuping  Zhao</span>, <span class="hlFld-ContribAuthor ">Muhammad  Bilal</span>, <span class="hlFld-ContribAuthor ">Ali  Raza</span>, <span class="hlFld-ContribAuthor ">Muhammad Imran  Khan</span>, <span class="hlFld-ContribAuthor ">Shahid  Mehmood</span>, <span class="hlFld-ContribAuthor ">Uzma  Hayat</span>, <span class="hlFld-ContribAuthor ">Sherif T.S.  Hassan</span>, <span class="hlFld-ContribAuthor ">Hafiz M.N.  Iqbal</span>. </span><span class="cited-content_cbyCitation_article-title">Tyrosine kinase inhibitors and their unique therapeutic potentialities to combat cancer. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Biological Macromolecules</span><span> <strong>2021,</strong> <em>168 </em>, 22-37. <a href="https://doi.org/10.1016/j.ijbiomac.2020.12.009" title="DOI URL">https://doi.org/10.1016/j.ijbiomac.2020.12.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijbiomac.2020.12.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijbiomac.2020.12.009%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Biological%2520Macromolecules%26atitle%3DTyrosine%252Bkinase%252Binhibitors%252Band%252Btheir%252Bunique%252Btherapeutic%252Bpotentialities%252Bto%252Bcombat%252Bcancer%26aulast%3DZhao%26aufirst%3DYuping%26date%3D2021%26volume%3D168%26spage%3D22%26epage%3D37" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leonard  Sung</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent drugs in development for immune-mediated diseases. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 33-74. <a href="https://doi.org/10.1016/bs.armc.2021.03.001" title="DOI URL">https://doi.org/10.1016/bs.armc.2021.03.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.armc.2021.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.armc.2021.03.001%26sid%3Dliteratum%253Aachs%26atitle%3DCovalent%252Bdrugs%252Bin%252Bdevelopment%252Bfor%252Bimmune-mediated%252Bdiseases%26aulast%3DSung%26aufirst%3DLeonard%26date%3D2021%26spage%3D33%26epage%3D74%26pub%3DElsevier%26atitle%3DThe%252BDesign%252Bof%252BCovalent-Based%252BInhibitors%26date%3D2021%26volume%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiaxian  Xu</span>, <span class="hlFld-ContribAuthor ">Fei  Chen</span>, <span class="hlFld-ContribAuthor ">Xuran  Xu</span>, <span class="hlFld-ContribAuthor ">Guo-Ping  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">The selective hydrogenation of nitroarenes and alkenes catalyzed by <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="336357737e7c7540">[email protected]</a>: The role of electronic interactions between Pd nanoparticles and MOFs on the reaction. </span><span class="cited-content_cbyCitation_journal-name">Molecular Catalysis</span><span> <strong>2020,</strong> <em>495 </em>, 111157. <a href="https://doi.org/10.1016/j.mcat.2020.111157" title="DOI URL">https://doi.org/10.1016/j.mcat.2020.111157</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.mcat.2020.111157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.mcat.2020.111157%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Catalysis%26atitle%3DThe%252Bselective%252Bhydrogenation%252Bof%252Bnitroarenes%252Band%252Balkenes%252Bcatalyzed%252Bby%252BPd%252540MOFs%25253A%252BThe%252Brole%252Bof%252Belectronic%252Binteractions%252Bbetween%252BPd%252Bnanoparticles%252Band%252BMOFs%252Bon%252Bthe%252Breaction%26aulast%3DXu%26aufirst%3DJiaxian%26date%3D2020%26volume%3D495%26spage%3D111157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Katsushi  Katayama</span>, <span class="hlFld-ContribAuthor ">Tomoyuki  Tsunemi</span>, <span class="hlFld-ContribAuthor ">Kazuo  Miyazaki</span>, <span class="hlFld-ContribAuthor ">Kouichi  Uoto</span>, <span class="hlFld-ContribAuthor ">Ryosuke  Yoshioka</span>, <span class="hlFld-ContribAuthor ">Hideki  Terashima</span>, <span class="hlFld-ContribAuthor ">Maki  Terakawa</span>, <span class="hlFld-ContribAuthor ">Kyoko  Yamashiro</span>, <span class="hlFld-ContribAuthor ">Munetada  Haruyama</span>, <span class="hlFld-ContribAuthor ">Hiroaki  Maeda</span>, <span class="hlFld-ContribAuthor ">Tomohiro  Makino</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and optimization of a series of 2-azaspiro[3.3]heptane derivatives as orally bioavailable fetal hemoglobin inducers. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (19)
                                     , 127425. <a href="https://doi.org/10.1016/j.bmcl.2020.127425" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127425</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127425%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Boptimization%252Bof%252Ba%252Bseries%252Bof%252B2-azaspiro%25255B3.3%25255Dheptane%252Bderivatives%252Bas%252Borally%252Bbioavailable%252Bfetal%252Bhemoglobin%252Binducers%26aulast%3DKatayama%26aufirst%3DKatsushi%26date%3D2020%26volume%3D30%26issue%3D19%26spage%3D127425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ngiap-Kie  Lim</span>, <span class="hlFld-ContribAuthor ">Haiming  Zhang</span>, <span class="hlFld-ContribAuthor ">C. Gregory  Sowell</span>, <span class="hlFld-ContribAuthor ">Francis  Gosselin</span>. </span><span class="cited-content_cbyCitation_article-title">A fit for purpose synthesis of Bruton’s tyrosine kinase inhibitor GDC-0852. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2020,</strong> <em>61 </em>
                                    (44)
                                     , 152447. <a href="https://doi.org/10.1016/j.tetlet.2020.152447" title="DOI URL">https://doi.org/10.1016/j.tetlet.2020.152447</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2020.152447&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2020.152447%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DA%252Bfit%252Bfor%252Bpurpose%252Bsynthesis%252Bof%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252Binhibitor%252BGDC-0852%26aulast%3DLim%26aufirst%3DNgiap-Kie%26date%3D2020%26volume%3D61%26issue%3D44%26spage%3D152447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Magdalena  Massalska</span>, <span class="hlFld-ContribAuthor ">Wlodzimierz  Maslinski</span>, <span class="hlFld-ContribAuthor ">Marzena  Ciechomska</span>. </span><span class="cited-content_cbyCitation_article-title">Small Molecule Inhibitors in the Treatment of Rheumatoid Arthritis and Beyond: Latest Updates and Potential Strategy for Fighting COVID-19. </span><span class="cited-content_cbyCitation_journal-name">Cells</span><span> <strong>2020,</strong> <em>9 </em>
                                    (8)
                                     , 1876. <a href="https://doi.org/10.3390/cells9081876" title="DOI URL">https://doi.org/10.3390/cells9081876</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cells9081876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcells9081876%26sid%3Dliteratum%253Aachs%26jtitle%3DCells%26atitle%3DSmall%252BMolecule%252BInhibitors%252Bin%252Bthe%252BTreatment%252Bof%252BRheumatoid%252BArthritis%252Band%252BBeyond%25253A%252BLatest%252BUpdates%252Band%252BPotential%252BStrategy%252Bfor%252BFighting%252BCOVID-19%26aulast%3DMassalska%26aufirst%3DMagdalena%26date%3D2020%26date%3D2020%26volume%3D9%26issue%3D8%26spage%3D1876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Julian Matthias  Metzler</span>, <span class="hlFld-ContribAuthor ">Laurin  Burla</span>, <span class="hlFld-ContribAuthor ">Daniel  Fink</span>, <span class="hlFld-ContribAuthor ">Patrick  Imesch</span>. </span><span class="cited-content_cbyCitation_article-title">Ibrutinib in Gynecological Malignancies and Breast Cancer: A Systematic Review. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (11)
                                     , 4154. <a href="https://doi.org/10.3390/ijms21114154" title="DOI URL">https://doi.org/10.3390/ijms21114154</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21114154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21114154%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DIbrutinib%252Bin%252BGynecological%252BMalignancies%252Band%252BBreast%252BCancer%25253A%252BA%252BSystematic%252BReview%26aulast%3DMetzler%26aufirst%3DJulian%2BMatthias%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D11%26spage%3D4154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/medium/jm9b00794_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/large/jm9b00794_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00794&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/medium/jm9b00794_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/large/jm9b00794_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. X-ray structure of BTK ligand <b>B43</b> bound to the BTK kinase domain.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/large/jm9b00794_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00794&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/medium/jm9b00794_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/large/jm9b00794_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Overlay of crystal structures of <b>A5</b> and <b>A7</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/large/jm9b00794_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00794&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/medium/jm9b00794_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/large/jm9b00794_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. PK/PD studies in mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/large/jm9b00794_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00794&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/medium/jm9b00794_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/large/jm9b00794_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Synthetic route for evobrutinib. (a) DBU, DMF, 90 °C, 91%; (b) 4-phenoxylphenyl boronic acid, Pd(OAc)<sub>2</sub>, <i>S</i>-phos, K<sub>2</sub>CO<sub>3</sub>, dioxane–H<sub>2</sub>O (10:1 v/v), 150 °C, 48%; (c) HCl, MeOH, rt; (d) acryloyl chloride, NaHCO<sub>3</sub>, H<sub>2</sub>O–THF (1:10, v/v), rt, 9%</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/large/jm9b00794_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00794&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/medium/jm9b00794_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/large/jm9b00794_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Crystal structure of evobrutinib bound to the BTK kinase domain.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/large/jm9b00794_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00794&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/medium/jm9b00794_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/large/jm9b00794_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Rat CIA model: rats treated with evobrutinib, MTX, or vehicle. (A) Ankle thickness, <i>n</i> = 4 for normal controls, <i>n</i> = 10 per treatment group; <i>P</i> ≤  0.05 ANOVA to vehicle control. (B) Histopathology score, <i>n</i> = 10 per treatment group; <i>P</i> ≤  0.05 ANOVA to vehicle control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00794/20190905/images/large/jm9b00794_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00794&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i58">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33684" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33684" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 27 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, T.</span></span> <span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase is involved in innate and adaptive immunity</span>. <i>Histol. Histopathol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">945</span>– <span class="NLM_lpage">955</span>, <span class="refDoi"> DOI: 10.14670/HH-20.945</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.14670%2FHH-20.945" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=15944945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpsFKjtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2005&pages=945-955&author=C.+Brunnerauthor=B.+Mullerauthor=T.+Wirth&title=Bruton%E2%80%99s+tyrosine+kinase+is+involved+in+innate+and+adaptive+immunity&doi=10.14670%2FHH-20.945"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's Tyrosine Kinase is involved in innate and adaptive immunity</span></div><div class="casAuthors">Brunner, C.; Mueller, B.; Wirth, T.</div><div class="citationInfo"><span class="NLM_cas:title">Histology and Histopathology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">945-955</span>CODEN:
                <span class="NLM_cas:coden">HIHIES</span>;
        ISSN:<span class="NLM_cas:issn">0213-3911</span>.
    
            (<span class="NLM_cas:orgname">Jimenez Godoy, S.A.</span>)
        </div><div class="casAbstract">A review.  Btk is a cytoplasmic tyrosine kinase, which is mainly involved in B cell receptor signaling.  Gene targeting expts. revealed that Btk is important for B cell development and function.  However, Btk is not only expressed in B cells, but also in most other hematopoietic lineages except for T cells and plasma cells.  Recently we found that Btk is involved in Toll-like receptor signaling.  Toll-like receptors play an important role in innate immunity.  They are highly expressed on mast cells, macrophages and dendritic cells, which are essential for the recognition and consequently for the elimination of microbial pathogens.  Therefore Btk might play an important role for the function of immunocompetent cells of innate as well as adaptive immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQA-9NFdeNr7Vg90H21EOLACvtfcHk0liP_-HlARZiQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpsFKjtL4%253D&md5=97cbcc5df2704d4b58933085ab8ff929</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.14670%2FHH-20.945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14670%252FHH-20.945%26sid%3Dliteratum%253Aachs%26aulast%3DBrunner%26aufirst%3DC.%26aulast%3DMuller%26aufirst%3DB.%26aulast%3DWirth%26aufirst%3DT.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520is%2520involved%2520in%2520innate%2520and%2520adaptive%2520immunity%26jtitle%3DHistol.%2520Histopathol.%26date%3D2005%26volume%3D20%26spage%3D945%26epage%3D955%26doi%3D10.14670%2FHH-20.945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Satterthwaite, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, O. N.</span></span> <span> </span><span class="NLM_article-title">Btk function in B cell development and response</span>. <i>Semin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">316</span>, <span class="refDoi"> DOI: 10.1006/smim.1998.0123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.1006%2Fsmim.1998.0123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=9695187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADyaK1cXltlCiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1998&pages=309-316&author=A.+B.+Satterthwaiteauthor=Z.+Liauthor=O.+N.+Witte&title=Btk+function+in+B+cell+development+and+response&doi=10.1006%2Fsmim.1998.0123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Btk function in B cell development and response</span></div><div class="casAuthors">Satterthwaite, Anne B.; Li, Zuomei; Witte, Owen N.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Immunology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">309-316</span>CODEN:
                <span class="NLM_cas:coden">SEIME2</span>;
        ISSN:<span class="NLM_cas:issn">1044-5323</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">A review with 85 refs.  Mutations in Bruton's tyrosine kinase (Btk) result in the B cell immunodeficiencies XLA (X-linked agammaglobulinemia) in humans and Xid (X-linked immunodeficiency) in mice.  Both the maintenance of peripheral B cell nos. and their response to B cell antigen receptor (BCR) crosslinking depend on Btk.  Btk integrates signals from multiple cell surface receptors, including BCR and G-protein coupled receptors.  These Btk dependent signals control B cell proliferation and survival by mediating Ca2+ flux, activating JNK and p38 and inducing cell cycle regulatory genes.  (c) 1998 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVrVOyUeT25bVg90H21EOLACvtfcHk0liP_-HlARZiQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXltlCiuro%253D&md5=f03605bc9f39d663d28794c7b7e40138</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1006%2Fsmim.1998.0123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fsmim.1998.0123%26sid%3Dliteratum%253Aachs%26aulast%3DSatterthwaite%26aufirst%3DA.%2BB.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26atitle%3DBtk%2520function%2520in%2520B%2520cell%2520development%2520and%2520response%26jtitle%3DSemin.%2520Immunol.%26date%3D1998%26volume%3D10%26spage%3D309%26epage%3D316%26doi%3D10.1006%2Fsmim.1998.0123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabuchi, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Astrakhan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humblet-Baron, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kipp, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chae, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellmeier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, O. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawlings, D. J.</span></span> <span> </span><span class="NLM_article-title">Sustained correction of B-cell development and function in a murine model of X-linked agammaglobulinemia (XLA) using retroviral-mediated gene transfer</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">1281</span>– <span class="NLM_lpage">1290</span>, <span class="refDoi"> DOI: 10.1182/blood-2003-09-3044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.1182%2Fblood-2003-09-3044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=15142874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnt1ekurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2004&pages=1281-1290&author=P.+W.+Yuauthor=R.+S.+Tabuchiauthor=R.+M.+Katoauthor=A.+Astrakhanauthor=S.+Humblet-Baronauthor=K.+Kippauthor=K.+Chaeauthor=W.+Ellmeierauthor=O.+N.+Witteauthor=D.+J.+Rawlings&title=Sustained+correction+of+B-cell+development+and+function+in+a+murine+model+of+X-linked+agammaglobulinemia+%28XLA%29+using+retroviral-mediated+gene+transfer&doi=10.1182%2Fblood-2003-09-3044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Sustained correction of B-cell development and function in a murine model of X-linked agammaglobulinemia (XLA) using retroviral-mediated gene transfer</span></div><div class="casAuthors">Yu, Phyllis W.; Tabuchi, Ruby S.; Kato, Roberta M.; Astrakhan, Alexander; Humblet-Baron, Stephanie; Kipp, Kevin; Chae, Keun; Ellmeier, Wilfried; Witte, Owen N.; Rawlings, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1281-1290</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">X-linked agammaglobulinemia (XLA) is a human immunodeficiency caused by mutations in Bruton tyrosine kinase (Btk) and characterized by an arrest in early B-cell development, near absence of serum Ig, and recurrent bacterial infections.  Using Btk- and Tec-deficient mice (BtkTec-/-) as a model for XLA, the authors detd. if Btk gene therapy could correct this disorder.  Bone marrow (BM) from 5-fluorouracil (5FU)-treated BtkTec-/- mice was transduced with a retroviral vector expressing human Btk and transplanted into BtkTec-/- recipients.  Mice engrafted with transduced hematopoietic cells exhibited rescue of both primary and peripheral B-lineage development, recovery of peritoneal B1 B cells, and correction of serum IgM and IgG3 levels.  Gene transfer also restored T-independent type II immune responses, and B-cell antigen receptor (BCR) proliferative responses.  B-cell progenitors derived from Btk-transduced stem cells exhibited higher levels of Btk expression than non-B cells; and marking studies demonstrated a selective advantage for Btk-transduced B-lineage cells.  BM derived from primary recipients also rescued Btk-dependent function in secondary hosts that had received a transplant.  Together, these data demonstrate that gene transfer into hematopoietic stem cells can reconstitute Btk-dependent B-cell development and function in vivo, and strongly support the feasibility of pursuing Btk gene transfer for XLA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWU45QAUL06rVg90H21EOLACvtfcHk0li9_ebr2l_iCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnt1ekurY%253D&md5=579ecc97f831b699fddb4cc2b8a3ddb9</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1182%2Fblood-2003-09-3044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2003-09-3044%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DP.%2BW.%26aulast%3DTabuchi%26aufirst%3DR.%2BS.%26aulast%3DKato%26aufirst%3DR.%2BM.%26aulast%3DAstrakhan%26aufirst%3DA.%26aulast%3DHumblet-Baron%26aufirst%3DS.%26aulast%3DKipp%26aufirst%3DK.%26aulast%3DChae%26aufirst%3DK.%26aulast%3DEllmeier%26aufirst%3DW.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26aulast%3DRawlings%26aufirst%3DD.%2BJ.%26atitle%3DSustained%2520correction%2520of%2520B-cell%2520development%2520and%2520function%2520in%2520a%2520murine%2520model%2520of%2520X-linked%2520agammaglobulinemia%2520%2528XLA%2529%2520using%2520retroviral-mediated%2520gene%2520transfer%26jtitle%3DBlood%26date%3D2004%26volume%3D104%26spage%3D1281%26epage%3D1290%26doi%3D10.1182%2Fblood-2003-09-3044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, W. N.</span></span> <span> </span><span class="NLM_article-title">Regulation of B lymphocyte development and activation by Bruton’s tyrosine kinase</span>. <i>Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">147</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1385/IR:23:2-3:147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.1385%2FIR%3A23%3A2-3%3A147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=11444380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltFWqsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2001&pages=147-156&author=W.+N.+Khan&title=Regulation+of+B+lymphocyte+development+and+activation+by+Bruton%E2%80%99s+tyrosine+kinase&doi=10.1385%2FIR%3A23%3A2-3%3A147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase</span></div><div class="casAuthors">Khan, Wasif N.</div><div class="citationInfo"><span class="NLM_cas:title">Immunologic Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2 & 3</span>),
    <span class="NLM_cas:pages">147-156</span>CODEN:
                <span class="NLM_cas:coden">IMRSEB</span>;
        ISSN:<span class="NLM_cas:issn">0257-277X</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">A review discussed the role of Bruton's tyrosine kinase in B lymphocyte development and activation.  The generation and maintenance of B lymphocytes is controlled by biochem. signals transmitted by the B cell antigen receptor (BCR) complex.  These signals are transduced by multiple cytoplasmic protein tyrosine kinases (PTKs) including Lyn, Syk, and Bruton's tyrosine kinase (BTK).  Upon BCR engagement, these PTKs activate downstream effectors, including transcription factors that modulate gene expression.  In turn, activation of downstream effectors is crit. for B cell survival, cell cycle progression, and antibody prodn.  Our studies focus on the role of BTK in these biol. responses.  We have discovered that BTK is required for activation of the BCR-responsive transcription factor, NF-κB.  Furthermore, BTK-dependent activation of NF-κB is essential for reprogramming the expression of genes that control B cell survival and proliferation.  The biochem. mechanisms by which BTK regulates signaling components that activate NF-κB, and the identification of BTK-responsive genes are under investigation.  Elucidation of these regulatory mechanisms is expected to reveal new therapeutic targets for B cell pathologies involving defects in BTK, including X-linked agammaglobulinemia (XLA).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx0btKIFSX9LVg90H21EOLACvtfcHk0li9_ebr2l_iCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltFWqsb0%253D&md5=564d950f06ab14daff2b45f5a3d863f4</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1385%2FIR%3A23%3A2-3%3A147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1385%252FIR%253A23%253A2-3%253A147%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DW.%2BN.%26atitle%3DRegulation%2520of%2520B%2520lymphocyte%2520development%2520and%2520activation%2520by%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DImmunol.%2520Res.%26date%3D2001%26volume%3D23%26spage%3D147%26epage%3D156%26doi%3D10.1385%2FIR%3A23%3A2-3%3A147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nyhoff, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barron, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonami, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kendall, P. L.</span></span> <span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase is not essential for B cell survival beyond early developmental stages</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>200</i></span>,  <span class="NLM_fpage">2352</span>– <span class="NLM_lpage">2361</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1701489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.4049%2Fjimmunol.1701489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=29483358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltFSltbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=200&publication_year=2018&pages=2352-2361&author=L.+E.+Nyhoffauthor=E.+S.+Clarkauthor=B.+L.+Barronauthor=R.+H.+Bonamiauthor=W.+N.+Khanauthor=P.+L.+Kendall&title=Bruton%E2%80%99s+tyrosine+kinase+is+not+essential+for+B+cell+survival+beyond+early+developmental+stages&doi=10.4049%2Fjimmunol.1701489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's Tyrosine Kinase Is Not Essential for B Cell Survival beyond Early Developmental Stages</span></div><div class="casAuthors">Nyhoff, Lindsay E.; Clark, Emily S.; Barron, Bridgette L.; Bonami, Rachel H.; Khan, Wasif N.; Kendall, Peggy L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">200</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2352-2361</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a crucial regulator of B cell signaling and is a therapeutic target for lymphoma and autoimmune disease.  BTK-deficient patients suffer from humoral immunodeficiency, as their B cells fail to progress beyond the bone marrow.  However, the role of Btk in fully developed, mature peripheral B cells is not well understood.  Anal. using BTK inhibitors is complicated by suboptimal inhibition, off-target effects, or failure to eliminate BTK's adaptor function.  Therefore a Btkflox/Cre-ERT2 mouse model was developed and used to excise Btk after B cell populations were established.  Mice lacking Btk from birth are known to have reduced follicular (FO) compartments, with expanded transitional populations, suggesting a block in development.  In adult Btkflox/Cre-ERT2 mice, Btk excision did not reduce FO B cells, which persisted for weeks.  Autoimmune-prone B1 cells also survived conditional Btk excision, contrasting their near absence in global Btk-deficient mice.  Therefore, Btk supports BCR signaling during selection into the FO and B1 compartments, but is not needed to maintain these cell populations.  B1-related natural IgM levels remained normal, contrasting global Btk deficiency, but B cell proliferation and T-independent type II immunization responses were blunted.  Thus, B cells have nuanced signaling responses that are differentially regulated by Btk for development, survival, and function.  These findings raise the possibility that Btk may also be expendable for survival of mature human B cells, therefore requiring prolonged dosing to be effective, and that success of BTK inhibitors may depend in part on off-target effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoP6akmBuHl2bVg90H21EOLACvtfcHk0li9_ebr2l_iCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltFSltbo%253D&md5=c1e633a39d298ce08a70906db3ad577c</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1701489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1701489%26sid%3Dliteratum%253Aachs%26aulast%3DNyhoff%26aufirst%3DL.%2BE.%26aulast%3DClark%26aufirst%3DE.%2BS.%26aulast%3DBarron%26aufirst%3DB.%2BL.%26aulast%3DBonami%26aufirst%3DR.%2BH.%26aulast%3DKhan%26aufirst%3DW.%2BN.%26aulast%3DKendall%26aufirst%3DP.%2BL.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520is%2520not%2520essential%2520for%2520B%2520cell%2520survival%2520beyond%2520early%2520developmental%2520stages%26jtitle%3DJ.%2520Immunol.%26date%3D2018%26volume%3D200%26spage%3D2352%26epage%3D2361%26doi%3D10.4049%2Fjimmunol.1701489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balazs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barck, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carano, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeForge, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrando, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallion, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannetti, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribling, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciejewski, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staker, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span> <span> </span><span class="NLM_article-title">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1038/nchembio.481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.1038%2Fnchembio.481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=21113169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=41-50&author=J.+A.+Di+Paoloauthor=T.+Huangauthor=M.+Balazsauthor=J.+Barbosaauthor=K.+H.+Barckauthor=B.+J.+Bravoauthor=R.+A.+Caranoauthor=J.+Darrowauthor=D.+R.+Daviesauthor=L.+E.+DeForgeauthor=L.+Diehlauthor=R.+Ferrandoauthor=S.+L.+Gallionauthor=A.+M.+Giannettiauthor=P.+Griblingauthor=V.+Hurezauthor=S.+G.+Hymowitzauthor=R.+Jonesauthor=J.+E.+Kropfauthor=W.+P.+Leeauthor=P.+M.+Maciejewskiauthor=S.+A.+Mitchellauthor=H.+Rongauthor=B.+L.+Stakerauthor=J.+A.+Whitneyauthor=S.+Yehauthor=W.+B.+Youngauthor=C.+Yuauthor=J.+Zhangauthor=K.+Reifauthor=K.+S.+Currie&title=Specific+Btk+inhibition+suppresses+B+cell-+and+myeloid+cell-mediated+arthritis&doi=10.1038%2Fnchembio.481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span></div><div class="casAuthors">Di Paolo, Julie A.; Huang, Tao; Balazs, Mercedesz; Barbosa, James; Barck, Kai H.; Bravo, Brandon J.; Carano, Richard A. D.; Darrow, James; Davies, Douglas R.; DeForge, Laura E.; Diehl, Lauri; Ferrando, Ronald; Gallion, Steven L.; Giannetti, Anthony M.; Gribling, Peter; Hurez, Vincent; Hymowitz, Sarah G.; Jones, Randall; Kropf, Jeffrey E.; Lee, Wyne P.; Maciejewski, Patricia M.; Mitchell, Scott A.; Rong, Hong; Staker, Bart L.; Whitney, J. Andrew; Yeh, Sherry; Young, Wendy B.; Yu, Christine; Zhang, Juan; Reif, Karin; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-50</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a therapeutic target for rheumatoid arthritis, but the cellular and mol. mechanisms by which Btk mediates inflammation are poorly understood.  Here we describe the discovery of CGI1746, a small-mol. Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation.  CGI1746 has exquisite selectivity for Btk and inhibits both auto- and transphosphorylation steps necessary for enzyme activation.  Using CGI1746, we demonstrate that Btk regulates inflammatory arthritis by two distinct mechanisms.  CGI1746 blocks B cell receptor-dependent B cell proliferation and in prophylactic regimens reduces autoantibody levels in collagen-induced arthritis.  In macrophages, Btk inhibition abolishes FcγRIII-induced TNFα, IL-1β and IL-6 prodn.  Accordingly, in myeloid- and FcγR-dependent autoantibody-induced arthritis, CGI1746 decreases cytokine levels within joints and ameliorates disease.  These results provide new understanding of the function of Btk in both B cell- or myeloid cell-driven disease processes and provide a compelling rationale for targeting Btk in rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoegiZYoitP57Vg90H21EOLACvtfcHk0lgUfLXISuhMMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP&md5=99d925c71bc1b201191ebde0f1c0b50f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.481%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBarck%26aufirst%3DK.%2BH.%26aulast%3DBravo%26aufirst%3DB.%2BJ.%26aulast%3DCarano%26aufirst%3DR.%2BA.%26aulast%3DDarrow%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DD.%2BR.%26aulast%3DDeForge%26aufirst%3DL.%2BE.%26aulast%3DDiehl%26aufirst%3DL.%26aulast%3DFerrando%26aufirst%3DR.%26aulast%3DGallion%26aufirst%3DS.%2BL.%26aulast%3DGiannetti%26aufirst%3DA.%2BM.%26aulast%3DGribling%26aufirst%3DP.%26aulast%3DHurez%26aufirst%3DV.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DMaciejewski%26aufirst%3DP.%2BM.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DStaker%26aufirst%3DB.%2BL.%26aulast%3DWhitney%26aufirst%3DJ.%2BA.%26aulast%3DYeh%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DSpecific%2520Btk%2520inhibition%2520suppresses%2520B%2520cell-%2520and%2520myeloid%2520cell-mediated%2520arthritis%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D41%26epage%3D50%26doi%3D10.1038%2Fnchembio.481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Puri, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gold, M. R.</span></span> <span> </span><span class="NLM_article-title">B-cell receptor signaling inhibitors for treatment of autoimmune inflammatory diseases and B-cell malignancies</span>. <i>Int. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">427</span>, <span class="refDoi"> DOI: 10.3109/08830185.2013.818140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.3109%2F08830185.2013.818140" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=23886342" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFygsrrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=397-427&author=K.+D.+Puriauthor=J.+A.+Di+Paoloauthor=M.+R.+Gold&title=B-cell+receptor+signaling+inhibitors+for+treatment+of+autoimmune+inflammatory+diseases+and+B-cell+malignancies&doi=10.3109%2F08830185.2013.818140"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">B-Cell Receptor Signaling Inhibitors for Treatment of Autoimmune Inflammatory Diseases and B-Cell Malignancies</span></div><div class="casAuthors">Puri, Kamal D.; Di Paolo, Julie A.; Gold, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">International Reviews of Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">397-427</span>CODEN:
                <span class="NLM_cas:coden">IRIMEH</span>;
        ISSN:<span class="NLM_cas:issn">0883-0185</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  B-cell receptor (BCR) signaling is essential for normal B-cell development, selection, survival, proliferation, and differentiation into antibody-secreting cells.  Similarly, this pathway plays a key role in the pathogenesis of multiple B-cell malignancies.  Genetic and pharmacol. approaches have established an important role for the Spleen tyrosine kinase (Syk), Bruton's tyrosine kinase (Btk), and phosphatidylinositol 3-kinase isoform p110delta (PI3Kδ) in coupling the BCR and other BCRs to B-cell survival, migration, and activation.  In the past few years, several small-mol. inhibitory drugs that target PI3Kδ, Btk, and Syk have been developed and shown to have efficacy in clin. trials for the treatment of several types of B-cell malignancies.  Emerging preclin. data have also shown a crit. role of BCR signaling in the activation and function of self-reactive B cells that contribute to autoimmune diseases.  Because BCR signaling plays a major role in both B-cell-mediated autoimmune inflammation and B-cell malignancies, inhibition of this pathway may represent a promising new strategy for treating these diseases.  This review summarizes recent achievements in the mechanism of action, pharmacol. properties, and clin. activity and toxicity of these BCR signaling inhibitors, with a focus on their emerging role in treating lymphoid malignancies and autoimmune disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpLDUjmfDEurVg90H21EOLACvtfcHk0lgUfLXISuhMMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFygsrrO&md5=85ace1d58bb75405311bfe4a613ae2a7</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.3109%2F08830185.2013.818140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F08830185.2013.818140%26sid%3Dliteratum%253Aachs%26aulast%3DPuri%26aufirst%3DK.%2BD.%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%2BA.%26aulast%3DGold%26aufirst%3DM.%2BR.%26atitle%3DB-cell%2520receptor%2520signaling%2520inhibitors%2520for%2520treatment%2520of%2520autoimmune%2520inflammatory%2520diseases%2520and%2520B-cell%2520malignancies%26jtitle%3DInt.%2520Rev.%2520Immunol.%26date%3D2013%26volume%3D32%26spage%3D397%26epage%3D427%26doi%3D10.3109%2F08830185.2013.818140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulligan, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaeger, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devereux, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barr, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kipps, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cymbalista, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pocock, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thornton, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caligaris-Cappio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robak, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuster, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montillo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dearden, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fardis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGreivy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmen, P.</span></span> <span> </span><span class="NLM_article-title">Resonate Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>371</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1400376</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.1056%2FNEJMoa1400376" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=24881631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1egsbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=213-223&author=J.+C.+Byrdauthor=J.+R.+Brownauthor=S.+O%E2%80%99Brienauthor=J.+C.+Barrientosauthor=N.+E.+Kayauthor=N.+M.+Reddyauthor=S.+Coutreauthor=C.+S.+Tamauthor=S.+P.+Mulliganauthor=U.+Jaegerauthor=S.+Devereuxauthor=P.+M.+Barrauthor=R.+R.+Furmanauthor=T.+J.+Kippsauthor=F.+Cymbalistaauthor=C.+Pocockauthor=P.+Thorntonauthor=F.+Caligaris-Cappioauthor=T.+Robakauthor=J.+Delgadoauthor=S.+J.+Schusterauthor=M.+Montilloauthor=A.+Schuhauthor=S.+de+Vosauthor=D.+Gillauthor=A.+Bloorauthor=C.+Deardenauthor=C.+Morenoauthor=J.+J.+Jonesauthor=A.+D.+Chuauthor=M.+Fardisauthor=J.+McGreivyauthor=F.+Clowauthor=D.+F.+Jamesauthor=P.+Hillmen&title=Resonate+Investigators.+Ibrutinib+versus+ofatumumab+in+previously+treated+chronic+lymphoid+leukemia&doi=10.1056%2FNEJMoa1400376"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia</span></div><div class="casAuthors">Byrd, J. C.; Brown, J. R.; O'Brien, S.; Barrientos, J. C.; Kay, N. E.; Reddy, N. M.; Coutre, S.; Tam, C. S.; Mulligan, S. P.; Jaeger, U.; Devereux, S.; Barr, P. M.; Furman, R. R.; Kipps, T. J.; Cymbalista, F.; Pocock, C.; Thornton, P.; Caligaris-Cappio, F.; Robak, T.; Delgado, J.; Schuster, S. J.; Montillo, M.; Schuh, A.; de Vos, S.; Gill, D.; Bloor, A.; Dearden, C.; Moreno, C.; Jones, J. J.; Chu, A. D.; Fardis, M.; McGreivy, J.; Clow, F.; James, D. F.; Hillmen, P.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">213-223, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are assocd. with a poor outcome.  We evaluated the efficacy of ibrutinib, a covalent inhibitor of Bruton's tyrosine kinase, in patients at risk for a poor outcome.  Methods: In this multicenter, open-label, phase 3 study, we randomly assigned 391 patients with relapsed or refractory CLL or SLL to receive daily ibrutinib or the anti-CD20 antibody ofatumumab.  The primary end point was the duration of progression-free survival, with the duration of overall survival and the overall response rate as secondary end points.  Results: At a median follow-up of 9.4 mo, ibrutinib significantly improved progression-free survival; the median duration was not reached in the ibrutinib group (with a rate of progression-free survival of 88% at 6 mo), as compared with a median of 8.1 mo in the ofatumumab group (hazard ratio for progression or death in the ibrutinib group, 0.22; P < 0.001).  Ibrutinib also significantly improved overall survival (hazard ratio for death, 0.43; P = 0.005).  At 12 mo, the overall survival rate was 90% in the ibrutinib group and 81% in the ofatumumab group.  The overall response rate was significantly higher in the ibrutinib group than in the ofatumumab group (42.6% vs. 4.1%, P < 0.001).  An addnl. 20% of ibrutinib-treated patients had a partial response with lymphocytosis.  Similar effects were obsd. regardless of whether patients had a chromosome 17p13.1 deletion or resistance to purine analogs.  The most frequent nonhematol. adverse events were diarrhea, fatigue, pyrexia, and nausea in the ibrutinib group and fatigue, infusion-related reactions, and cough in the ofatumumab group.  Conclusions: Ibrutinib, as compared with ofatumumab, significantly improved progression-free survival, overall survival, and response rate among patients with previously treated CLL or SLL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCuX1vrLZxQLVg90H21EOLACvtfcHk0lgUfLXISuhMMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1egsbrN&md5=87b692d35faa0fb8666bb945746fb9b0</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1400376&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1400376%26sid%3Dliteratum%253Aachs%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DKay%26aufirst%3DN.%2BE.%26aulast%3DReddy%26aufirst%3DN.%2BM.%26aulast%3DCoutre%26aufirst%3DS.%26aulast%3DTam%26aufirst%3DC.%2BS.%26aulast%3DMulligan%26aufirst%3DS.%2BP.%26aulast%3DJaeger%26aufirst%3DU.%26aulast%3DDevereux%26aufirst%3DS.%26aulast%3DBarr%26aufirst%3DP.%2BM.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DKipps%26aufirst%3DT.%2BJ.%26aulast%3DCymbalista%26aufirst%3DF.%26aulast%3DPocock%26aufirst%3DC.%26aulast%3DThornton%26aufirst%3DP.%26aulast%3DCaligaris-Cappio%26aufirst%3DF.%26aulast%3DRobak%26aufirst%3DT.%26aulast%3DDelgado%26aufirst%3DJ.%26aulast%3DSchuster%26aufirst%3DS.%2BJ.%26aulast%3DMontillo%26aufirst%3DM.%26aulast%3DSchuh%26aufirst%3DA.%26aulast%3Dde%2BVos%26aufirst%3DS.%26aulast%3DGill%26aufirst%3DD.%26aulast%3DBloor%26aufirst%3DA.%26aulast%3DDearden%26aufirst%3DC.%26aulast%3DMoreno%26aufirst%3DC.%26aulast%3DJones%26aufirst%3DJ.%2BJ.%26aulast%3DChu%26aufirst%3DA.%2BD.%26aulast%3DFardis%26aufirst%3DM.%26aulast%3DMcGreivy%26aufirst%3DJ.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DJames%26aufirst%3DD.%2BF.%26aulast%3DHillmen%26aufirst%3DP.%26atitle%3DResonate%2520Investigators.%2520Ibrutinib%2520versus%2520ofatumumab%2520in%2520previously%2520treated%2520chronic%2520lymphoid%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26spage%3D213%26epage%3D223%26doi%3D10.1056%2FNEJMoa1400376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devereux, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaves, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awan, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woyach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lannutti, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fardis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGreivy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamdy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothbaum, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diacovo, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span> <span> </span><span class="NLM_article-title">Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1509981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.1056%2FNEJMoa1509981" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=26641137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOlur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=323-332&author=J.+C.+Byrdauthor=B.+Harringtonauthor=S.+O%E2%80%99Brienauthor=J.+A.+Jonesauthor=A.+Schuhauthor=S.+Devereuxauthor=J.+Chavesauthor=W.+G.+Wierdaauthor=F.+T.+Awanauthor=J.+R.+Brownauthor=P.+Hillmenauthor=D.+M.+Stephensauthor=P.+Ghiaauthor=J.+C.+Barrientosauthor=J.+M.+Pagelauthor=J.+Woyachauthor=D.+Johnsonauthor=J.+Huangauthor=X.+Wangauthor=A.+Kapteinauthor=B.+J.+Lannuttiauthor=T.+Coveyauthor=M.+Fardisauthor=J.+McGreivyauthor=A.+Hamdyauthor=W.+Rothbaumauthor=R.+Izumiauthor=T.+G.+Diacovoauthor=A.+J.+Johnsonauthor=R.+R.+Furman&title=Acalabrutinib+%28ACP-196%29+in+relapsed+chronic+lymphocytic+leukemia&doi=10.1056%2FNEJMoa1509981"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia</span></div><div class="casAuthors">Byrd, John C.; Harrington, Bonnie; O'Brien, Susan; Jones, Jeffrey A.; Schuh, Anna; Devereux, Steve; Chaves, Jorge; Wierda, William G.; Awan, Farrukh T.; Brown, Jennifer R.; Hillmen, Peter; Stephens, Deborah M.; Ghia, Paolo; Barrientos, Jacqueline C.; Pagel, John M.; Woyach, Jennifer; Johnson, Dave; Huang, Jane; Wang, Xiaolin; Kaptein, Allard; Lannutti, Brian J.; Covey, Todd; Fardis, Maria; McGreivy, Jesse; Hamdy, Ahmed; Rothbaum, Wayne; Izumi, Raquel; Diacovo, Thomas G.; Johnson, Amy J.; Furman, Richard R.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">323-332</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Irreversible inhibition of Bruton's tyrosine kinase (BTK) by ibrutinib represents an important therapeutic advance for the treatment of chronic lymphocytic leukemia (CLL).  However, ibrutinib also irreversibly inhibits alternative kinase targets, which potentially compromises its therapeutic index.  Acalabrutinib (ACP-196) is a more selective, irreversible BTK inhibitor that is specifically designed to improve on the safety and efficacy of first-generation BTK inhibitors.  In this uncontrolled, phase 1-2, multicenter study, we administered oral acalabrutinib to 61 patients who had relapsed CLL to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of acalabrutinib.  Patients were treated with acalabrutinib at a dose of 100 to 400 mg once daily in the dose-escalation (phase 1) portion of the study and 100 mg twice daily in the expansion (phase 2) portion.  The median age of the patients was 62 years, and patients had received a median of three previous therapies for CLL; 31% had chromosome 17p13.1 deletion, and 75% had unmutated Ig heavy-chain variable genes.  No dose-limiting toxic effects occurred during the dose-escalation portion of the study.  The most common adverse events obsd. were headache (in 43% of the patients), diarrhea (in 39%), and in- creased wt. (in 26%).  Most adverse events were of grade 1 or 2.  At a median follow- up of 14.3 mo, the overall response rate was 95%, including 85% with a partial response and 10% with a partial response with lymphocytosis; the remaining 5% of patients had stable disease.  Among patients with chromosome 17p13.1 deletion, the overall response rate was 100%.  No cases of Richter's transformation (CLL that has evolved into large-cell lymphoma) and only one case of CLL progression have occurred.  In this study, the selective BTK inhibitor acalabrutinib had promising safety and efficacy profiles in patients with relapsed CLL, including those with chromosome 17p13.1 deletion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGHCPciF9hPrVg90H21EOLACvtfcHk0lg_P8tmrT56sA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOlur%252FI&md5=d20e0158f9ea308b9d06fa668154516e</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1509981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1509981%26sid%3Dliteratum%253Aachs%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DHarrington%26aufirst%3DB.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DJ.%2BA.%26aulast%3DSchuh%26aufirst%3DA.%26aulast%3DDevereux%26aufirst%3DS.%26aulast%3DChaves%26aufirst%3DJ.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DAwan%26aufirst%3DF.%2BT.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DHillmen%26aufirst%3DP.%26aulast%3DStephens%26aufirst%3DD.%2BM.%26aulast%3DGhia%26aufirst%3DP.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DPagel%26aufirst%3DJ.%2BM.%26aulast%3DWoyach%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DKaptein%26aufirst%3DA.%26aulast%3DLannutti%26aufirst%3DB.%2BJ.%26aulast%3DCovey%26aufirst%3DT.%26aulast%3DFardis%26aufirst%3DM.%26aulast%3DMcGreivy%26aufirst%3DJ.%26aulast%3DHamdy%26aufirst%3DA.%26aulast%3DRothbaum%26aufirst%3DW.%26aulast%3DIzumi%26aufirst%3DR.%26aulast%3DDiacovo%26aufirst%3DT.%2BG.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26atitle%3DAcalabrutinib%2520%2528ACP-196%2529%2520in%2520relapsed%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26spage%3D323%26epage%3D332%26doi%3D10.1056%2FNEJMoa1509981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bitar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadeghian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murina, A.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib-associated pityriasis rosea-like rash</span>. <i>JAAD Case Rep</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">55</span>– <span class="NLM_lpage">57</span>, <span class="refDoi"> DOI: 10.1016/j.jdcr.2017.06.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.1016%2Fj.jdcr.2017.06.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=29387749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A280%3ADC%252BC1MvmtVOguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&pages=55-57&author=C.+Bitarauthor=A.+Sadeghianauthor=L.+Sullivanauthor=A.+Murina&title=Ibrutinib-associated+pityriasis+rosea-like+rash&doi=10.1016%2Fj.jdcr.2017.06.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib-associated pityriasis rosea-like rash</span></div><div class="casAuthors">Bitar Carole; Sadeghian Azeen; Murina Andrea; Sullivan Lacey</div><div class="citationInfo"><span class="NLM_cas:title">JAAD case reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-57</span>
        ISSN:<span class="NLM_cas:issn">2352-5126</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQbpurTOGw_P02yPDyEFiigfW6udTcc2eYPnUFSlCwSn7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvmtVOguw%253D%253D&md5=cfaa97dc12fe02df38ea167eba2f012a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.jdcr.2017.06.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jdcr.2017.06.035%26sid%3Dliteratum%253Aachs%26aulast%3DBitar%26aufirst%3DC.%26aulast%3DSadeghian%26aufirst%3DA.%26aulast%3DSullivan%26aufirst%3DL.%26aulast%3DMurina%26aufirst%3DA.%26atitle%3DIbrutinib-associated%2520pityriasis%2520rosea-like%2520rash%26jtitle%3DJAAD%2520Case%2520Rep%26date%3D2018%26volume%3D4%26spage%3D55%26epage%3D57%26doi%3D10.1016%2Fj.jdcr.2017.06.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Weerdt, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koopmans, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kater, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Gelder, M.</span></span> <span> </span><span class="NLM_article-title">Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">1629</span>– <span class="NLM_lpage">1639</span>, <span class="refDoi"> DOI: 10.3324/haematol.2017.164103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.3324%2Fhaematol.2017.164103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=28775119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2js7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2017&pages=1629-1639&author=I.+de+Weerdtauthor=S.+M.+Koopmansauthor=A.+P.+Katerauthor=M.+van+Gelder&title=Incidence+and+management+of+toxicity+associated+with+ibrutinib+and+idelalisib%3A+a+practical+approach&doi=10.3324%2Fhaematol.2017.164103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach</span></div><div class="casAuthors">de Weerdt, Iris; Koopmans, Suzanne M.; Kater, Arnon P.; Van Gelder, Michel</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1629-1639</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">1592-8721</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">The use of novel B-cell receptor signaling inhibitors results in high response rates and long progression-free survival in patients with indolent B-cell malignancies, such as chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma and Waldenstrom macroglobulinemia.  Ibrutinib, the first-in-class inhibitor of Bruton tyrosine kinase, and idelalisib, the first-in-class inhibitor of phosphatidylinositol 3-kinase α, have recently been approved for the treatment of several indolent B-cell malignancies.  These drugs are esp. being used for previously unmet needs, i.e., for patients with relapsed or refractory disease, high-risk cytogenetic or mol. abnormalities, or with comorbidities.  Treatment with ibrutinib and idelalisib is generally well tolerated, even by elderly patients.  However, the use of these drugs may come with toxicities that are distinct from the side effects of immunochemotherapy.  In this review we discuss the most commonly reported and/or most clin. relevant adverse events assocd. with these B-cell receptor inhibitors, with special emphasis on recommendations for their management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyZRp7XuwODLVg90H21EOLACvtfcHk0lhHD9SNfnh4SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2js7jE&md5=63198531f21c5cc5ca64ead536e5684a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2017.164103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2017.164103%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BWeerdt%26aufirst%3DI.%26aulast%3DKoopmans%26aufirst%3DS.%2BM.%26aulast%3DKater%26aufirst%3DA.%2BP.%26aulast%3Dvan%2BGelder%26aufirst%3DM.%26atitle%3DIncidence%2520and%2520management%2520of%2520toxicity%2520associated%2520with%2520ibrutinib%2520and%2520idelalisib%253A%2520a%2520practical%2520approach%26jtitle%3DHaematologica%26date%3D2017%26volume%3D102%26spage%3D1629%26epage%3D1639%26doi%3D10.3324%2Fhaematol.2017.164103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McMullen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boey, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ooi, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seymour, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, C. S.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">3829</span>– <span class="NLM_lpage">3830</span>, <span class="refDoi"> DOI: 10.1182/blood-2014-10-604272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.1182%2Fblood-2014-10-604272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=25498454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvFGi" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=3829-3830&author=J.+R.+McMullenauthor=E.+J.+Boeyauthor=J.+Y.+Ooiauthor=J.+F.+Seymourauthor=M.+J.+Keatingauthor=C.+S.+Tam&title=Ibrutinib+increases+the+risk+of+atrial+fibrillation%2C+potentially+through+inhibition+of+cardiac+PI3K-Akt+signaling&doi=10.1182%2Fblood-2014-10-604272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling</span></div><div class="casAuthors">McMullen, Julie R.; Boey, Esther J. H.; Ooi, Jenny Y. Y.; Seymour, John F.; Keating, Michael J.; Tam, Constantine S.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">3829-3830</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">This article describes on ibrutinib increases risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling.  Ibrutinib-induced atrial fibrillation (AF) may be due to on-target inhibition of Bruton's tyrosine kinase BTK and related kinases such as tec protein tyrosine kinase (TEC) were expressed in human heart tissue.  The expressions of BTK and TEC transcripts were higher in atrial tissue under conditions of AF than sinus rhythm.  Ibrutinib significantly reduced PI3K-Akt activity in cardiac cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ5R0Y9luwnLVg90H21EOLACvtfcHk0lhHD9SNfnh4SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvFGi&md5=365755ef44550dc25545e683414c8b58</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-10-604272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-10-604272%26sid%3Dliteratum%253Aachs%26aulast%3DMcMullen%26aufirst%3DJ.%2BR.%26aulast%3DBoey%26aufirst%3DE.%2BJ.%26aulast%3DOoi%26aufirst%3DJ.%2BY.%26aulast%3DSeymour%26aufirst%3DJ.%2BF.%26aulast%3DKeating%26aufirst%3DM.%2BJ.%26aulast%3DTam%26aufirst%3DC.%2BS.%26atitle%3DIbrutinib%2520increases%2520the%2520risk%2520of%2520atrial%2520fibrillation%252C%2520potentially%2520through%2520inhibition%2520of%2520cardiac%2520PI3K-Akt%2520signaling%26jtitle%3DBlood%26date%3D2014%26volume%3D124%26spage%3D3829%26epage%3D3830%26doi%3D10.1182%2Fblood-2014-10-604272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span> <span> </span><span class="NLM_article-title">Second-generation inhibitors of Bruton tyrosine kinase</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">80</span>, <span class="refDoi"> DOI: 10.1186/s13045-016-0313-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.1186%2Fs13045-016-0313-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=27590878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVajtr7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=80&author=J.+Wuauthor=C.+Liuauthor=S.+T.+Tsuiauthor=D.+Liu&title=Second-generation+inhibitors+of+Bruton+tyrosine+kinase&doi=10.1186%2Fs13045-016-0313-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Second-generation inhibitors of Bruton tyrosine kinase</span></div><div class="casAuthors">Wu, Jingjing; Liu, Christina; Tsui, Stella T.; Liu, Delong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">80/1-80/7</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Bruton tyrosine kinase (BTK) is a crit. effector mol. for B cell development and plays a major role in lymphoma genesis.  Ibrutinib is the first-generation BTK inhibitor.  Ibrutinib has off-target effects on EGFR, ITK, and Tec family kinases, which explains the untoward effects of ibrutinib.  Resistance to ibrutinib was also reported.  The C481S mutation in the BTK kinase domain was reported to be a major mechanism of resistance to ibrutinib.  This review summarizes the clin. development of novel BTK inhibitors, ACP-196 (acalabrutinib), ONO/GS-4059, and BGB-3111.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb086cwyJYLrVg90H21EOLACvtfcHk0lhHD9SNfnh4SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVajtr7L&md5=b6140d9f7a24665131f5e772d55f29eb</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1186%2Fs13045-016-0313-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-016-0313-y%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DTsui%26aufirst%3DS.%2BT.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DSecond-generation%2520inhibitors%2520of%2520Bruton%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D9%26spage%3D80%26doi%3D10.1186%2Fs13045-016-0313-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span> <i>CALQUENCE (Acalabrutinib) US Prescribing Information</i>; <span class="NLM_publisher-name">US Food and Drug Administration</span>, <span class="NLM_year">2017</span>; <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/210259s000lbl.pdf" class="extLink">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/210259s000lbl.pdf</a> (accessed December 6, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+CALQUENCE+%28Acalabrutinib%29+US+Prescribing+Information%3B+US+Food+and+Drug+Administration%2C+2017%3B+https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2017%2F210259s000lbl.pdf+%28accessed+December+6%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DCALQUENCE%2520%2528Acalabrutinib%2529%2520US%2520Prescribing%2520Information%26pub%3DUS%2520Food%2520and%2520Drug%2520Administration%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haselmayer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camps, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu-Bujalski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Head, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Mahony, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerli, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruns, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grenningloh, R.</span></span> <span> </span><span class="NLM_article-title">Efficacy and pharmacodynamic modeling of the BTK inhibitor evobrutinib in autoimmune disease models</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>202</i></span>,  <span class="NLM_fpage">2888</span>– <span class="NLM_lpage">2906</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1800583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.4049%2Fjimmunol.1800583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=30988116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvF2ntLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=202&publication_year=2019&pages=2888-2906&author=P.+Haselmayerauthor=M.+Campsauthor=L.+Liu-Bujalskiauthor=N.+Nguyenauthor=F.+Morandiauthor=J.+Headauthor=A.+O%E2%80%99Mahonyauthor=S.+C.+Zimmerliauthor=L.+Brunsauthor=A.+Benderauthor=P.+Schroederauthor=R.+Grenningloh&title=Efficacy+and+pharmacodynamic+modeling+of+the+BTK+inhibitor+evobrutinib+in+autoimmune+disease+models&doi=10.4049%2Fjimmunol.1800583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and pharmacodynamic modeling of the BTK inhibitor evobrutinib in autoimmune disease models</span></div><div class="casAuthors">Haselmayer, Philipp; Camps, Montserrat; Liu-Bujalski, Lesley; Nguyen, Ngan; Morandi, Federica; Head, Jared; O'Mahony, Alison; Zimmerli, Simone C.; Bruns, Lisa; Bender, Andrew T.; Schroeder, Patricia; Grenningloh, Roland</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">202</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2888-2906</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Because of its role in mediating both B cell and Fc receptor signaling, Bruton's tyrosine kinase (BTK) is a promising target for the treatment of autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).  Evobrutinib is a novel, highly selective, irreversible BTK inhibitor that potently inhibits BCR- and Fc receptor-mediated signaling and, thus, subsequent activation and function of human B cells and innate immune cells such as monocytes and basophils.  We evaluated evobrutinib in preclin. models of RA and SLE and characterized the relationship between BTK occupancy and inhibition of disease activity.  In mouse models of RA and SLE, orally administered evobrutinib displayed robust efficacy, as demonstrated by redn. of disease severity and histol. damage.  In the SLE model, evobrutinib inhibited B cell activation, reduced autoantibody prodn. and plasma cell nos., and normalized B and T cell subsets.  In the RA model, efficacy was achieved despite failure to reduce autoantibodies.  Pharmacokinetic/pharmacodynamic modeling showed that mean BTK occupancy in blood cells of 80% was linked to near-complete disease inhibition in both RA and SLE mouse models.  In addn., evobrutinib inhibited mast cell activation in a passive cutaneous anaphylaxis model.  Thus, evobrutinib achieves efficacy by acting both on B cells and innate immune cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLVxS4palhvbVg90H21EOLACvtfcHk0lgX8lPI6VMUcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvF2ntLg%253D&md5=9a339003f40e52527127ac12a2593ae9</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1800583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1800583%26sid%3Dliteratum%253Aachs%26aulast%3DHaselmayer%26aufirst%3DP.%26aulast%3DCamps%26aufirst%3DM.%26aulast%3DLiu-Bujalski%26aufirst%3DL.%26aulast%3DNguyen%26aufirst%3DN.%26aulast%3DMorandi%26aufirst%3DF.%26aulast%3DHead%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DA.%26aulast%3DZimmerli%26aufirst%3DS.%2BC.%26aulast%3DBruns%26aufirst%3DL.%26aulast%3DBender%26aufirst%3DA.%26aulast%3DSchroeder%26aufirst%3DP.%26aulast%3DGrenningloh%26aufirst%3DR.%26atitle%3DEfficacy%2520and%2520pharmacodynamic%2520modeling%2520of%2520the%2520BTK%2520inhibitor%2520evobrutinib%2520in%2520autoimmune%2520disease%2520models%26jtitle%3DJ.%2520Immunol.%26date%3D2019%26volume%3D202%26spage%3D2888%26epage%3D2906%26doi%3D10.4049%2Fjimmunol.1800583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montalban, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staikov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piasecka-Stryczynska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willmer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dangond, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syed, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolinsky, J.</span></span> <span> </span><span class="NLM_article-title">on behalf of the Evobrutinib Phase 2 Study Group. Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>380</i></span>,  <span class="NLM_fpage">2406</span>– <span class="NLM_lpage">2417</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1901981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.1056%2FNEJMoa1901981" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=31075187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A280%3ADC%252BB3M7ksVagtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2019&pages=2406-2417&author=X.+Montalbanauthor=D.+L.+Arnoldauthor=M.+S.+Weberauthor=I.+Staikovauthor=K.+Piasecka-Stryczynskaauthor=J.+Willmerauthor=E.+C.+Martinauthor=F.+Dangondauthor=S.+Syedauthor=J.+Wolinsky&title=on+behalf+of+the+Evobrutinib+Phase+2+Study+Group.+Placebo-controlled+trial+of+an+oral+BTK+inhibitor+in+multiple+sclerosis&doi=10.1056%2FNEJMoa1901981"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis</span></div><div class="casAuthors">Montalban Xavier; Arnold Douglas L; Weber Martin S; Staikov Ivan; Piasecka-Stryczynska Karolina; Willmer Jonathan; Martin Emily C; Dangond Fernando; Syed Sana; Wolinsky Jerry S</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2406-2417</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Bruton's tyrosine kinase (BTK) regulates the functions of B cells and myeloid cells that are implicated in the pathogenesis of multiple sclerosis.  Evobrutinib is a selective oral BTK inhibitor that has been shown to inhibit B-cell activation both in vitro and in vivo.  METHODS:  In this double-blind, randomized, phase 2 trial, we assigned patients with relapsing multiple sclerosis to one of five groups: placebo, evobrutinib (at a dose of 25 mg once daily, 75 mg once daily, or 75 mg twice daily), or open-label dimethyl fumarate (DMF) as a reference.  The primary end point was the total (cumulative) number of gadolinium-enhancing lesions identified on T1-weighted magnetic resonance imaging at weeks 12, 16, 20, and 24.  Key secondary end points included the annualized relapse rate and change from baseline in the score on the Expanded Disability Status Scale (EDSS).  RESULTS:  A total of 267 patients were randomly assigned to a trial group.  The mean (±SD) total number of gadolinium-enhancing lesions during weeks 12 through 24 was 3.85±5.44 in the placebo group, 4.06±8.02 in the evobrutinib 25-mg group, 1.69±4.69 in the evobrutinib 75-mg once-daily group, 1.15±3.70 in the evobrutinib 75-mg twice-daily group, and 4.78±22.05 in the DMF group.  The baseline adjusted rate ratios for the total number of lesions over time as compared with placebo were 1.45 in the evobrutinib 25-mg group (P = 0.32), 0.30 in the evobrutinib 75-mg once-daily group (P = 0.005), and 0.44 in the evobrutinib 75-mg twice-daily group (P = 0.06).  The unadjusted annualized relapse rate at week 24 was 0.37 in the placebo group, 0.57 in the evobrutinib 25-mg group, 0.13 in the evobrutinib 75-mg once-daily group, 0.08 in the evobrutinib 75-mg twice-daily group, and 0.20 in the DMF group.  There was no significant effect of trial group on the change from baseline in the EDSS score.  Elevations in liver aminotransferase values were observed with evobrutinib.  CONCLUSIONS:  Patients with relapsing multiple sclerosis who received 75 mg of evobrutinib once daily had significantly fewer enhancing lesions during weeks 12 through 24 than those who received placebo.  There was no significant difference with placebo for either the 25-mg once-daily or 75-mg twice-daily dose of evobrutinib, nor in the annualized relapse rate or disability progression at any dose.  Longer and larger trials are required to determine the effect and risks of evobrutinib in patients with multiple sclerosis. (Funded by EMD Serono; ClinicalTrials.gov number, NCT02975349.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS0eXPD9j4rwiO2kE7krGOBfW6udTcc2eZYQnkX4PAz17ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7ksVagtA%253D%253D&md5=f3e5d3911404f5df778d06340b986ccf</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1901981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1901981%26sid%3Dliteratum%253Aachs%26aulast%3DMontalban%26aufirst%3DX.%26aulast%3DArnold%26aufirst%3DD.%2BL.%26aulast%3DWeber%26aufirst%3DM.%2BS.%26aulast%3DStaikov%26aufirst%3DI.%26aulast%3DPiasecka-Stryczynska%26aufirst%3DK.%26aulast%3DWillmer%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DE.%2BC.%26aulast%3DDangond%26aufirst%3DF.%26aulast%3DSyed%26aufirst%3DS.%26aulast%3DWolinsky%26aufirst%3DJ.%26atitle%3Don%2520behalf%2520of%2520the%2520Evobrutinib%2520Phase%25202%2520Study%2520Group.%2520Placebo-controlled%2520trial%2520of%2520an%2520oral%2520BTK%2520inhibitor%2520in%2520multiple%2520sclerosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D380%26spage%3D2406%26epage%3D2417%26doi%3D10.1056%2FNEJMoa1901981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, R. G.</span></span> <span> </span><span class="NLM_article-title">Idiosyncratic toxicity: a convergence of risk factors</span>. <i>Annu. Rev. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1146/annurev.med.58.072905.160823</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.1146%2Fannurev.med.58.072905.160823" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=16958561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisV2jsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2007&pages=17-34&author=R.+G.+Ulrich&title=Idiosyncratic+toxicity%3A+a+convergence+of+risk+factors&doi=10.1146%2Fannurev.med.58.072905.160823"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Idiosyncratic toxicity: a convergence of risk factors</span></div><div class="casAuthors">Ulrich, Roger G.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">17-34</span>CODEN:
                <span class="NLM_cas:coden">ARMCAH</span>;
        ISSN:<span class="NLM_cas:issn">0066-4219</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The therapeutic margin for any drug is based on both toxicity and efficacy.  Generally, toxicity is dose-dependent and is driven either by the therapeutic target or by an untoward target.  However, idiosyncratic toxicities are usually not obsd. until a drug has been on the market and has gained broad exposure.  Except in the case of pharmacokinetic interactions, these toxicities are not driven solely by drug exposure but rather depend on several drug- and patient-related risk factors.  Drug-related risk factors include metab., bioactivation and covalent binding, and the inhibition of key cell functions.  Patient-related risk factors include underlying disease, age, gender, comedications, nutritional status, activation of the innate immune system, phys. activity, and genetic predispositions.  Idiosyncratic toxicity can occur when a convergence of risk factors, including drug exposure, tips the risk-benefit balance away from benefit and toward risk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4gp_C2QKITbVg90H21EOLACvtfcHk0lgX8lPI6VMUcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisV2jsLs%253D&md5=8f2b7ffb21a38b648a83bc1a8430a17c</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1146%2Fannurev.med.58.072905.160823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.med.58.072905.160823%26sid%3Dliteratum%253Aachs%26aulast%3DUlrich%26aufirst%3DR.%2BG.%26atitle%3DIdiosyncratic%2520toxicity%253A%2520a%2520convergence%2520of%2520risk%2520factors%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2007%26volume%3D58%26spage%3D17%26epage%3D34%26doi%3D10.1146%2Fannurev.med.58.072905.160823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuglstatter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondru, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span> <span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">4539</span>– <span class="NLM_lpage">4550</span>, <span class="refDoi"> DOI: 10.1021/jm300035p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300035p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsVChsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4539-4550&author=Y.+Louauthor=T.+D.+Owensauthor=A.+Kuglstatterauthor=R.+K.+Kondruauthor=D.+M.+Goldstein&title=Bruton%E2%80%99s+tyrosine+kinase+inhibitors%3A+approaches+to+potent+and+selective+inhibition%2C+preclinical+and+clinical+evaluation+for+inflammatory+diseases+and+B+cell+malignancies&doi=10.1021%2Fjm300035p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's Tyrosine Kinase Inhibitors: Approaches to Potent and Selective Inhibition, Preclinical and Clinical Evaluation for Inflammatory Diseases and B Cell Malignancies</span></div><div class="casAuthors">Lou, Yan; Owens, Timothy D.; Kuglstatter, Andreas; Kondru, Rama K.; Goldstein, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4539-4550</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRzAwa4gtFprVg90H21EOLACvtfcHk0lgX8lPI6VMUcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsVChsb8%253D&md5=b470ba4ec4867e4bfb8d1cfa92b1cc6d</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm300035p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300035p%26sid%3Dliteratum%253Aachs%26aulast%3DLou%26aufirst%3DY.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DKondru%26aufirst%3DR.%2BK.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%253A%2520approaches%2520to%2520potent%2520and%2520selective%2520inhibition%252C%2520preclinical%2520and%2520clinical%2520evaluation%2520for%2520inflammatory%2520diseases%2520and%2520B%2520cell%2520malignancies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4539%26epage%3D4550%26doi%3D10.1021%2Fjm300035p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheerens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprengeler, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrill, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendonca, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grothaus, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffery, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spoerke, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honigberg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalrymple, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, J. T.</span></span> <span> </span><span class="NLM_article-title">Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200600221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.1002%2Fcmdc.200600221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=17154430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=58-61&author=Z.+Panauthor=H.+Scheerensauthor=S.+J.+Liauthor=B.+E.+Schultzauthor=P.+A.+Sprengelerauthor=L.+C.+Burrillauthor=R.+V.+Mendoncaauthor=M.+D.+Sweeneyauthor=K.+C.+Scottauthor=P.+G.+Grothausauthor=D.+A.+Jefferyauthor=J.+M.+Spoerkeauthor=L.+A.+Honigbergauthor=P.+R.+Youngauthor=S.+A.+Dalrympleauthor=J.+T.+Palmer&title=Discovery+of+selective+irreversible+inhibitors+for+Bruton%E2%80%99s+tyrosine+kinase&doi=10.1002%2Fcmdc.200600221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective irreversible inhibitors for bruton's tyrosine kinase</span></div><div class="casAuthors">Pan, Zhengying; Scheerens, Heleen; Li, Shyr-Jiann; Schultz, Brian E.; Sprengeler, Paul A.; Burrill, L. Chuck; Mendonca, Rohan V.; Sweeney, Michael D.; Scott, Keana C. K.; Grothaus, Paul G.; Jeffery, Douglas A.; Spoerke, Jill M.; Honigberg, Lee A.; Young, Peter R.; Dalrymple, Stacie A.; Palmer, James T.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-61</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Synthesis and pharmacol. evaluation of a series of peptidomimetic quinoline derivs. was undertaken to evaluate their efficacy in acting as selective irreversible inhibitors of Bruton's tyrosine kinase (Btk).  With the relative scarcity of knowledge on the inhibition of Btk it is crucial to discover a potent and selective tool compd. for this kinase.  Herein is described the discovery of selective irreversible Btk inhibitors and their efficacy in a mouse RA model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovT3kBCYECdbVg90H21EOLACvtfcHk0li2tPJ_IdVhMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbg%253D&md5=023ba8bca9942ad0127d7cf32293e9d2</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200600221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200600221%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DS.%2BJ.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DBurrill%26aufirst%3DL.%2BC.%26aulast%3DMendonca%26aufirst%3DR.%2BV.%26aulast%3DSweeney%26aufirst%3DM.%2BD.%26aulast%3DScott%26aufirst%3DK.%2BC.%26aulast%3DGrothaus%26aufirst%3DP.%2BG.%26aulast%3DJeffery%26aufirst%3DD.%2BA.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DYoung%26aufirst%3DP.%2BR.%26aulast%3DDalrymple%26aufirst%3DS.%2BA.%26aulast%3DPalmer%26aufirst%3DJ.%2BT.%26atitle%3DDiscovery%2520of%2520selective%2520irreversible%2520inhibitors%2520for%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D58%26epage%3D61%26doi%3D10.1002%2Fcmdc.200600221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marcotte, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arduini, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hession, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miatkowski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wildes, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cullen, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mertsching, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romanowski, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvian, L. F.</span></span> <span> </span><span class="NLM_article-title">Structures of human Bruton’s tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases</span>. <i>Protein Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">429</span>– <span class="NLM_lpage">439</span>, <span class="refDoi"> DOI: 10.1002/pro.321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.1002%2Fpro.321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=20052711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisFOhtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2010&pages=429-439&author=D.+J.+Marcotteauthor=Y.+T.+Liuauthor=R.+M.+Arduiniauthor=C.+A.+Hessionauthor=K.+Miatkowskiauthor=C.+P.+Wildesauthor=P.+F.+Cullenauthor=V.+Hongauthor=B.+T.+Hopkinsauthor=E.+Mertschingauthor=T.+J.+Jenkinsauthor=M.+J.+Romanowskiauthor=D.+P.+Bakerauthor=L.+F.+Silvian&title=Structures+of+human+Bruton%E2%80%99s+tyrosine+kinase+in+active+and+inactive+conformations+suggest+a+mechanism+of+activation+for+TEC+family+kinases&doi=10.1002%2Fpro.321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases</span></div><div class="casAuthors">Marcotte, Douglas J.; Liu, Yu-Ting; Arduini, Robert M.; Hession, Catherine A.; Miatkowski, Konrad; Wildes, Craig P.; Cullen, Patrick F.; Hong, Victor; Hopkins, Brian T.; Mertsching, Elisabeth; Jenkins, Tracy J.; Romanowski, Michael J.; Baker, Darren P.; Silvian, Laura F.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">429-439</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">1469-896X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK), a member of the TEC family of kinases, plays a crucial role in B-cell maturation and mast cell activation.  Although the structures of the unphosphorylated mouse BTK kinase domain and the unphosphorylated and phosphorylated kinase domains of human ITK are known, understanding the kinase selectivity profiles of BTK inhibitors has been hampered by the lack of availability of a high resoln., ligand-bound BTK structure.  Here, we report the crystal structures of the human BTK kinase domain bound to either Dasatinib (BMS-354825) at 1.9 Å resoln. or to 4-amino-5-(4-phenoxyphenyl)-7H-pyrrolospyrimidin-7-yl-cyclopentane at 1.6 Å resoln.  This data provides information relevant to the development of small mol. inhibitors targeting BTK and the TEC family of nonreceptor tyrosine kinases.  Anal. of the structural differences between the TEC and Src families of kinases near the Trp-Glu-Ile motif in the N-terminal region of the kinase domain suggests a mechanism of regulation of the TEC family members.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBETS8unO82rVg90H21EOLACvtfcHk0li2tPJ_IdVhMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisFOhtbs%253D&md5=8c2dae6949f8bdb627d68ee14edc8d4f</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Fpro.321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpro.321%26sid%3Dliteratum%253Aachs%26aulast%3DMarcotte%26aufirst%3DD.%2BJ.%26aulast%3DLiu%26aufirst%3DY.%2BT.%26aulast%3DArduini%26aufirst%3DR.%2BM.%26aulast%3DHession%26aufirst%3DC.%2BA.%26aulast%3DMiatkowski%26aufirst%3DK.%26aulast%3DWildes%26aufirst%3DC.%2BP.%26aulast%3DCullen%26aufirst%3DP.%2BF.%26aulast%3DHong%26aufirst%3DV.%26aulast%3DHopkins%26aufirst%3DB.%2BT.%26aulast%3DMertsching%26aufirst%3DE.%26aulast%3DJenkins%26aufirst%3DT.%2BJ.%26aulast%3DRomanowski%26aufirst%3DM.%2BJ.%26aulast%3DBaker%26aufirst%3DD.%2BP.%26aulast%3DSilvian%26aufirst%3DL.%2BF.%26atitle%3DStructures%2520of%2520human%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520active%2520and%2520inactive%2520conformations%2520suggest%2520a%2520mechanism%2520of%2520activation%2520for%2520TEC%2520family%2520kinases%26jtitle%3DProtein%2520Sci.%26date%3D2010%26volume%3D19%26spage%3D429%26epage%3D439%26doi%3D10.1002%2Fpro.321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu-Bujalski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Follis, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goutopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grenningloh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Head, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mochalkin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neagu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherer, B.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">2939</span>– <span class="NLM_lpage">2944</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.07.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.1016%2Fj.bmcl.2018.07.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=30122225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1yrsrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=2939-2944&author=H.+Qiuauthor=L.+Liu-Bujalskiauthor=R.+D.+Caldwellauthor=A.+V.+Follisauthor=A.+Gardbergauthor=A.+Goutopoulosauthor=R.+Grenninglohauthor=J.+Headauthor=T.+Johnsonauthor=R.+Jonesauthor=I.+Mochalkinauthor=F.+Morandiauthor=C.+Neaguauthor=B.+Sherer&title=Discovery+of+potent%2C+highly+selective+covalent+irreversible+BTK+inhibitors+from+a+fragment+hit&doi=10.1016%2Fj.bmcl.2018.07.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit</span></div><div class="casAuthors">Qiu, Hui; Liu-Bujalski, Lesley; Caldwell, Richard D.; Follis, Ariele Viacava; Gardberg, Anna; Goutopoulos, Andreas; Grenningloh, Roland; Head, Jared; Johnson, Theresa; Jones, Reinaldo; Mochalkin, Igor; Morandi, Federica; Neagu, Constantin; Sherer, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2939-2944</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Bruton's Tyrosine Kinase (BTK) is a member of the TEC kinase family that is expressed in cells of hematopoietic lineage (e.g., in B cells, macrophages, monocytes, and mast cells).  Small mol. covalent irreversible BTK inhibitor targeting Cys481 within the ATP-binding pocket, for example ibrutinib, has been applied in the treatment of B-cell malignancies.  Starting from a fragment hit, we discovered a novel series of potent covalent irreversible BTK inhibitors that occupy selectivity pocket of the active site of the BTK kinase domain.  Guided by x-ray structures and a fragment-based drug design (FBDD) approach, we generated mols. showing comparable cellular potency to ibrutinib and higher kinome selectivity against undesirable off-targets like EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUzH2Fde_MUbVg90H21EOLACvtfcHk0lhDtom-6XSmSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1yrsrfJ&md5=f4019ea46ab1a06cab875c0b7af5b1fd</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.07.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.07.008%26sid%3Dliteratum%253Aachs%26aulast%3DQiu%26aufirst%3DH.%26aulast%3DLiu-Bujalski%26aufirst%3DL.%26aulast%3DCaldwell%26aufirst%3DR.%2BD.%26aulast%3DFollis%26aufirst%3DA.%2BV.%26aulast%3DGardberg%26aufirst%3DA.%26aulast%3DGoutopoulos%26aufirst%3DA.%26aulast%3DGrenningloh%26aufirst%3DR.%26aulast%3DHead%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DMochalkin%26aufirst%3DI.%26aulast%3DMorandi%26aufirst%3DF.%26aulast%3DNeagu%26aufirst%3DC.%26aulast%3DSherer%26aufirst%3DB.%26atitle%3DDiscovery%2520of%2520potent%252C%2520highly%2520selective%2520covalent%2520irreversible%2520BTK%2520inhibitors%2520from%2520a%2520fragment%2520hit%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D2939%26epage%3D2944%26doi%3D10.1016%2Fj.bmcl.2018.07.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widen, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harki, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brummond, K. M.</span></span> <span> </span><span class="NLM_article-title">Covalent modifiers: a chemical perspective on the reactivity of alpha, beta-unsaturated carbonyls with thiols via hetero-Michael addition reactions</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">839</span>– <span class="NLM_lpage">885</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00788</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00788" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BC28XitV2rtbnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=839-885&author=P.+A.+Jacksonauthor=J.+C.+Widenauthor=D.+A.+Harkiauthor=K.+M.+Brummond&title=Covalent+modifiers%3A+a+chemical+perspective+on+the+reactivity+of+alpha%2C+beta-unsaturated+carbonyls+with+thiols+via+hetero-Michael+addition+reactions&doi=10.1021%2Facs.jmedchem.6b00788"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions</span></div><div class="casAuthors">Jackson, Paul A.; Widen, John C.; Harki, Daniel A.; Brummond, Kay M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">839-885</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Although Michael acceptors display a potent and broad spectrum of bioactivity, they have largely been ignored in drug discovery because of their presumed indiscriminate reactivity.  As such, a dearth of information exists relevant to the thiol reactivity of natural products and their analogs possessing this moiety.  In the midst of recently approved acrylamide-contg. drugs, it is clear that a good understanding of the hetero-Michael addn. reaction and the relative reactivities of biol. thiols with Michael acceptors under physiol. conditions is needed for the design and use of these compds. as biol. tools and potential therapeutics.  This Perspective provides information that will contribute to this understanding, such as kinetics of thiol addn. reactions, bioactivities, as well as steric and electronic factors that influence the electrophilicity and reversibility of Michael acceptors.  This Perspective is focused on α,β-unsatd. carbonyls given their preponderance in bioactive natural products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn4jDqxoos17Vg90H21EOLACvtfcHk0lhDtom-6XSmSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitV2rtbnM&md5=36d3be5bf688c4e4a8cf4bcf42073009</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00788%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DP.%2BA.%26aulast%3DWiden%26aufirst%3DJ.%2BC.%26aulast%3DHarki%26aufirst%3DD.%2BA.%26aulast%3DBrummond%26aufirst%3DK.%2BM.%26atitle%3DCovalent%2520modifiers%253A%2520a%2520chemical%2520perspective%2520on%2520the%2520reactivity%2520of%2520alpha%252C%2520beta-unsaturated%2520carbonyls%2520with%2520thiols%2520via%2520hetero-Michael%2520addition%2520reactions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D839%26epage%3D885%26doi%3D10.1021%2Facs.jmedchem.6b00788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwobel, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wondrousch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koleva, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madden, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuurmann, G.</span></span> <span> </span><span class="NLM_article-title">Prediction of Michael-type acceptor reactivity toward glutathione</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1576</span>– <span class="NLM_lpage">1585</span>, <span class="refDoi"> DOI: 10.1021/tx100172x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx100172x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1akt7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2010&pages=1576-1585&author=J.+A.+Schwobelauthor=D.+Wondrouschauthor=Y.+K.+Kolevaauthor=J.+C.+Maddenauthor=M.+T.+Croninauthor=G.+Schuurmann&title=Prediction+of+Michael-type+acceptor+reactivity+toward+glutathione&doi=10.1021%2Ftx100172x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of Michael-Type Acceptor Reactivity toward Glutathione</span></div><div class="casAuthors">Schwobel, Johannes A. H.; Wondrousch, Dominik; Koleva, Yana K.; Madden, Judith C.; Cronin, Mark T. D.; Schuurmann, Gerrit</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1576-1585</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A model has been developed to predict the kinetic rate consts. (kGSH) of α,β-unsatd. Michael acceptor compds. for their reaction with glutathione (GSH).  The model uses the local charge-limited electrophilicity index ωq at the β-carbon atom as a descriptor of reactivity, a descriptor for resonance stabilization of the transition state, and one for steric hindrance at the reaction sites involved.  Overall, the Michael addn. model performs well (r2 = 0.91; rms = 0.34).  It includes various classes of compds. with double and triple bonds, linear and cyclic systems, and compds. with and without substituents in the α-position.  Comparison of exptl. and predicted rate consts. demonstrates even better performance of the model for individual classes of compds. (e.g., for aldehydes, r2 = 0.97 and rms = 0.15; for ketones, r2 = 0.95 and rms = 0.35).  The model also allows for the prediction of the RC50 values from the Schultz chemoassay, the accuracy being close to the interlab. exptl. error.  Furthermore, kGSH and assocd. RC50 values can be predicted in cases where exptl. measurements are not possible or restricted, for example, because of low soly. or high volatility.  The model has the potential to provide information to assist in the assessment and categorization of toxicants and in the application of integrated testing strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomptlZNO-ZPrVg90H21EOLACvtfcHk0lhDtom-6XSmSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1akt7jL&md5=a4ec98f9001e66973e994520aca58492</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Ftx100172x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx100172x%26sid%3Dliteratum%253Aachs%26aulast%3DSchwobel%26aufirst%3DJ.%2BA.%26aulast%3DWondrousch%26aufirst%3DD.%26aulast%3DKoleva%26aufirst%3DY.%2BK.%26aulast%3DMadden%26aufirst%3DJ.%2BC.%26aulast%3DCronin%26aufirst%3DM.%2BT.%26aulast%3DSchuurmann%26aufirst%3DG.%26atitle%3DPrediction%2520of%2520Michael-type%2520acceptor%2520reactivity%2520toward%2520glutathione%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2010%26volume%3D23%26spage%3D1576%26epage%3D1585%26doi%3D10.1021%2Ftx100172x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grenningloh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Head, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haselmayer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu-Bujalski, L.</span></span> <span> </span><span class="NLM_article-title">Ability of Bruton’s tyrosine kinase inhibitors to sequester Y551 and prevent phosphorylation determines potency for inhibition of Fc receptor but not B-cell receptor signaling</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">208</span>– <span class="NLM_lpage">219</span>, <span class="refDoi"> DOI: 10.1124/mol.116.107037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.1124%2Fmol.116.107037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=28062735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpsFajtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2017&pages=208-219&author=A.+T.+Benderauthor=A.+Gardbergauthor=A.+Pereiraauthor=T.+Johnsonauthor=Y.+Wuauthor=R.+Grenninglohauthor=J.+Headauthor=F.+Morandiauthor=P.+Haselmayerauthor=L.+Liu-Bujalski&title=Ability+of+Bruton%E2%80%99s+tyrosine+kinase+inhibitors+to+sequester+Y551+and+prevent+phosphorylation+determines+potency+for+inhibition+of+Fc+receptor+but+not+B-cell+receptor+signaling&doi=10.1124%2Fmol.116.107037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Ability of Bruton's tyrosine kinase inhibitors to sequester Y551 and prevent phosphorylation determines potency for inhibition of Fc receptor but not B-cell receptor signaling</span></div><div class="casAuthors">Bender, Andrew T.; Gardberg, Anna; Pereira, Albertina; Johnson, Theresa; Wu, Yin; Grenningloh, Roland; Head, Jared; Morandi, Federica; Haselmayer, Philipp; Liu-Bujalski, Lesley</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">208-219</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is expressed in a variety of hematopoietic cells.  Btk has been demonstrated to regulate signaling downstream of the B-cell receptor (BCR), Fc receptors (FcRs), and toll-like receptors.  It has become an attractive drug target because its inhibition may provide significant efficacy by simultaneously blocking multiple disease mechanisms.  Consequently, a large no. of Btk inhibitors have been developed.  These compds. have diverse binding modes, and both reversible and irreversible inhibitors have been developed.  Reported herein, we have tested nine Btk inhibitors and characterized on a mol. level how their interactions with Btk define their ability to block different signaling pathways.  By solving the crystal structures of Btk inhibitors bound to the enzyme, we discovered that the compds. can be classified by their ability to trigger sequestration of Btk residue Y551.  In cells, we found that sequestration of Y551 renders it inaccessible for phosphorylation.  The ability to sequester Y551 was an important determinant of potency against FcγR signaling as Y551 sequestering compds. were more potent for inhibiting basophils and mast cells.  This result was true for the inhibition of FcγR signaling as well.  In contrast, Y551 sequestration was less a factor in detg. potency against BCR signaling.  We also found that Btk activity is regulated differentially in basophils and B cells.  These results elucidate important determinants for Btk inhibitor potency against different signaling pathways and provide insight for designing new compds. with a broader inhibitory profile that will likely result in greater efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrN8F--ON3M7Vg90H21EOLACvtfcHk0lhDtom-6XSmSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpsFajtr8%253D&md5=f869d52d6bc1aabf352988787ff1cbcf</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1124%2Fmol.116.107037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.116.107037%26sid%3Dliteratum%253Aachs%26aulast%3DBender%26aufirst%3DA.%2BT.%26aulast%3DGardberg%26aufirst%3DA.%26aulast%3DPereira%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DGrenningloh%26aufirst%3DR.%26aulast%3DHead%26aufirst%3DJ.%26aulast%3DMorandi%26aufirst%3DF.%26aulast%3DHaselmayer%26aufirst%3DP.%26aulast%3DLiu-Bujalski%26aufirst%3DL.%26atitle%3DAbility%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%2520to%2520sequester%2520Y551%2520and%2520prevent%2520phosphorylation%2520determines%2520potency%2520for%2520inhibition%2520of%2520Fc%2520receptor%2520but%2520not%2520B-cell%2520receptor%2520signaling%26jtitle%3DMol.%2520Pharmacol.%26date%3D2017%26volume%3D91%26spage%3D208%26epage%3D219%26doi%3D10.1124%2Fmol.116.107037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitty, A.</span></span> <span> </span><span class="NLM_article-title">The resurgence of covalent drugs</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1038/nrd3410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=10.1038%2Fnrd3410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=21455239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=307-317&author=J.+Singhauthor=R.+C.+Petterauthor=T.+A.+Baillieauthor=A.+Whitty&title=The+resurgence+of+covalent+drugs&doi=10.1038%2Fnrd3410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of covalent drugs</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Baillie, Thomas A.; Whitty, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-317</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Covalent drugs haveproved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project.  There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium.  This Review surveys the prevalence and pharmacol. advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreDCEmORV_NbVg90H21EOLACvtfcHk0liigEWGl-mI_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D&md5=2190289081e151416c097be4a5b04460</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrd3410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3410%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DWhitty%26aufirst%3DA.%26atitle%3DThe%2520resurgence%2520of%2520covalent%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D307%26epage%3D317%26doi%3D10.1038%2Fnrd3410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bendele, A.</span></span> <span> </span><span class="NLM_article-title">Animal models of rheumatoid arthritis</span>. <i>J. Musculoskelet. Neuron. Interact.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">377</span>– <span class="NLM_lpage">385</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=15758488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltVOhu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2001&pages=377-385&author=A.+Bendele&title=Animal+models+of+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Animal models of rheumatoid arthritis</span></div><div class="casAuthors">Bendele, A. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Musculoskeletal & Neuronal Interactions</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">377-385</span>CODEN:
                <span class="NLM_cas:coden">JMNIB3</span>;
        ISSN:<span class="NLM_cas:issn">1108-7161</span>.
    
            (<span class="NLM_cas:orgname">Journal of Musculoskeletal and Neuronal Interactions</span>)
        </div><div class="casAbstract">A review.  Animal models of arthritis are used to study pathogenesis of disease and to evaluate potential anti-arthritic drugs for clin. use.  Therefore morphol. similarities to human disease and capacity of the model to predict efficacy in humans are important criteria in model selection.  Animal models of rheumatoid arthritis (RA) with a proven track record of predictability for efficacy in humans include: rat adjuvant arthritis, rat type II collagen arthritis, mouse type II collagen arthritis and antigen-induced arthritis in several species.  Agents currently in clin. use (or trials) that are active in these models include: corticosteroids, methotrexate, nonsteroidal anti-inflammatory drugs, cyclosporin A, leflunomide interleukin-1 receptor antagonist (IL-1ra) and sol. TNF receptors.  For some of these agents, the models also predict that toxicities seen at higher doses for prolonged dosing periods would preclude dosing in humans at levels that might provide disease modifying effects.  Data, conduct and features of the various models of these commonly utilized models of RA as well as some transgenic mouse models and less commonly utilized rodent models will be discussed with emphasis on their similarities to human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwhtLWBEJFcbVg90H21EOLACvtfcHk0liigEWGl-mI_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltVOhu7o%253D&md5=21f16894bcfdad981a6b7d32773431cf</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBendele%26aufirst%3DA.%26atitle%3DAnimal%2520models%2520of%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Musculoskelet.%2520Neuron.%2520Interact.%26date%3D2001%26volume%3D1%26spage%3D377%26epage%3D385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span> <i>Collagen Induced Arthritis (CIA) in Rat</i>; <span class="NLM_publisher-name">Bolder BioPath</span>, <span class="NLM_year">2015</span>; <a href="https://bolderbiopath.com/study/collagen-induced-arthritis-rat/" class="extLink">https://bolderbiopath.com/study/collagen-induced-arthritis-rat/</a> (accessed January 7, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Collagen+Induced+Arthritis+%28CIA%29+in+Rat%3B+Bolder+BioPath%2C+2015%3B+https%3A%2F%2Fbolderbiopath.com%2Fstudy%2Fcollagen-induced-arthritis-rat%2F+%28accessed+January+7%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DCollagen%2520Induced%2520Arthritis%2520%2528CIA%2529%2520in%2520Rat%26pub%3DBolder%2520BioPath%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3gen" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3gen','PDB','3gen'); return false;">PDB: 3gen</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5p9j" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5p9j','PDB','5p9j'); return false;">PDB: 5p9j</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5yu9" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5yu9','PDB','5yu9'); return false;">PDB: 5yu9</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i43"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00794">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_21875"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b00794">10.1021/acs.jmedchem.9b00794</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Assay details; mass spectrometry; isothermal calorimetry; jump dilution assay; kinase selectivity; animal studies; preclinical PK studies; synthesis of compounds <b>A4</b>–<b>A7</b>, <b>A10</b>–<b>A17</b>, <b>A19</b>; synthesis of compounds <b>A20</b>–<b>A26</b>; synthesis of compounds <b>A27</b>–<b>A31</b>; references and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00794/suppl_file/jm9b00794_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00794/suppl_file/jm9b00794_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00794/suppl_file/jm9b00794_si_001.pdf">jm9b00794_si_001.pdf (1.08 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00794/suppl_file/jm9b00794_si_002.csv">jm9b00794_si_002.csv (2.83 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDBs <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3gen">3gen</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5p9j">5p9j</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5yu9">5yu9</a>]. Authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-17%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00794%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00794" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799630a3a5d3d18","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
